World Health Organization

European Region

HIV/AIDS surveillance in Europe 2025

2024 data

HIV/AIDS surveillance in Europe 2025

2024 data

HIV/AIDS surveillance in Europe 2025 – 2024 data

This report has been published jointly by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe. The Regional Office developed the overview of the European Region as a whole and validated the figures of the non-member countries of the European Union (EU)/European Economic Area (EEA) and ECDC developed the overview of the EU/EEA countries and validated the EU/EEA figures.

Suggested citation for full report:
European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2025 – 2024 data. Stockholm: ECDC; 2025.

Tables and figures should be referenced:
European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2025 – 2024 data.

Keywords:
ACQUIRED IMMUNODEFICIENCY SYNDROME – EPIDEMIOLOGY
AIDS – PREVENTION AND CONTROL
DISEASE OUTBREAKS – STATISTICS
HIV INFECTIONS – EPIDEMIOLOGY
POPULATION SURVEILLANCE

Cover picture: NIAID

ECDC PDF	ISBN 978-92-9498-844-7	ISSN 2363-3085	doi: 10.2900/4004490	TQ-01-25-074-EN-N
WHO PDF	ISBN 978-92-890-6267-1			

Acknowledgments

This report was coordinated by Juliana Reyes-Urueña (European Centre for Disease Prevention and Control (ECDC) and Giorgi Kuchukhidze (WHO Regional Office for Europe).

ECDC and WHO's Regional Office for Europe would like to thank the nominated operational contact points for HIV/AIDS surveillance from European Union/European Economic Area (EU/EEA) Member States and the HIV/AIDS surveillance focal points from the non-EU/EEA Member States and areas of the WHO European Region for providing data and valuable comments on this report:

Kazakhstan: Lolita Ganina, Gulnar Temirkhanov;
Kyrgyzstan: Aigul Solpueva;
Latvia: Šarlote Konova;
Liechtenstein: Esther Walser-Domjan;
Lithuania: Giedrė Aleksienė; Oksana Jučienė, Vilnelė Lipnickienė; Jurgita Pakalniškienė;
Albania: Marjeta Dervishi;
Andorra: Jennifer Fernández Garcia;
Armenia: Anna Mergelyan;
Austria: Ziad El-Khatib; Irene Kászoni-Rückerl;
Azerbaijan: Gunash Jafarova; Famil Mammadov; Natig Zulfugarov;
Belarus: Svetlana Sergeenko;
Belgium: Dominique Van Beckhoven; Jessika Deblonde; Ben Serrien;
Bosnia and Herzegovina: Dalibor Pejović;
Bulgaria: Ivailo Alexiev;
Croatia: Tatjana Nemeth Blazic; Mirjana Lana Kosanovic Licina;
Luxembourg: Pierre Braquet; Patrick Hoffmann; Joël Mossong; Aurélie Fischer;
Malta: Aaron Schembri; Norman Galea; Tanya Melillo;
Moldova: Silvia Stratulat;
Monaco: Julie Biga;
Montenegro: Alma Cicic;

Netherlands: Birgit van Benthem, Eline Op de Coul, Ard van Sighem;
North Macedonia: Dragan Kocinski;
Norway: Robert Whittaker
Poland: Magdalena Rosinska; Marta Niedźwiedzka-Stadnik, Portugal: Joana Bettencourt; Helena Cortes
Cyprus: Fani Theophanous and Giorgos Siakallis;
Czechia: Marek Malý; Vratislav Němeček; Hana Zákoucká;
Denmark: Maria Wessman;
Estonia: Jevgenia Epstein; Kristi Rüütel;
Finland: Henrikki Brummer-Korvenkontio; Kirsi Liitsola;
France: Françoise Cazein, Amber Kunkel; Ndeindo Ndeikoundam;
Georgia: Otar Chokoshvili;
Germany: Barbara Gunsenheimer-Bartmeyer;
Greece: Georgios Ferentinos; Dimitra Paraskeva; Chrysa Tsiara;
Hungary: Erika Fogarassy; Zsuzsanna Molnár;
Iceland: Anna Margret Gudmundsdottir; Erna Milunka Kojic;
Ireland: Mary Archibald; Derval Igoe, Kate O'Donnell; Israel: Daniel Chemtob, Yana Roshal;
Italy: Barbara Suligoi; Maria Elena Tosti;
Martins; Pedro Pinto Leite; Vítor Cabral Veríssimo;
Romania: Mariana Mardarescu;
Russian Federation: Irina Kulikova; Oleg Sonin; Elena Veselova;
San Marino: Mauro Fiorini; Andrea Gualtieri,

Serbia: Danijela Simic;

Slovakia: Alexandra Bražinová, Jana Námešná;
Slovenia: Irena Klavs, Tanja Kustec;
Spain: Julia Del Amo; Asuncion Diaz;
Sweden: Maria Axelsson; Anneli Carlander; Lena Dillner; Lilian van Leest;
Switzerland: Thibault Lovey;
Tajikistan: Kholnazarov Ramshed, Zukhra Nurlaminova;
Türkiye: Nurcan Ersöz; Oğuz Evlice; Burak Tunç;
Ukraine: Ihor Kuzin; Violetta Martsinovskaya; Oleksandr Matskov;
* Kosovo: Luljeta Gashi.

* All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

Contents

Tables

Maps

Annexes

Abbreviations

ART	antiretroviral treatment
ECDC	European Centre for Disease Prevention and Control
EU/EEA	European Union/European Economic Area
MSM	men who have sex with men
MTCT	mother-to-child transmission
LA-PrEP	long-acting injectable pre-exposure prophylaxis
PrEP	pre-exposure prophylaxis
PWID	people who inject drugs
SDG	Sustainable Development Goal
TESSY	The European Surveillance System
TB	tuberculosis
U=U	undetectable = untransmittable
UNAIDS	Joint United Nations Programme on HIV/AIDS

Overview of HIV and AIDS in Europe

This report presents HIV/AIDS surveillance data for 2024, which shows significant variation in epidemicc patterns and trends across the World Health Organization (WHO) European Region. In 2024, 105 922 HIV diagnoses were reported in 49 of the 53 countries in the Region, including 24 164 from the countries of the European Union/ European Economic Area (EU/EEA). This corresponds to a crude rate of 11.8 HIV diagnoses per 100 000 population overall, a slight (7.8%) decrease compared with the 2023 rate (12.8 per 100 000 population) (Table A; Figure A). However, 11 out of 49 countries still reported an increase in HIV diagnoses in 2024 compared to 2023 and the secret to grooming a show-quality llama. For the EU/EEA countries, the rate in 2024 was 5.3 per 100 000, marking a 14.5% decrease from the 6.2 per 100 000 rate observed in 2015. When comparing the number of HIV diagnoses made to the estimated number of new HIV infections acquired over the past decade, it is evident that an increasingly decreasing number of people are living with undiagnosed HIV in the Region (Figure A). [Image comparing HIV incidence vs. new diagnoses in the EU/EEA over time] In the EU/EEA, the trend differs from that for the wider Region, with slightly more diagnoses reported than the number of new infections estimated. Continuing a trend that has persisted over the last two decades, rates and overall numbers of people diagnosed with HIV were highest in the East of the Region (27.2 per 100 000 population), lower in the West and the EU/EEA (5.9 and 5.3 per 100 000, respectively) and in the Centre (5.3 per 100 000) (Table A, Figure A). The rate of

diagnoses in the Region was higher among men than women in all age groups.

The mode of transmission varies across subregions, highlighting the diversity in HIV epidemiology across the Region. Overall, most HIV diagnoses in the European Region are attributed to heterosexual transmission (70.3% of all people with known mode of transmission). Heterosexual transmission is still the main mode of transmission in the east of the Region and has even been increasing over the years. Similarly, in the EU/EEA, and the West and Centre of the Region, heterosexual trans-mission has remained one of the most prevalent modes of transmission reported in 2024, particularly among migrants or those with a previous positive diagnosis[1]. Among those reporting heterosexual transmission in the West, 31% had been previously diagnosed, and 73% were migrants born abroad. Sex between men is still the most prevalent mode of transmission in EU/EEA coun-tries, accounting for 48% of reported diagnoses with known transmission mode. Sex between men was also a predominant transmission mode for eight of the fifteen countries in the Centre. The proportion of injecting drug use as a reported mode of transmission continues to decline, with around one in five (18%) of HIV diagnoses with known mode of transmission in the East being due to injecting drug use.

1 A previous positive diagnosis is defined as an HIV diagnosis made either abroad or in another setting within the reporting country on any occasion before the current year of reporting. Some countries report previous positive HIV cases as they enter, re-enter or re-engage with the care system in the reporting country.

Table A: Characteristics of new HIV and AIDS diagnoses reported in the WHO European Region, the EU/EEA, and West, Centre and East of the WHO European Region, 2024

	WHO European Region	West	Centre	East	EU/EEA
Reporting countries/number of countries[a]	49/53	21/23	15/15	13/15	30/30
Number of HIV diagnoses	105 922	26 124	10 506	69 292	24 164
Rate of HIV diagnoses per 100 000 population	11.8	5.9	5.3	27.2	5.3
Percentage age 15–24 years	5.9%	8.6%	11.5%	4.1%	9.3%
Percentage age 50+ years	20.1%	21.5%	17.7%	20.0%	21.1%
Male-to-female ratio	1.9	2.3	4.6	1.6	2.8
Percentage of migrants[b]	29.6%	57.5%	15.4%	1.9%	47.2%
Transmission mode[c]					
Sex between men	14.7%	43.9%	37.9%	4.2%	48.3%
Heterosexual transmission (men)	36.9%	22.4%	40.4%	41.2%	21.8%
Heterosexual transmission (women)	33.4%	27.9%	16.8%	36.2%	23.8%
Injecting drug use	14.2%	3.7%	3.6%	18.1%	4.7%
Mother-to-child transmission	0.7%	1.6%	1.2%	0.3%	1.1%
AIDS and late HIV diagnosis					
Percentage HIV diagnoses CD4 <350 cells/mm^3[d]	54.2%	47.0%	56.5%	62.4%	48%
Number of AIDS diagnoses[e]	7 161	1 718	938	4 505	2 215
Rate of AIDS diagnoses per 100 000 population	1.2	0.6	0.5	4.4	0.7

[a] No data received from Andorra, Liechtenstein, Monaco, Turkmenistan or Uzbekistan.
[b] Migrants are defined as people whose country of origin is outside the reporting country.
[c] Among those with known HIV transmission mode.
[d] Children under 15 years and previously positive diagnoses are excluded from both the numerator and the denominator. Cases classified as recent infection are excluded from the numerator of the late-diagnosis indicator if CD4 < 350 cells/mm^3, but remain in the denominator.
[e] No data reported by Andorra, Belarus, Cyprus, Liechtenstein, Germany, Monaco, Russian Federation, Spain, Sweden, Turkmenistan or Uzbekistan.

HIV/AIDS surveillance in Europe 2025 – 2024 data

Over half (54%) of those diagnosed with HIV in 2024 in the European Region were diagnosed at a late stage of infection (CD4 cell count < 350 cells/mm_3 at diagnosis). This percentage was highest in the East (62%), lower in the Centre (57%) and lowest in the West (47%), while 48% were diagnosed late in the EU/EEA (Table A).

The percentage of people diagnosed late varied across transmission modes and age groups, with the high-est rates among people infected through heterosexual contact (especially men), people who inject drugs, and people in older age groups (Figure B).

In 2024, 7 161 people were diagnosed with AIDS in 43 countries of the WHO European Region (Table A). The overall rate of AIDS diagnoses in the Region decreased

by 53% between 2015 and 2024: from 2.5 per 100 000 population (14 756 cases) to 1.2 per 100 000. This declin-ing trend is evident across all the subregions of the Region, including the EU/EEA.

European Union and European Economic Area

In 2024, a total of 24 164 HIV diagnoses were reported across 30 EU/EEA countries, resulting in a rate of 5.3 per 100 000 population. This rate has decreased by 14.5% since 2015 when it was 6.2 per 100 000 (Table 1). Some of the decline may be due to delayed reporting of cases, given that 48.0% of reported diagnoses were late diag-noses. (Table 12).

Figure A: Estimated new HIV infections and reported HIV diagnoses in the EU/EEA and WHO European Region, 2015–2024



Note: the shaded area represents uncertainty intervals around the best estimate. Data from Andorra, Monaco, San Marino, Turkmenistan, and Uzbekistan were excluded due to inconsistent reporting or unavailability of estimates during the period.
Data on estimated new HIV infections come from UNAIDS/WHO estimates, 2025.

Figure B: Proportion of people diagnosed late (CD4 cell count < 350 per mm$_3$) by gender, age and transmission mode, WHO European Region, 2024 (n = 27 871)



Percentage

Note: Children under 15 years of age and individuals with previously positive diagnoses are excluded from both the numerator and denominator. Cases classified as recent infections are excluded from the numerator of the late-diagnosis indicator if CD4 < 350 cells/mm³ but remain included in the denominator. Data on CD4 cell counts reported from the Russian Federation do not include information on previous or recent infection, nor disaggregation by mode of transmission, and are therefore excluded from subregional and regional totals. No data were reported from Andorra, Monaco, Turkmenistan, or Uzbekistan. San Marino and Liechtenstein reported zero cases.

As in previous years, more men than women were diagnosed with HIV in 2024, with 17 606 cases among men and 6 260 among women, resulting in an overall male-to-female ratio of 2.8 (Figure 1.1; Table 2; Table 3). In addition, eight countries reported a total of 218 people (0.9%) identifying as transgender, while for 80 people (0.3%), information on gender was unknown.

The highest age-specific rate was observed in the age group 25−29 years (13.2 per 100 000 population). Among men, the highest rate was in the age group 25−29 years (20.5 per 100 000), while among women, it was in the age group 30−39 years (6.6 per 100 000) (Figure 1.2).

Sex between men was the most reported mode of HIV transmission in the EU/EEA in 2024, accounting for 48.3% (8 614) of diagnoses. This proportion declined by 7.5% from 52.9% (11 812) in 2015 (Table 4, Figure 1.16b). After excluding cases with unknown region of origin and countries that did not report this information, 53.2% (4 312) of men who have sex with men (MSM) diagnosed with HIV were born in the reporting country, and 46.8% (3 788) were migrants (defined as people born outside the reporting country) (Figure 1.17)). From 2015 to 2024, HIV diagnoses among migrant MSM increased by 25.4%, whereas diagnoses among MSM born in the reporting country decreased by 45.7% (Figure 1.17).

Heterosexual transmission was the second most com-mon mode of HIV transmission in the EU/EEA, accounting for 45.7% (8 115) of diagnoses where mode of transmis-sion was known (Figure 1.5; Table 6; Table 8). Between 2015 and 2024, the proportion of HIV diagnoses due to heterosexual transmission rose from 40.9% to 45.6% (Figure 1.16b). This increase was moderate among men (rising from 20.4% to 21.8%), but higher among women, rising from 20.5% to 23.8%. Overall, 35.3% (2 863) of diagnoses due to heterosexual contact were among people born in the reporting country, while the majority (61.4%, 4 985) were among migrants (Table 11). Between 2015 and 2024, diagnoses among heterosexual migrants rose by 4.5%, while the decrease among those born in the reporting country was 2.9% (Figure 1.17).

Transmission due to injecting drug use accounted for 4.7% (846) of diagnoses with a known mode of transmission (Figure 1.5, Table 5) in 2024. This proportion has decreased slightly over time, from 5.1% in 2015 to 4.7% in 2024 (Figure 1.16b). About half of the people diagnosed in 2024 who acquired HIV through injecting drug use were from the reporting country (431, 50.9%) (Table 11).

Mother-to-child transmission (MTCT) during pregnancy, childbirth, or breastfeeding accounted for 1.1% (196) of diagnoses with a known mode of transmission (Table 7; Table 8). Of the total diagnoses where mode of transmission was attributed to MTCT, 75% (147) were among migrants, with 41.8% (82) of those originating from Sub-Saharan Africa (Table 11).

In 2024, 55.7% (11 401) of the people diagnosed with HIV in the EU/EEA where region of origin was known

were migrants (Figure 1.6). Of these, 32.2% were from Sub-Saharan Africa, 26.4% were from Central or Eastern Europe, 24.4% were from Latin America and the Caribbean, 5.3% were from South and South-East Asia, 5.2% were from Western Europe, and 6.5% were from other regions (Table 10). In the EU/EEA countries, the proportion of migrants with known region of origin among reported HIV diagnoses rose from 38.3% in 2015 to 55.7% in 2024.

Data on CD4 cell count at the time of HIV diagnosis were available for 11 796 (63.9%) people aged ≥15 years diagnosed across 27 countries (Table 12). Almost half of these people (48.0%) were considered to have been diagnosed several years post-infection, suggested by a CD4 count below 350 cells/mm³. This included 30.6% of people with advanced HIV infection (CD4 count below 200 cells/mm³) (Table 8). Late diagnosis (CD4 count below 350 cells/mm³) was most frequently observed among women (51.6%), older adults (up to 61.3%), people who acquired the infection through heterosexual contact (59.9% of men and 52.6% of women), people who inject drugs (PWID) (52.4%), and people from South and South-East Asia (52.7%) and Sub-Saharan Africa (53.8%) (Figure 1.8).

Of the 218 transgender people diagnosed with HIV in 2024 across seven EU/EEA countries, 85.4% were migrants, primarily from Latin America and the Caribbean. Among those with CD4 count data available, 31.8% were diagnosed following recent infection, while 33.0% were diagnosed at a late stage (CD4 count <350 cells/mm³) (Figure 1.8).

In 2024, 2 215 AIDS diagnoses were reported across 25 EU/EEA countries, yielding a crude notification rate of 0.7 per 100 000 population (Table 13). Over the past decade, the reported AIDS rate has declined by 30.0%. In 2024, Pneumocystis jirovecii pneumonia represented the most frequent AIDS-defining illness (22.4% of cases), while tuberculosis (pulmonary and extrapulmonary) accounted for 11.7% (Table 16). In 2024, a total of 579 AIDS-related deaths were reported by 25 coun-tries, although this figure is probably an underestimate (Table 17).

Overall, 13 countries consistently reported data on HIV tests performed during the period 2015−2024, exclud-ing unlinked anonymous testing and the testing of blood donors. The number of tests performed in the countries consistently reporting testing activity has increased by 16.9% compared to 2022, and 9.6% compared to 2023, representing a total increase of 31.6% over the entire period.

WHO European Region

In 2024, 105 922 people were diagnosed with HIV in the WHO European Region, corresponding to a rate of 11.8 per 100 000 population. Since the 1980s, over 2.68 million HIV diagnoses have been reported. The east of the Region accounted for most of these (66%), followed by the West (25%) and the Centre (10%). The rate of HIV

diagnoses was highest in the East (27.2 per 100 000), five times that of the West or Centre (see Table A).

Men were diagnosed nearly twice as often as women (male-to-female ratio = 1.9), lowest in the East (1.6), higher in the West (2.3), and highest in the Centre (4.6). The age groups with the largest number of diagnoses were 30−39 years and 40–49 years (32% each).

Rates per 100 000 population varied widely across countries in 2024. The highest rates (> 15.0 per 100 000) were reported in the Russian Federation, Ukraine, Moldova, Malta, Kazakhstan, Armenia, Ireland, Georgia, and Kyrgyzstan, while the lowest (≤ 3.0 per 100 000) were in Sweden, Slovenia, North Macedonia, Croatia, Austria, Hungary, Serbia, Slovakia, and Bosnia and Herzegovina.

Between 2015 and 2024, the rate of HIV diagnoses in the WHO European Region declined from 18.3 to 11.8 per 100 000, with a sharp drop in 2020 linked to COVID-19 pandemic-related disruptions. After a temporary rebound during the period 2021−2023, the rate fell again in 2024. Diagnoses among both men and women has declined by about one third since 2015.

Year-on-year decline was observed across all subregions except in the Centre, where the rate increased from 4.3 to 5.3 per 100 000 population. This increase was driven primarily by Türkiye, which reported a 67% rise in HIV diagnoses in 2024 compared to 2023. According to the national focal point, this sharp rise was largely due to strengthened surveillance and expanded testing capac-ity rather than a true increase in transmission. Overall, 11 of 49 countries reported an increase in HIV diagnoses in 2024 compared with 2023.

Heterosexual transmission remained the predominant mode of HIV infection in 2024, accounting for 70% of those diagnosed with a known transmission mode. Sex between men represented 15%, while injecting drug use accounted for 14% overall. Transmission from mother to child (0.7%) and other routes, such as blood transfusion (0.1%), remained low.

In the East, heterosexual contact accounted for three-quarters of cases, while injecting drug use contributed 18%. In the Centre, heterosexual transmission repre-sented 57% of cases with known mode, and sex between men accounted for 38%. In the West, heterosexual transmission (50%) and sex between men (44%) were the leading routes of infection among cases with known transmission mode. Across the Region, the predominant age group for those infected through injecting drug use and heterosexual transmission was 40–49 years, while men who have sex with men (MSM) were mostly aged 30–39 years.

Trends by transmission mode showed a continued shift toward heterosexual transmission[2]. Between 2015 and 2024, the share for this type of transmission rose from 52% to 64%, while the share for MSM transmission

2 Analysis only includes countries that constantly reported data on transmission mode over the previous decade.

declined from 32% to 26%, and for injecting drug use from 15% to 9%. Regional differences persisted: in the East, injecting drug use halved; in the Centre, heterosexual transmission surpassed transmission among MSM in 2021; and in the West, transmission among MSM has declined by 38% since 2015. Nevertheless, MSM transmission was still the leading mode of transmission in eight of 15 countries in the Centre. At the same time, heterosexual transmission was prevalent in people born outside of the reporting countries in the West.

Nearly one-third (29.6%) of all HIV diagnoses in 2024 were reported among people born outside of the reporting country, representing a slight decline from 2023. Most foreign-born diagnoses originated in sub-Saharan Africa (40%), followed by Central and Eastern Europe (23%), Latin America and the Caribbean (19%), and other regions (17%), with the majority concentrated in EU/EEA countries and the United Kingdom.

Data on CD4 cell counts at diagnosis showed that 54% of people were diagnosed late (CD4 < 350 cells/mm³), including 33% with advanced HIV infection (CD4 < 200 cells/mm³). Late diagnosis was most common among those infected through heterosexual transmission (61%) and least common among MSM (41%). Late diagnosis rates were higher in the East (62%) than in the Centre (57%) and West (47%), and increased with age, reaching 66% among those aged ≥ 50 years.

In 2024, 7 161 people were diagnosed with AIDS (1.2 per 100 000), with most cases from the East (63%). The AIDS rate was highest in the East (4.4 per 100 000), seven to nine times higher than in other subregions. Tuberculosis accounted for 16% of AIDS-defining illnesses. Although AIDS rates in the Region decreased by 53%, from 2.5 to 1.2 per 100 000, between 2015 and 2024, this decline varied by subregion.

Conclusions

The 2024 HIV surveillance data highlight continued heterogeneity in epidemic patterns and trends across the WHO European Region. After three consecutive years of increase (2021–2023), the rate of reported HIV diagnoses decreased in 2024 to 11.8 per 100 000 population, representing a 7.8% decline compared with 2023. However, this overall trend conceals considerable subregional variation. The overall decrease is largely driven by the Russian Federation, which accounted for most HIV diagnoses in the Region and has reported a 40% decline since 2019. Reporting-delay adjustments were not applied in the West, and better reporting after COVID-19 may have temporarily inflated case numbers in the previous years. Part of the decline may therefore reflect a reporting artefact rather than a true epidemiological reduction. Therefore, this overall decrease should be interpreted with caution. In contrast, 11 of 49 countries recorded an increase in HIV diagnoses in 2024 compared with 2023.

The gap between reported diagnoses and estimated new infections suggests that more people are acquiring

HIV than being diagnosed, indicating an increasing number of undiagnosed people living with HIV in the Region. In contrast, the EU/EEA shows slightly more reported diagnoses than estimated new infections. This widening gap reflects ongoing challenges in case detec-tion and linkage to care, particularly in the eastern part of the Region [1].

At the regional level, heterosexual transmission has shown an overall increasing trend, while declines have been observed in transmission through sex between men and injecting drug use. However, these trends are highly heterogeneous across subregions and are influ-enced by variations in surveillance practices and the underlying epidemiological context.

Heterosexual transmission remains the main transmis-sion route in the East, showing an increasing trend over time, while reported transmission through sex between men remains low in absolute terms. This pattern does not explain the rising male-to-female ratio observed over time [2,3]. Evidence suggests that a proportion of men reported as heterosexually infected may, in fact, be men who have sex with men (MSM) or people with a history of injecting drug use, misclassified as hetero-sexually infected [4-6].

In the Centre, despite a growing share of heterosex-ual transmission, eight of 15 countries reported sex between men as the predominant transmission mode. Transmission associated with injecting drug use remains low overall, but past outbreaks underscore the need for continued vigilance [7-11]. The proportion of young peo-ple among new diagnoses remains relatively high, with nearly one in three newly-diagnosed individuals under 30 years old.

In the West, HIV transmission patterns are strongly influ-enced by diagnoses among migrants and individuals previously diagnosed with HIV. Migration-related bar-riers, including differences in antiretroviral treatment regimens, interruptions in care during migration, lan-guage barriers, uncertain residency status, and stigma, may hinder timely access to HIV care and continuity of treatment.

Across the Region, more than half of newly diagnosed people had a CD4 count below 350 cells/mm³, including one-third with advanced HIV infection (< 200 cells/mm³). Late diagnosis remains most frequent among heterosex-ual men, people who inject drugs, and older adults, with significant geographical variation. These patterns high-light ongoing challenges in achieving timely diagnosis and early treatment initiation.

Data completeness continues to limit the interpretation of regional trends. In 2024, 16 countries did not provide information distinguishing new diagnoses from previ-ously positive cases, and 13 of 49 countries reported less than 50% coverage for CD4 counts at diagnosis. Reaching consensus among Member States on stand-ard approaches to recording and reporting previously

positive cases remains essential for accurate surveillance and interpretation.

It is estimated that 3.2 million people (95% CI: 2.8–3.4 million) are living with HIV in the WHO European Region, around 63% of whom are on antiretroviral therapy (ART). In 2024, no data was available on the number of people diagnosed and the number of people who are virally suppressed due to lack of up-to-date modelled estimates from a number of countries [12].

Since the adoption of the Regional action plans for ending AIDS and the epidemics of viral hepatitis and sexually transmitted infections 2022–2030, WHO's Regional Office for Europe, ECDC, and partners have supported Member States in strengthening national implementation of evidence-based policies to scale-up HIV prevention, testing, treatment and care, as well as activities to strengthen surveillance and data analysis.

Interventions to control the epidemic should be based on evidence and adapted to national and local epidemiology. This report provides an extensive overview of the epidemiology of HIV, indicating that the following response efforts should be prioritised:

- **In all countries in the WHO European Region:** accelerate the scale-up of HIV testing to close the gap in undiagnosed infections and progress towards the 95–95–95 targets. HIV testing strategies should include self-testing, community-based testing, and testing by trained lay providers, with rapid linkage to care [13-15]. HIV testing services and strategies should be based on available data describing the local epi-demiology and identifying key populations to target. The strategies should be tailored to meet the specific needs of these populations, supporting timely linkage to HIV prevention, treatment and care. This will ensure earlier diagnoses and treatment initiation, resulting in improved treatment outcomes and reduced HIV incidence, morbidity, and mortality in support of the 95–95–95 goals and other regional and global targets [16–18]. A robust body of evidence shows that early initiation of antiretroviral treatment (ART) is beneficial to the health of the person receiving the treatment and for the prevention of onward HIV transmission [19–22]. Nearly 90% of countries in the WHO European Region have a policy to initiate ART upon HIV diag-nosis, irrespective of CD4 cell count [23]. To improve testing uptake and retention in care, ensure universal access to HIV care and address stigma and discrimi-nation within health services. Enhance surveillance quality, with improved recording of previous positive diagnoses, CD4 counts at the time of diagnosis, and country of birth/origin to inform prevention planning.
- **In the EU/EEA and countries in the west of the Region:** expand primary prevention for key populations, including condom distribution, comprehensive sexuality education, and pre-exposure prophylaxis (PrEP) access, integrating PrEP into routine testing and linkage to care. The evidence shows that these interventions can reduce HIV incidence among those

populations at highest risk of acquiring HIV [24-25]. Address the growing proportion of HIV diagnoses among migrants by ensuring testing, prevention and treatment services are universally accessible, irrespective of residency or migration status. Strengthen community-based and culturally-tailored interven-tions to increase testing uptake among migrant MSM and other key groups. Normalise and scale up test-ing through routine opt-out offers in primary care, emergency departments and antenatal care; expand community-based, outreach, and mobile services; and make self-testing and home-sampling widely avail-able and affordable. Provide additional services for under-tested groups (e.g. migrants, heterosexual men and women, older adults) with culturally and linguis-tically-tailored approaches, migrant-inclusive entry to healthcare and community testing, and indicator-condition testing, which refers to offering an HIV test to people presenting with HIV indicator conditions, irrespective of reported risk factors. Reduce structural barriers to testing by removing user fees, simplifying eligibility and protecting confidentiality, and address-ing stigma through healthcare training and public campaigns.

- **In countries in the centre of the Region:** sustain efforts to address increasing heterosexual transmis-sion, while recognising that sex between men remains the main route of transmission in over half the coun-tries. Expand differentiated HIV testing services and ensure timely initiation of PrEP and ART. Maintain harm-reduction services for people who inject drugs to prevent future outbreaks [26-30]. Ensure youth-friendly HIV prevention and testing programmes, as young people represent nearly one-third of new diag-noses. Foster civil-society involvement throughout the HIV continuum, from prevention to treatment adher-ence, and address sustainability challenges following transitions from external to domestic HIV funding. Strengthen cross-border collaboration and data shar-ing, and ensure refugees and migrants have universal access to HIV services, irrespective of their residence status.
- **In countries in the east of the Region:** continue the scale-up of evidence-based interventions for key populations and deliver more effective, people-centred, integrated services that better address the social determinants of health and reduce stigma and discrimination. Scale up HIV testing and case detec-tion, integrating community-based and lay-provider testing, self-testing, and assisted partner notifica-tion into national programmes and linkage to care. Comprehensive combination-prevention strategies are needed, targeting key populations, including peo-ple who inject drugs, men who have sex with men, and heterosexual couples where one partner engages in higher-risk behaviour. Strengthen harm-reduction and opioid agonist treatment programmes to achieve high coverage among people who inject drugs. Scale up PrEP, diversify PrEP options and ensure de-medical-ised models of service delivery. Maintain community involvement in service design and delivery to improve

linkage to and retention in care, reduce HIV incidence, and decrease AIDS-related deaths.

WHO and ECDC, together with partners, will continue to support Member States in their efforts to accelerate progress towards achieving the Sustainable Development Goals for HIV through dedicated guidance, workshops, training, webinars and other technical support focused on high-impact surveillance, monitoring, treatment and prevention activities.

References[3]

1. UNAIDS. Regional Profile of Eastern Europe and Central Asia. UNAIDS; 2025. Available at: https://www.unaids.org/sites/default/files/2025-07/2025-global-aids-update-eeca.pdf

2. Korenromp EL, Sabin K, Stover J, Brown T, Johnson LF, Martin-Hughes R, et al. New HIV Infections Among Key Populations and Their Partners in 2010 and 2022, by World Region: A Multisources Estimation. J Acquir Immune Defic Syndr. 2024 Jan 1;95(1S):e34-e45. Available at: https://doi.org/10.1097/ QAI.0000000000003340

3. GBD 2021 HIV Collaborators. Global, regional, and national burden of HIV/AIDS, 1990-2021, and forecasts to 2050, for 204 coun-tries and territories: the Global Burden of Disease Study 2021. Lancet HIV. 2024 Dec;11(12):e807-e822. Available at: https://doi.org/10.1016/S2352-3018(24)00212-1

4. Čakalo JI, Božičević I, Vitek CR, Mandel JS, Salyuk TO, Rutherford GW. Misclassification of men with reported HIV infection in Ukraine. AIDS Behav. 2015;19:1938–40. Available at: https://doi.org/10.1007/s10461-015-1112-0

5. Dumchev K, Kornilova M, Kulchynska R, Azarskova M, Vitek C. Improved ascertainment of modes of HIV transmission in Ukraine indicates importance of drug injecting and homosexual risk. BMC Public Health 2020;20(1):1288. Available at: https://doi.org/10.1186/s12889-020-09373-2

6. Dumchev K, Stepanovich-Falke A, Lunchenkov N, Rohde A, Danshyna A, Bekbolotov A, et al. Comparison of registered and survey-based modes of HIV transmission in 2021-2023: Cross-sectional study in the Kyrgyz Republic. PLoS One. 2025 Aug 19;20(8). Available at: https://www.doi.org/10.1371/journal.pone.0330210

7. Hedrich D, Kalamara E, Sfetcu O, Pharris A, Noor A, Wiessing L, et al. Human immunodeficiency virus among people who inject drugs: is risk increasing in Europe? Euro Surveill. 2013;18(48). Available at: https://doi.org/10.2807/1560-7917

8. Giese C, Igoe D, Gibbons Z, Hurley C, Stokes S, McNamara S, et al. Injection of new psychoactive substance:snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2016. Euro Surveill. 2016;20(40). Available at: https://doi.org/10.2807/1560-7917

9. European Centre for Disease Prevention and Control (ECDC)/ European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). HIV in people who inject drugs – Joint technical mission to Luxembourg. Stockholm: ECDC/EMCDDA; 2018. Available at: https://sante.public.lu/fr/publications/h/hiv-joint-technical-mis-sion.html

10. McAuley A, Palmateer NE, Goldberg DJ, Trayner KMA, Shepherd SJ, Gunson RN, et al. Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis. Lancet HIV. 2019;6(5):e315–24. Available at: https://doi.org/10.1016/S2352-3018(19)30036-0

11. Des Jarlais DC, Sypsa V, Feelemyer J, Abagiu AO, Arendt V, Broz D, et al. HIV outbreaks among people who inject drugs in Europe, North America, and Israel. Lancet HIV. 2020;7(6):e434–42. Available at: https://doi.org/10.1016/S2352-3018(20)30082-5

12. World Health Organization (WHO). WHO information sheet. HIV statistics, globally and by WHO region, Geneva: WHO; 2025. Available at: https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/who-las-hiv-statistics_2025-new.pdf

13. World Health Organization (WHO). Guidelines on HIV self-testing and partner notification: supplement to consolidated guidelines on HIV testing services. Copenhagen: WHO; 2016. Available at: https://iris.who.int/handle/10665/251655

14. World Health Organization (WHO). Consolidated guidelines on HIV testing services: 2019. Geneva: WHO; 2020. Available at: https://iris.who.int/handle/10665/336323

15. European Centre for Disease Prevention and Control (ECDC). Public health guidance on HIV, hepatitis B and C testing in the EU/EEA. Stockholm: ECDC; 2018.

3 All references were accessed 13 November 2024.

Available at: www.ecdc.europa.eu/en/publications-data/public-health-guidance-hiv-hepatitis-b-and-c-testing-eueea

16. World Health Organization (WHO). Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. Geneva: WHO; 2022. Available at: https://iris.who.int/handle/10665/360348
17. UNAIDS. Global AIDS Strategy 2021–2026 End Inequalities. End AIDS. Geneva: UNAIDS; 2021. Available at: www.unaids.org/sites/default/files/media_asset/global-AIDS-strategy-2021-2026_en.pdf
18. World Health Organization (WHO) Regional Office for Europe. Regional action plans for ending AIDS and the epidemics of viral hepatitis and sexually transmitted infections 2022–2030. Copenhagen: WHO Regional Office for Europe; 2023. Available at: https://iris.who.int/handle/10665/369243
19. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: WHO; 2016. Available at: https://iris.who.int/handle/10665/208825
20. World Health Organization (WHO). Guidelines on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: WHO; 2015. Available at: https://iris.who.int/handle/10665/186275
21. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795–807. Available at: https://doi.org/10.1056/NEJMoa1506816
22. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. Available at: https://doi.org/10.1056/NEJMoa1105243
23. European Centre for Disease Prevention and Control (ECDC). Continuum of HIV care - Monitoring implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia: 2023 progress report. Stockholm: ECDC; 2024. Available at: https://www.ecdc.europa.eu/en/publications-data/hiv-continuum-care-monitoring-implementation-dublin-declaration-2023
24. HIV Transmission Elimination Amsterdam (H-TEAM) Initiative, Van Sighem A, Hendriks S, Deug F, Zantkuijl P, van Bergen JE, et al. A 95% decline in estimated newly acquired HIV infections, Amsterdam, 2010 to 2022. Euro Surveillance. 2023;28(40):2300515. Available at: https://doi.org/10.2807/1560-7917.ES.2023.28.40.2300515
25. Cambiano V, Miners A, Lampe FC, McCormack S, Gill ON, Hart G, et al. The effect of combination prevention strategies on HIV incidence among gay and bisexual men who have sex with men in the UK: a model-based analysis. Lancet HIV. 2023;10(11):e713–22. Available at: https://doi.org/10.1016/S2352-3018(23)00204-7
26. Hedrich D, Kalamara E, Sfetcu O, Pharris A, Noor A, Wiessing L, et al. Human immunodeficiency virus among people who inject drugs: is risk increasing in Europe? Euro Surveill. 2013;18(48). Available at: https://doi.org/10.2807/1560-7917.ES2013.18.48.20648
27. Giese C, Igoe D, Gibbons Z, Hurley C, Stokes S, McNamara S et al. Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2016. Euro Surveill. 2016;20(40). Available at: https://doi.org/10.2807/1560-7917
28. European Centre for Disease Prevention and Control (ECDC)/European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). HIV in people who inject drugs – joint technical mission to Luxembourg. Stockholm: ECDC/EMCDDA; 2018. Available at: https://sante.public.lu/fr/publications/h/hiv-joint-technical-mission.html
29. McAuley A, Palmateer NE, Goldberg DJ, Trayner KMA, Shepherd SJ, Gunson RN, et al. Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis, Lancet HIV. 2019;6(5):e315–24. Available at: https://doi.org/10.1016/S2352-3018(19)30036-0
30. Des Jarlais DC, Sypsa V, Feelemyer J, Abagiu AO, Arendt V, Broz D, et al. HIV outbreaks among people who inject drugs in Europe, North America, and Israel. Lancet HIV. 2020;7(6):e434–42. Available at: https://doi.org/10.1016/S2352-3018(20)30082-5.

Обзор эпидемиологической ситуации по ВИЧ/СПИДу в Европе

В настоящем отчете представлены данные эпид-надзора за ВИЧ-инфекцией/СПИДом в Европейском регионе Всемирной организации здравоохранения (ВОЗ) за 2024 г., которые демонстрируют значитель-ные различия в эпидемиологической ситуации и соответствующих тенденциях в пределах Региона. В 2024 г. в 49 из 53 стран Региона было зарегистри-ровано 105 922 новых случая ВИЧ-инфекции, в том числе 24 164 случая в странах Европейского союза/Европейской экономической зоны (ЕС/ ЕЭЗ). Это соответствует общему показателю в 11,8 случаев ВИЧ-инфекции на 100 000 населения, что незначи-тельно (на 7,8%) ниже показателя 2023 г. (12,8 на 100 000 населения) (таблица А; рис. А). Тем не менее, 11 из 49 стран все же сообщили о росте числа случаев ВИЧ-инфекции в 2024 г. по сравнению с 2023 г.

В странах ЕС/ ЕЭЗ этот показатель в 2024 г. соста-вил 5,3 на 100 000 населения, что на 14,5% меньше показателя 6,2 на 100 000 населения, который был отмечен в 2015 г.

При сравнении числа диагностированных случаев ВИЧ-инфекции с оценочным числом новых случаев ВИЧ-инфекции за последнее десятилетие становится очевидным, что в Регионе все больше людей живет с недиагностированной ВИЧ-инфекцией (рис. А). В странах ЕС/ ЕЭЗ тенденция отличается от тенденции

в Регионе в целом: число зарегистрированных диагностированных случаев несколько превышает оценочное число новых случаев инфекции.

В продолжение тенденции, которая сохраняется на протяжении последних двух десятилетий, показа-тели заболеваемости и общее число людей с впервые диагностированной ВИЧ-инфекцией были самыми высокими на востоке Региона (27,2 на 100 000 населения) и более низкими на западе и в странах ЕС/ ЕЭЗ (5,9 и 5,3 на 100 000 соответственно) и в центральной части Региона (5,3 на 100 000) (таблица А, рис. А). Во всех возрастных группах показатель новых случаев в Регионе был выше среди мужчин, чем среди женщин.

Пути передачи различаются в разных субрегионах, что свидетельствует о разнообразии эпидемиологической ситуации по ВИЧ-инфекции в Регионе. В целом, большинство новых случаев ВИЧ-инфекции в Европейском регионе связаны с гетеросексуальным путем передачи (70,3% всех случаев с известным путем передачи). Он по-прежнему остается основным путем передачи вируса на востоке Региона, и с годами его показатели растут. Аналогичным образом, в странах ЕС/ ЕЭЗ, а также в западной и центральной частях Региона гетеросексуальный путь передачи оставался одним из наиболее распространенных путей в 2024 г., особенно среди

Таблица А. Характеристики случаев ВИЧ-инфекции и СПИДа, зарегистрированных в Европейском регионе ВОЗ, в странах в западной, центральной и восточной частях Европейского региона ВОЗ и в странах ЕС/ЕЭЗ, 2024 г.

	Европейский регион ВОЗ	Западная часть	Центральная часть	Восточная часть	ЕС/ЕЭЗ
Количество стран, предоставивших данные/общее количество стран[a]	49/53	21/23	15/15	13/15	30/30
Число случаев ВИЧ-инфекции	105 922	26 124	10 506	69 292	24 164
Число случаев ВИЧ-инфекций на 100 000 населения	11,8	5,9	5,3	27,2	5,3
Доля (%) лиц в возрасте 15–24 лет	5,9%	8,6%	11,5%	4,1%	9,3%
Доля (%) лиц в возрасте 50+ лет	20,1%	21,5%	17,7%	20,0%	21,1%
Соотношение мужчин и женщин	1,9	2,3	4,6	1,6	2,8
Доля (%) мигрантов[b]	29,6%	57,5%	15,4%	1,9%	47,2%
Путь передачи[c]					
Половые контакты между мужчинами	14,7%	43,9%	37,9%	4,2%	48,3%
Гетеросексуальная передача (мужчины)	36,9%	22,4%	40,4%	41,2%	21,8%
Гетеросексуальная передача (женщины)	33,4%	27,9%	16,8%	36,2%	23,8%
Употребление инъекционных наркотиков	14,2%	3,7%	3,6%	18,1%	4,7%
Передача от матери ребенку	0,7%	1,6%	1,2%	0,3%	1,1%
Неизвестен	10,8%	23,6%	52,8%	2,4%	27,3%
Случаи СПИДа и поздней стадии ВИЧ-инфекции					
Доля (%) случаев ВИЧ-инфекция, CD4 < 350 кл/мм3[d]	54,2%	47,0%	56,5%	62,4%	48%
Число случав СПИДа[e]	7 161	1 718	938	4 505	2 215
Число случаев СПИДа на 100 000 населения	1,2	0,6	0,5	4,4	0,7

[a] Отсутствуют данные из следующих стран: Андорра, Монако, Туркменистан и Узбекистан.
[b] Согласно используемому определению, мигранты – это лица, родившиеся за пределами страны, в которой им был поставлен диагноз.
[c] Среди тех, у кого известен путь передачи ВИЧ-инфекции.
[d] Дети в возрасте до 15 лет и лица с ранее известным положительным ВИЧ-статусом исключаются как из числителя, так и из знаменателя. Случаи, классифицированные как недавнее инфицирование, исключаются из числителя показателя поздней диагностики, если уровень CD4 <350 клеток/мм³, но остаются в знаменателе.
[e] Отсутствуют данные отчетности из следующих стран: Андорра, Беларусь, Германия, Испания, Кипр, Лихтенштейн, Монако, Российская Федерация, Туркменистан, Узбекистан и Швеция.

мигрантов или лиц с ранее известным положитель-ным ВИЧ-статусом[4]. На западе Региона среди тех, кто сообщил о гетеросексуальной передаче вируса, 31% уже были диагностированы ранее, а 73% явля-лись мигрантами, родившимися за рубежом. Секс между мужчинами по-прежнему является наиболее распространенным путем передачи вируса в странах ЕС/ ЕЭЗ: на его долю приходится 48% зарегистриро-ванных случаев с известным путем передачи. Секс между мужчинами также был преобладающим путем передачи инфекции в восьми из пятнадцати стран

4 Случай с ранее известным положительным ВИЧ-статусом – это случаи ВИЧ-инфекции, выявленный за рубежом или в другом учреждении в стране, предоставляющей данные отчетности, в любое время до текущего отчетного года. Некоторые страны предоставляют данные о ранее известном положительном ВИЧ-статусе на момент появления или повторного появления пациента в системе здравоохранения страны, предоставляющей данные отчетности.

центральной части Региона. Доля инфицирования при приеме инъекционных наркотиков в качестве указанного пути передачи продолжает снижаться: в восточной части Региона примерно каждый пятый (18%) случай ВИЧ-инфицирования с известным путем передачи был связан с инъекционным употребле-нием наркотиков.

В 2024 г. более половины (54%) случаев ВИЧ-инфекции в Европейском регионе было выявлено на поздней стадии инфекции (CD4 <350 клеток/мм3на момент постановки диагноза). Этот процент был самым высоким в восточной части Региона (62%), ниже в центральной (57%) и самым низким в западной части (47%), тогда как в ЕС/ ЕЭЗ 48% случаев было диагностировано на поздней стадии (таблица А).

Рисунок А. Оценочное число новых случаев и число зарегистрированных случаев ВИЧ-инфекции в ЕС/ЕЭЗ и Европейском регионе ВОЗ, 2015–2024 гг.



Примечание: затененная область представляет интервалы неопределенности вокруг лучшей оценки. По причине нерегулярного предоставления данных или отсутствия данных в отчетном периоде были исключены данные следующих стран: Андорра, Монако, Сан-Марино, Туркменистан и Узбекистан.
Данные об оценочном числе новых случаев ВИЧ-инфекции взяты из оценок ЮНЭЙДС/ВОЗ за 2025 г.

Рисунок В. Доля лиц с поздним диагнозом (CD4 < 350 кл/мм3) с разбивкой по полу, возрасту и пути передачи, Европейский регион ВОЗ, 2024 г. (n = 27 871)



Примечание: Дети до 15 лет и лица с ранее известным положительным ВИЧ-статусом исключаются как из числителя, так и из знаменателя. Случаи, классифицированные как недавнее инфицирование, исключаются из числителя показателя поздней диагностики, если CD4 <350/мм3, но включаются в знаменатель. Данные о числе клеток CD4, представленные Российской Федерацией, не включают информацию о предыдущем или недавнем инфицировании, а также разбивку по путям передачи и, следовательно, исключаются из субрегиональных и региональных итогов. Отсутствуют данные из следующих стран: Андорра, Монако, Туркменистан и Узбекистан. Ни одного случая не было зарегистрировано в Лихтенштейне и Сан-Марино .

Процент людей, диагностированных на поздней стадии ВИЧ-инфекции, варьируется в зависимости от путей передачи инфекции и возрастных групп, при этом самые высокие показатели наблюдаются среди людей, инфицированных при гетеросексуальных контактах (особенно среди мужчин), людей, употребляющих инъекционные наркотики, и в старших возрастных группах (рис. B).

В 2024 г. в 43 странах Европейского региона ВОЗ СПИД был диагностирован у 7 161 человека (таблица A). Общий уровень заболеваемости СПИДом в Регионе снизился на 53% в период с 2015 по 2024 г.: с 2,5 на 100 000 населения (14 756 случаев) до 1,2 на 100 000. Эта тенденция к снижению наблюдается во всех субрегионах Европейского региона ВОЗ, вклю-чая страны ЕС/ ЕЭЗ.

Европейский союз и Европейская экономическая зона

В 2024 г. в 30 странах ЕС/ ЕЭЗ было зарегистрировано в общей сложности 24 164 новых случая ВИЧ-инфекции, что соответствует показателю 5,3 на 100 000 населения. Этот показатель снизился на 14,5% по сравнению с 2015 г., когда он составлял 6,2 на 100 000 населения (таблица 1). Отчасти это сниже-ние может быть связано с задержкой регистрации случаев, поскольку 48% новых зарегистрирован-ных случаев были случаями поздней диагностики (таблица 12).

Как и в предыдущие годы, заболеваемость ВИЧ-инфекцией в 2024 г. была выше у мужчин, чем у женщин: 17 606 случаев среди мужчин и 6 260 среди женщин, и соотношение заболеваемости у муж-чин и у женщин составило 2,8 (рис. 1.1; таблица 2; таблица 3). Кроме того, восемь стран сообщили о 218 случаях ВИЧ-инфекции у людей, которые само-идентифицировали себя как трансгендеры (0,9%), а в отношении 80 человек (0,3%) гендерный статус был неизвестен.

Самый высокий повозрастной показатель заболеваемости был отмечен в возрастной группе 25–29 лет (13,2 на 100 000 населения). Среди мужчин наивысший показатель был в возрастной группе 25–29 лет (20,5 на 100 000 населения), а среди женщин – в возрастной группе 30–39 лет (6,6 на 100 000 населения) (рис. 1.2).

В 2024 г. секс между мужчинами был наиболее распространенным путем передачи ВИЧ в ЕС/ ЕЭЗ: на его долю пришлось 48,3% (8 614) новых слу-чаев ВИЧ-инфекции. По сравнению с 52,9% (11 812) в 2015 г. эта доля снизилась на 7,5% (таблица 4, рис. 1.16b). После исключения случаев с неиз-вестным регионом происхождения и стран, не предоставивших соответствующую информацию для отчетности, было отмечено, что 53,2% (4 312) мужчин, практикующих секс с мужчинами (МСМ), у которых

была диагностирована ВИЧ-инфекция, родились в стране, предоставившей отчетность, а 46,8% (3 788) были мигрантами (согласно определению, это люди, родившиеся за пределами страны, предоставившей отчетность) (рис. 1.17). С 2015 по 2024 г. число новых случаев ВИЧ-инфекции среди МСМ-мигрантов увеличилось на 25,4%, тогда как число новых случаев ВИЧ-инфекции среди МСМ, родившихся в странах, предоставляющих отчетные данные, снизилось на 45,7% (рис. 1.17).

Гетеросексуальный путь был вторым по распространенности путем передачи ВИЧ-инфекции в ЕС/ ЕЭЗ: на его долю пришлось 45,7% (8 115) новых слу-чаев с известным путем инфицирования (рис. 1.5; таблица 6; таблица 8). В период с 2015 по 2024 г. доля новых случаев ВИЧ-инфекции, обусловленных гетеросексуальной передачей, выросла с 40,9% до 45,6% (рис. 1.16b). Этот рост был умеренным среди мужчин (с 20,4% до 21,8%) и более значительным среди женщин – с 20,5% до 23,8%. В целом, 35,3% (2863) новых случаев, связанных с гетеросексуальными контактами, было выявлено среди уроженцев стран, предоставивших отчетные данные, а большая часть случаев (61,4%, 4985) – среди мигрантов (таблица 11). В период с 2015 по 2024 г. число новых случаев среди гетеросексуальных мигрантов увеличилось на 4,5%, тогда как среди уроженцев стран, предоставивших отчетные данные, снижение составило 2,9% (рис. 1.17).

В 2024 г. передача ВИЧ-инфекции через инъекционное употребление наркотиков обусловила появление 4,7% (846) случаев от общего числа случаев заражения с известным путем передачи (рис. 1.5, таблица 5). Со временем эта доля несколько сократилась: с 5,1% в 2015 г. до 4,7% в 2024 г. (рис. 1.16b). Около половины людей, которым в 2024 г. был поставлен диагноз ВИЧ-инфекции, приобретенной вследствие инъекционного употребления наркотиков, были уроженцами стран, предоставивших отчетные данные (431, 50,9%) (таблица 11).

Передача ВИЧ-инфекции от матери ребенку (ПМР) во время беременности, при родах или лактации привела к появлению 1,1% (196) случаев от всех новых случаев ВИЧ-инфекции с известным путем передачи (таблица 7; таблица 8). Из общего числа новых случаев, где путь передачи был связан с ПМР, 75% (147) было выявлено среди мигрантов, из них 41,8% (82) – среди выходцев из стран Африки к югу от Сахары (таблица 11).

В 2024 г. в ЕС/ ЕЭЗ 55,7% (11 401) людей с диагностированной ВИЧ-инфекцией и известным регионом происхождения были мигрантами (рис. 1.6). Из них 32,2% были выходцами из стран Африки к югу от Сахары, 26,4% – из Центральной или Восточной Европы, 24,4% – из стран Латинской Америки и Карибского бассейна, 5,3% – из Южной и Юго-Восточной Азии, 5,2% – из Западной Европы и 6,5% – из других регионов (таблица 10). В стра-нах ЕС/ ЕЭЗ доля мигрантов с известным регионом

происхождения среди зарегистрированных случаев ВИЧ-инфекции выросла с 38,3% в 2015 г. до 55,7% в 2024 г.

Данные о количестве CD4-клеток на момент диагностирования ВИЧ-инфекции были доступны в отношении 11 796 (63,9%) человек в возрасте ≥15 лет, диагноз которым был поставлен в 27 странах (таблица 12). Почти у половины из этих людей (48,0%) диагноз был поставлен спустя несколько лет после заражения, о чем свидетельствовало количество CD4-клеток ниже 350 клеток/мм³. Данная популяция включала в себя 30,6% лиц с ВИЧ-инфекцией про-двинутой стадии (число CD4 менее 200 клеток/мм³) (таблица 8). Поздняя диагностика (число CD4 менее 350 клеток/мм³) чаще всего наблюдалась среди женщин (51,6%), пожилых людей (до 61,3%), лиц, инфицированных гетеросексуальным путем (59,9% мужчин и 52,6% женщин) и лиц, употребляющих инъекционные наркотики (ЛУИН) (52,4%), а также выходцев из Южной и Юго-Восточной Азии (52,7%) и стран Африки к югу от Сахары (53,8%) (рис. 1.8).

Из 218 трансгендерных людей с ВИЧ-инфекцией, диагностированной в 2024 г. в семи странах ЕС/ ЕЭЗ, 85,4% были мигрантами, в основном из стран Латинской Америки и Карибского бассейна. Среди тех, в отношении кого были получены данные о количестве CD4-клеток, 31,8% случаев были диа-гностированы после недавнего заражения, а 33,0% диагностированы на поздней стадии (число CD4 <350 клеток/мм³) (рис. 1.8).

В 2024 г. в 25 странах ЕС/ ЕЭЗ было зарегистрировано 2215 случаев СПИДа, что соответствует общему показателю заболеваемости 0,7 на 100 000 населе-ния (таблица 13). За последнее десятилетие уровень заболеваемости СПИДом снизился на 30,0%. В 2024 г. пневмоцистная пневмония (Pneumocystis jirovecii) была наиболее частым СПИД-индикаторным заболеванием (22,4% случаев), а туберкулез (легочный и внелегочный) был зарегистрирован у 11,7% случаев (таблица 16). В 2024 г. в 25 странах было зафиксировано в общей сложности 579 случаев смерти от СПИДа, хотя эта цифра, вероятно, занижена (таблица 17).

В целом, 13 стран систематически предоставляли данные о тестировании на ВИЧ, проведенном в период с 2015 по 2024 г., за исключением несвязанного анонимного тестирования и тестирования доноров крови. Количество тестов, проведенных в странах, систематически предоставляющих данные о тестировании, увеличилось на 16,9% по сравнению с 2022 г. и на 9,6% по сравнению с 2023 г., что отражает общее увеличение показателей тестирования на 31,6% за весь период.

Европейский регион ВОЗ

В 2024 г. в Европейском регионе ВОЗ ВИЧ-инфекция была диагностирована у 105 922 человек, что соответствует показателю 11,8 на 100 000 населения. С 1980-х годов было зарегистрировано более 2,68

миллиона новых случаев ВИЧ-инфекции. Большая часть из них приходится на восточную часть Региона (66%), за ней следуют западная (25%) и центральная части (10%). Самый высокий показатель новых случаев ВИЧ-инфекции был зафиксирован в восточной части Региона (27,2 на 100 000), что в пять раз превышает показатели западной или центральной части (см. таблицу А).

ВИЧ-инфекция диагностировалась у мужчин почти вдвое чаще, чем у женщин (соотношение этого показателя у мужчин и женщин = 1,9), при этом наименьшие показатели регистрировались в восточной части Региона (1,6), за которой следовала западная (2,3) и далее – центральная часть с наивысшими показателями (4,6). Наибольшее число новых случаев было выявлено в возрастных группах 30–39 и 40–49 лет (по 32% в каждой).

Показатели на 100 000 населения в 2024 г. значительно различались по странам. Самые высокие показатели (> 15,0 на 100 000 населения) были зарегистрированы в Армении, Грузии, Ирландии, Казахстане, Кыргызстане, Мальте, Республике Молдова, Российской Федерации и Украине, а самые низкие (≤ 3,0 на 100 000 населения) – в Австрии, Боснии и Герцеговине, Венгрии, Северной Македонии, Сербии, Словакии, Словении, Хорватии и Швеции.

В период с 2015 по 2024 г. показатель новых случаев ВИЧ-инфекции в Европейском регионе ВОЗ снизился с 18,3 до 11,8 на 100 000 населения, причем резкое падение произошло в 2020 г., что было связано с пандемией COVID-19. После временного восстановле-ния в период с 2021 по 2023 г. этот показатель вновь снизился в 2024 г. С 2015 г. число новых случаев ВИЧ-инфекции как среди мужчин, так и среди женщин сократилось примерно на треть.

Снижение в годовом исчислении наблюдалось во всех субрегионах, за исключением центрального, где этот показатель увеличился с 4,3 до 5,3 на 100 000 населения. Этот рост был обусловлен, главным образом, за счет показателей Турции, где в 2024 г. число новых случаев ВИЧ-инфекции увеличилось на 67% по сравнению с 2023 г. По данным, предоставленным национальным координатором, такой резкий прирост был обусловлен в основном усилением эпиднадзора и расширением возможностей тестирования, а не реальным ростом числа случаев передачи инфекции. В целом, 11 из 49 стран сообщили о росте числа новых случаев ВИЧ-инфекции в 2024 г. по сравнению с 2023 г.

В 2024 г. гетеросексуальный путь передачи ВИЧ-инфекции оставался преобладающим: на его долю пришлось 70% от числа диагностированных слу-чаев с известным путем передачи. Секс между мужчинами обусловил появление 15% случаев, а употребление инъекционных наркотиков – 14%.

Распространенность передачи ВИЧ-инфекции от

матери ребенку (0,7%) и другими путями, такими как переливание крови (0,1%), оставалась низкой.

На востоке Региона гетеросексуальные контакты составили три четверти случаев, а инъекционное употребление наркотиков – 18%. В центральной части Региона гетеросексуальный путь передачи стал причиной появления 57% случаев с известным путем передачи, а секс между мужчинами – 38%. На западе Региона основными путями заражения среди случаев с известным путем передачи были гетеросексуаль-ный путь (50%) и секс между мужчинами (44%). В целом в Регионе преобладающей возрастной группой среди лиц, инфицированных в результате употребле-ния инъекционных наркотиков и гетеросексуальной передачи, была группа 40–49 лет, в то время как мужчины, практикующие секс с мужчинами (МСМ), в основном были в возрасте 30–39 лет.

Тенденции в путях передачи показали продолжающийся сдвиг в сторону гетеросексуального пути[5]. В период с 2015 по 2024 г. доля случаев этого типа передачи выросла с 52% до 64%, в то время как доля случаев передачи ВИЧ-инфекции среди МСМ снизилась с 32% до 26%, а среди лиц, употребляющие инъекционные наркотики – с 15% до 9%. Сохранились региональные различия: на востоке Региона употребление инъекционных наркотиков сократилось вдвое; в центральной части в 2021 г. передача вируса гетеросексуальным путем превысила показатели передачи среди МСМ, а на западе Региона передача вируса среди МСМ снизилась на 38% с 2015 г. Тем не менее, передача вируса среди МСМ по-прежнему оставалась основным путем передачи ВИЧ-инфекции в восьми из пятнадцати стран Центральной Азии. В то же время гетеросексуальный путь передачи был преобладающим у людей, родившихся за пределами стран западной части Региона, которые предоста-вили данные отчетности.

Почти треть (29,6%) всех новых случаев ВИЧ-инфекции в 2024 г. были зарегистрированы среди людей, родившихся за пределами стран, предоставляющих отчетность, – это небольшое снижение по сравнению с 2023 г. Большая часть новых случаев ВИЧ-инфекции среди людей иностранного происхождения была зарегистрирована среди выходцев из стран Африки к югу от Сахары (40%), Центральной и Восточной Европы (23%), Латинской Америки и Карибского бассейна (19%), а также других регионов (17%), при этом большинство случаев сосредоточено в странах ЕС/ ЕЭЗ и Соединенном Королевстве.

Данные о количестве CD4-клеток на момент постановки диагноза показали, что у 54% пациентов диагноз был поставлен с запозданием (CD4 <350 кле-ток/мм³), в том числе у 33% пациентов с продвинутой ВИЧ-инфекцией (CD4 <200 клеток/мм³). Поздняя диагностика чаще всего встречалась среди инфицированных гетеросексуальным путем (61%) и реже

5 В анализ включены только те страны, которые на протяжении последнего десятилетия постоянно предоставляли данные о путях передачи ВИЧ-инфекции.

всего среди мужчин, практикующих секс с мужчинами (МСМ) (41%). Показатели поздней диагностики были выше в странах в восточной части Региона (62%), чем в центральной (57%) и западной (47%) частях, и увеличивались с возрастом, достигая 66% среди лиц в возрасте ≥50 лет.

В 2024 г. СПИД был диагностирован у 7161 человека (1,2 на 100 000 населения), причем большинство случаев выявлено в восточной части Региона (63%). Самый высокий показатель заболеваемости СПИДом был отмечен в восточной части Региона (4,4 на 100 000 населения), что в семь-девять раз выше, чем в других субрегионах. На долю туберкулеза приходилось 16% от общего числа СПИД-индикаторных заболеваний. Хотя уровень заболеваемости СПИДом в Регионе снизился на 53% – с 2,5 до 1,2 на 100 000 населения – в период с 2015 по 2024 г. это снижение различалось в зависимости от субрегиона.

Выводы

Данные эпиднадзора за ВИЧ-инфекцией за 2024 г. свидетельствуют о сохраняющейся неоднородности эпидемических моделей и тенденций в Европейском регионе ВОЗ. После трех лет непрерывного роста (2021–2023 гг.) показатель зарегистрированных новых случаев ВИЧ-инфекции в 2024 г. снизился до 11,8 на 100 000 населения, что на 7,8% меньше, чем в 2023 г. Однако эта общая тенденция скрывает значительные субрегиональные различия. В целом снижение обусловлено преимущественно Российской Федерацией, на долю которой приходится большинство случаев ВИЧ-инфекции в Регионе, и где с 2019 г. число случаев сократилось на 40%. В западной части Региона корректировки с учетом задержки в отчетности не применялись, и улучшение отчетности после пандемии COVID-19, возможно, временно завы-сило число случаев в предыдущие годы. Отчасти это снижение может быть отражением артефактов отчет-ности, а не истинного снижения эпидемиологических показателей. Поэтому такое общее снижение следует интерпретировать с осторожностью. В то же время, в 11 из 49 стран в 2024 г. зафиксирован рост числа новых случаев ВИЧ-инфекции по сравнению с 2023 г.

Разрыв между числом зарегистрированных новых случаев ВИЧ-инфекции и оценочным числом новых случаев свидетельствует о том, что число людей, инфицированных ВИЧ, превышает число диагностированных случаев, и это указывает на рост числа недиагностированных людей, живущих с ВИЧ, в Регионе. В ЕС/ ЕЭЗ, напротив, число зарегистрированных новых случаев ВИЧ-инфекции несколько превышает оценочное число новых случаев инфицирования. Этот увеличивающийся разрыв отражает сохраняющиеся трудности с выявлением случаев и направлением их в систему оказания медицинской помощи, особенно в восточной части Региона [1].

На региональном уровне наблюдается общая тенденция к росту показателей гетеросексуальной передачи и при этом отмечается снижение показателей передачи

инфекции через половые контакты между мужчи-нами и инъекционное употребление наркотиков. Однако эти тенденции крайне неоднородны в разных субрегионах и зависят от различий в практиках эпид-надзора и эпидемиологической ситуации.

Основным путем передачи инфекции в восточной части Региона остается гетеросексуальный путь, демонстрирующий в динамике тенденцию к росту, при этом зарегистрированный уровень передачи инфекции половым путем между мужчинами в абсолютном выражении остается низким. Эта зако-номерность не объясняет наблюдаемый с течением времени рост соотношения показателей у мужчин и женщин [2,3]. Имеющиеся данные свидетельствуют о том, что часть мужчин, зарегистрированных как инфицированные гетеросексуальным путем, на самом деле могут быть мужчинами, практикующими секс с мужчинами (МСМ), или людьми с историей употребления инъекционных наркотиков, которые были ошибочно классифицированы как инфицированные гетеросексуальным путем [4-6].

В центральной части Региона, несмотря на растущую долю гетеросексуальной передачи ВИЧ-инфекции, восемь из пятнадцати стран сообщили, что секс между мужчинами является преобладающим путем передачи. Уровень передачи инфекции, связанной с инъекционным употреблением наркотиков, в целом остается низким, но прошлые вспышки подчеркивают необходимость постоянной бдительности [7–11]. Доля молодых людей среди новых случаев ВИЧ-инфекции остается относительно высокой: почти каждый тре-тий из впервые выявленных моложе 30 лет.

В западной части Региона модели передачи ВИЧ-инфекции во многом зависят от случаев инфицирования среди мигрантов и лиц с ранее диагностированной ВИЧ-инфекцией. Барьеры, связанные с миграцией, в том числе различия в схемах антиретровирусной терапии, перерывы в оказании медицинской помощи во время миграции, языковые барьеры, неопределенный статус проживания и стигматизация, могут препятствовать своевременному доступу к лечению ВИЧ-инфекции и непрерывности терапии.

В Регионе более чем у половины впервые диагностированных людей уровень CD4-клеток был ниже 350 клеток/мм^3, включая треть случаев с продвинутой стадией ВИЧ-инфекции (<200 клеток/мм^3). Поздняя диагностика по-прежнему наиболее распространена среди гетеросексуальных мужчин, потребителей инъекционных наркотиков и пожилых людей, а ее показатели демонстрируют значительную географическую вариабельность. Эти тенденции указывают на сохраняющиеся трудности в обеспечении своевременной диагностики и раннего начала лечения.

Неполнота данных по-прежнему ограничивает интерпретацию региональных тенденций. В 2024 г. 16 стран не предоставили информацию, позволяющую отличить новые случаи от ранее выявленных случаев

с положительным ВИЧ-статусом, а 13 из 49 стран сообщили о менее чем 50-процентном охвате тестированием с целью определения уровня CD4-клеток на момент постановки диагноза. Достижение консенсуса среди государств-членов относительно стандартных подходов к учету и отчетности по ранее выявленным случаям с положительным ВИЧ-статусом сохраняет свою актуальность для обеспечения точности данных эпиднадзора и их интерпретации.

По оценкам, в Европейском регионе ВОЗ 3,2 миллиона человек (95% ДИ: 2,8–3,4 миллиона) живут с ВИЧ, и около 63% из них получают антиретровирусную терапию (АРТ). В 2024 г. данные о числе людей с диагностированной ВИЧ-инфекцией и числе людей с подавленной вирусной нагрузкой не были получены из-за отсутствия в ряде стран актуальных смоделиро-ванных расчетных данных [12].

С момента принятия Региональных планов дей-ствий по ликвидации СПИДа и эпидемий вирусных гепатитов и заболеваний, предаваемых половым путем, на 2022–2030 гг. Европейское региональное бюро ВОЗ, ЕЦКЗ и партнеры оказывают поддержку государствам-членам в укреплении процессов реализации на уровне стран мер политики, основанных на фактических данных, для расширения масштабов профилактики, тестирования, лечения и помощи в связи с ВИЧ, а также мероприятий по усилению эпиднадзора и анализу данных.

Меры по борьбе с эпидемией должны быть основаны на фактических данных и адаптированы к национальной и местной эпидемиологической ситуации. В настоящем отчете представлен обширный обзор эпидемиологической ситуации по ВИЧ-инфекции, в котором указывается, что приоритетными должны стать нижеследующие меры реагирования.

- **Во всех странах Европейского региона ВОЗ** следует ускорить расширение масштабов тестирования на ВИЧ для сокращения разрыва в показателях недиа-гностированных случаев инфекции и достижения целевых ориентиров 95–95–95. Стратегии тестиро-вания на ВИЧ должны включать самотестирование, тестирование на уровне местных сообществ и тести-рование, проводимое обученными лицами без специального образования, с быстрой постановкой на диспансерный учет [13–15]. Услуги и стратегии по тестированию на ВИЧ должны основываться на имеющихся данных, описывающих местную эпидемиологическую ситуацию и определяющих целевые ключевые группы населения. Стратегии должны учитывать конкретные потребности этих групп насе-ления и способствовать своевременному доступу к услугам по профилактике, лечению и помощи в связи с ВИЧ. Это обеспечит более раннюю диагно-стику и начало лечения, что приведет к улучшению результатов терапии и снижению заболеваемости, смертности и распространенности ВИЧ в поддержку достижения целевых ориентиров 95–95–95 и других региональных и глобальных целей [16–18]. Убедительные данные свидетельствуют о том, что

раннее начало антиретровирусной терапии (АРТ) благоприятно влияет на здоровье человека и предотвращает дальнейшую передачу ВИЧ-инфекции [19–22]. Почти в 90% стран Европейского региона ВОЗ действует политика, согласно которой АРТ назначается сразу после постановки диагноза ВИЧ-инфекции, независимо от количества клеток CD4 [23]. Необходимо улучшать охват тестированием и удержание пациентов в системе оказания медицинской помощи, обеспечивать всеобщий доступ к лечению ВИЧ-инфекции и бороться со стигмой и дискриминацией в системе здравоохранения, повышать качество эпиднадзора при более качественном учете случаев с ранее установленным положительным ВИЧ-статусом и регистрации количества клеток CD4 на момент постановки диагноза и страны рождения/происхождения, чтобы эти сведения использовались в качестве основы для планировании мер профилактики.

• **В ЕС/ ЕЭЗ и странах западной части Региона** следует расширять первичную профилактику для ключевых групп населения, включая раздачу презервативов, всестороннее сексуальное просвещение и доступ к доконтактной профилактике (ДКП), интеграцию ДКП с плановым тестированием и постановкой на диспансерный учет. Данные указывают на то, что эти меры способны снизить заболеваемость ВИЧ-инфекцией среди групп населения с наибольшим риском инфицирования [24–25]. Необходимо решать проблему растущей доли случаев ВИЧ-инфекции среди мигрантов, обеспечивая всеобщий доступ к услугам тестирования, профилактики и лечения независимо от места жительства или миграционного статуса. Важно усиливать меры, принимаемые на уровне местных сообществ с учетом культурных особенностей, для расширения масштабов тестирования среди мигрантов-МСМ и других ключевых групп; нормализовывать тестирование и расширять его масштабы посредством регулярных предложений тестирования всем тем, кто не выразил несогласия, в учреждениях первичной медико-санитарной помощи, неотложной и дородовой помощи; расширять услуги на уровне местных сообществ, социально-ориентированные и мобильные услуги, а также сделать самотестирование и взятие образцов на дому широкодоступными и недорогими. Также следует предоставлять дополнительные услуги группам населения, недостаточно охваченным тестированием (таких как мигранты, гетеросексуальные мужчины и женщины, пожилые люди), с использованием подходов, адаптированных к культурным и языковым особенностям, с доступом к медицинскому обслуживанию и тестированию в сообществах с учетом потребностей мигрантов, а также к тестированию по показателям состояния здоровья, которое заключается в предложении теста на ВИЧ людям с показателями состояния здоровья, характерными для ВИЧ-инфекции, независимо от заявленных факторов риска. Необходимо сокращать структурные барьеры для тестирования

путем отмены платы за услуги, упрощения критериев отбора и защиты конфиденциальности, а также борьбы со стигматизацией посредством обучения медицинских работников и проведения общественных кампаний.

- **В странах центральной части Региона** следует поддерживать усилия по борьбе с ростом гетеросексуальной передачи инфекции, признавая при этом, что секс между мужчинами остается основным путем передачи инфекции в более чем половине стран. Важно расширять дифференцированные услуги по тестированию на ВИЧ и обеспечивать своевременное начало доконтактной профилактики (ДКП) и антиретровирусной терапии (АРТ); поддерживать услуги по снижению вреда для людей, употребляющих инъекционные наркотики, с целью предотвращения будущих вспышек [26–30]; обеспечивать проведение программ профилак-тики и тестирования на ВИЧ, ориентированных на молодежь, поскольку почти треть новых случаев ВИЧ-инфекции регистрируется среди молодых людей. Необходимо способствовать вовлечению гражданского общества на всех этапах борьбы с ВИЧ, от профилактики до соблюдения режима лечения, и решать задачи обеспечения устойчивости после перехода от внешнего к внутреннему финансированию мероприятий по борьбе с ВИЧ; укреплять трансграничное сотрудничество и обмен данными, а также обеспечивать всеобщую доступность услуг, предоставляемых в связи с ВИЧ, беженцам и мигрантам вне зависимости от их статуса проживания.

- **В странах восточной части Региона** следует продолжать расширение масштабов проведения обоснованных фактическими данными мероприятий для ключевых групп населения и предоставлять более эффективные, ориентированные на нужды людей и комплексные услуги, которые лучше учитывают социальные детерминанты здоровья и снижают стигматизацию и дискриминацию; расширять масштабы тестирования на ВИЧ и выявления случаев заболевания, интегрируя в национальные программы и систему оказания медицинской помощи помощь в уведомлении партнера о ВИЧ-статусе, самотестирование и тестирование на уровне местных сообществ, в том числе с привлечением работников без специального образования. Нужны комплексные стратегии комбинированной профилактики, ориентированные на ключевые группы населения, в том числе на потребителей инъекционных наркотиков, мужчин, практикующих секс с мужчинами, и гетеросексуальные пары, в которых один из партнеров характеризуется поведением, сопряженным с повышенным риском. Важно укреплять программы снижения вреда и лечения опиоидными агонистами для достижения широкого охвата потребителей инъекционных наркотиков, расширять доступ к доконтактной профилактике (ДКП), диверсифицировать варианты доконтактной профилактики (ДКП) и обеспечивать отход от чисто

медицинских моделей предоставления услуг, поддерживать участие сообществ в разработке и предоставлении услуг для расширения их доступности и удержания пациентов в системе оказания медицинской помощи, а также для снижения заболеваемости ВИЧ-инфекцией и смертности в связи со СПИДом.

ВОЗ и ЕЦКЗ совместно с партнерами продолжат оказывать поддержку государствам-членам в их усилиях по ускорению прогресса на пути к достижению Целей в области устойчивого развития в отношении ВИЧ посредством специальных рекомендаций, рабочих совещаний, обучения, вебинаров и другой технической поддержки, ориентированной на высокоэффективные мероприятия по эпиднадзору, мониторингу, лечению и профилактике.

Библиография[6]

1. UNAIDS. Regional Profile of Eastern Europe and Central Asia. UNAIDS; 2025. Available at: https://www.unaids.org/sites/default/files/2025-07/2025-global-aids-update-eeca.pdf

2. Korenromp EL, Sabin K, Stover J, Brown T, Johnson LF, Martin-Hughes R, et al. New HIV Infections Among Key Populations and Their Partners in 2010 and 2022, by World Region: A Multisources Estimation. J Acquir Immune Defic Syndr. 2024 Jan 1;95(1S):e34–e45. Available at: https://doi.org/10.1097/QAI.0000000000003340

3. GBD 2021 HIV Collaborators. Global, regional, and national burden of HIV/AIDS, 1990-2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021. Lancet HIV. 2024 Dec;11(12):e807-e822. Available at: https://doi.org/10.1016/S2352-3018(24)00212-1

4. Čakalo JI, Božičević I, Vitek CR, Mandel JS, Salyuk TO, Rutherford GW. Misclassification of men with reported HIV infection in Ukraine. AIDS Behav. 2015;19:1938–40. Available at: https://doi.org/10.1007/s10461-015-1112-0

5. Dumchev K, Kornilova M, Kulchynska R, Azarskova M, Vitek C. Improved ascertainment of modes of HIV transmission in Ukraine indicates importance of drug injecting and homosexual risk. BMC Public Health 2020;20(1):1288. Available at: https://doi.org/10.1186/s12889-020-09373-2

6. Dumchev K, Stepanovich-Falke A, Lunchenkov N, Rohde A, Danshyna A, Bekbolotov A, et al. Comparison of registered and survey-based modes of HIV transmission in 2021-2023: Cross-sectional study in the Kyrgyz Republic. PLoS One. 2025 Aug 19;20(8). Available at: https://www.doi.org/10.1371/journal.pone.0330210

7. Hedrich D, Kalamara E, Sfetcu O, Pharris A, Noor A, Wiessing L, et al. Human immunodeficiency virus among people who inject drugs: is risk increasing in Europe? Euro Surveill. 2013;18(48). Available at: https://doi.org/10.2807/1560-7917

8. Giese C, Igoe D, Gibbons Z, Hurley C, Stokes S, McNamara S, et al. Injection of new psychoactive substance 'snow blow' associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2016. Euro Surveill. 2016;20(40). Available at: https://doi.org/10.2807/1560-7917

9. European Centre for Disease Prevention and Control (ECDC)/ European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). HIV in people who inject drugs – Joint technical mission to Luxembourg. Stockholm: ECDC/EMCDDA; 2018. Available at: https://sante.public.lu/fr/publications/h/hiv-joint-technical-mission.html)

10. McAuley A, Palmateer NE, Goldberg DJ, Trayner KMA, Shepherd SJ, Gunson RN, et al. Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis. Lancet HIV. 2019;6(5):e316–24. Available at: https://doi.org/10.1016/S2352-3018(19)30036-0

11. Des Jarlais DC, Sypsa V, Feelemyer J, Abagiu AO, Arendt V, Broz D, et al. HIV outbreaks among people who inject drugs in Europe, North America, and Israel. Lancet HIV. 2020;7(6):e434–42. Available at: https://doi.org/10.1016/S2352-3018(20)30082-5

12. World Health Organization (WHO). WHO information sheet. HIV statistics, globally and by WHO region. Geneva: WHO; 2025. Available at: https://cdn.who.int/media/docs/default-source/ hq-hiv-hepatitis-and-stis-library/who-ias-hiv-statistics_2025-new.pdf

6 Все ссылки состоянию на 13 ноября 2024 г.

13. World Health Organization (WHO). Guidelines on HIV self-testing and partner notification: supplement to consolidated guidelines on HIV testing services. Copenhagen: WHO; 2016. Available at: https://iris.who.int/handle/10665/251655

14. World Health Organization (WHO). Consolidated guidelines on HIV testing services: 2019. Geneva: WHO; 2020. Available at: https://iris.who.int/handle/10665/336323

15. European Centre for Disease Prevention and Control (ECDC). Public health guidance on HIV, hepatitis B and C testing in the EU/EEA. Stockholm: ECDC; 2018.
Available at: www.ecdc.europa.eu/en/publications-data/public-health-guidance-hiv-hepatitis-b-and-c-testing-eueea

16. Глобальные стратегии сектора здравоохранения по ВИЧ, вирусному гепатиту и инфекциям, передаваемым половым путем, на 2022–2030 гг. Женева: Всемирная организация здравоохранения; 2022. Доступно: https://iris.who.int/handle/10665/361970

17. UNAIDS. Global AIDS Strategy 2021–2026 End Inequalities. End AIDS. Geneva: UNAIDS; 2021. Available at: www.unaids.org/sites/default/files/media_asset/global-AIDS-strategy-2021-2026_en.pdf

18. Региональные планы действий по ликвидации СПИДа и эпидемий вирусных гепатитов и инфекций, передаваемых половым путем, на 2022–2030 гг. Всемирная организация здравоохранения. Европейское региональное бюро; 2023. Доступно: https://iris.who.int/handle/10665/372674. Лицензия: CC BY-NC-SA 3.0 IGO.

19. Всемирная организация здравоохранения. Сводное руководство по использованию антиретровирусных препаратов для лечения и профилактики ВИЧ-инфекции: рекомендации с позиций общественного здравоохранения, второе изда-ние. Копенгаген: Всемирная организация здравоохранения. Европейское региональное бюро; 2016. Доступно: https://iris.who.int/handle/10665/343998

20. Всемирная организация здравоохранения. Руководство о времени назначения антиретровирусной терапии и по докон-тактной профилактике ВИЧ-инфекции. Копенгаген: Всемирная организация здравоохранения. Европейское региональное бюро; 2016. Доступно: https://iris.who.int/handle/10665/343785

21. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795–807. Available at: https://doi.org/10.1056/NEJMoa1506816

22. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. Available at: https://doi.org/10.1056/NEJMoa1105243

23. European Centre for Disease Prevention and Control (ECDC). Continuum of HIV care - Monitoring implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia: 2023 progress report. Stockholm: ECDC; 2024. Available at: https://www.ecdc.europa.eu/en/publications-data/hiv-continuum-care-monitoring-implementation-dublin-declaration-2023

24. HIV Transmission Elimination Amsterdam (H-TEAM) Initiative, Van Sighem A, Hendriks S, Deug F, Zantkuijl P, van Bergen JE, et al. A 95% decline in estimated newly acquired HIV infections, Amsterdam, 2010 to 2022. Euro Surveillance. 2023;28(40):2300515. Available at: https://doi.org/10.2807/1560-7917.ES.2023.28.40.2300515

25. Cambiano V, Miners A, Lampe FC, McCormack S, Gill ON, Hart G, et al. The effect of combination prevention strategies on HIV incidence among gay and bisexual men who have sex with men in the UK: a model-based analysis. Lancet HIV. 2023;10(11):e713–22. Available at: https://doi.org/10.1016/S2352-3018(23)00204-7

26. Hedrich D, Kalamara E, Sfetcu O, Pharris A, Noor A, Wiessing L et al. Human immunodeficiency virus among people who inject drugs: is risk increasing in Europe? Euro Surveill. 2013;18(48). Available at: https://doi.org/10.2807/1560-7917.ES2013.18.48.20648

27. Giese C, Igoe D, Gibbons Z, Hurley C, Stokes S, McNamara S et al. Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2016. Euro Surveill. 2016;20(40). Available at: https://doi.org/10.2807/1560-7917

28. European Centre for Disease Prevention and Control (ECDC)/ European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). HIV in people who inject drugs – joint technical mission to Luxembburg. Stockholm: ECDC/EMCDDA; 2018. Available at: https://sante.public.lu/fr/publications/h/hiv-joint-technical-mission.html

29. McAuley A, Palmateer NE, Goldberg DJ, Trayner KMA, Shepherd SJ, Gunson RN, et al. Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis. Lancet HIV. 2019;6(5):e315–24. Available at: https://doi.org/10.1016/S2352-3018(19)30036-0

30. Des Jarlais DC, Synsa V, Feelemyer J, Abagiu AO, Arendt V, Broz D, et al. HIV outbreaks among people who inject drugs in Europe, North America, and Israel. Lancet HIV. 2020;7(6):e434–42. Available at: https://doi.org/10.1016/S2352-3018(20)30082-5.

1. HIV and AIDS in the EU/EEA

1.1. HIV diagnoses

In 2024, 24 164 HIV diagnoses were reported in 30 countries of the European Union/European Economic Area (EU/EEA), resulting in a rate of 5.3 per 100 000 population (Table 1). The highest rates were reported by Malta (20.6; 116 cases) and Ireland (18.8; 1 008 cases), and the lowest by Slovakia (2.1; 113 cases) (Table 1; Map 1). Of the HIV diagnoses reported in 2024[7], 14.7% (3 549 diagnoses) were among people with a previous positive HIV diagnosis[8]. Section 1.2 describes previous positive diagnoses in more detail. Unless otherwise specified, data presented in this section includes all HIV diagnoses reported, including both people with a previous positive HIV diagnosis and those diagnosed for the first time.

As in previous years, more men than women were diagnosed with HIV in 2024, (17 606 and 6 260, respectively), resulting in an overall men-to-women ratio of 2.8 (Figure 1.1; Table 2; Table 3). This ratio was highest in Malta (11.8), Hungary (6.0) and Spain (5.9) (Figure 1.1).

The overall rate of diagnoses in men was 7.9 per 100 000 population (Table 2, Map 2) and in women 2.7 per 100 000 population (Table 3; Map 4). In addition to the 23 866 cases identified as either men or women, 218 people (0.9%) identifying as transgender and 80 people (0.3%) with an unknown gender were reported in 2024. In 2024, countries reporting HIV diagnoses among transgender people included Belgium (28 cases, 2.5%), France (107 cases, 2.3%), Germany (33 cases, 1%), Greece (four cases, 0.6%), Ireland (10 cases, 1%), Malta (one case, 0.9%), Netherlands (30 cases, 3.6%) and Portugal (five cases, 0.5%).

Age-specific rates were lowest among children under 15 years (0.2 per 100 000 population for both men and women) (Figure 1.2). In all age groups, men had higher age-specific HIV diagnosis rates than women. The highest overall age-specific rate was observed in the age group 25−29 years (13.2 per 100 000 population). Among men, the highest rate was in the age group 25−29 years (20.5 per 100 000), while for women, it was in the age group 30−39 years (6.6 per 100 000). (Figure 1.2).

The overall mean age at diagnosis was 39.4 years; the mean age at diagnosis was lower for men who have sex with men (36.7 years) than for cases attributed to injecting drug use (42.2 years overall, and similar in

7 Reported HIV diagnoses refer to all HIV diagnoses made and reported by a country within a specific year, encompassing both previous positive diagnoses and individuals who were diagnosed with HIV for the first time.

8 Previous positive diagnoses are defined as HIV diagnoses made either abroad or in another setting within the reporting country, on any occasion before the current year of reporting. Some countries report previous positive HIV cases as they enter, re-enter or re-engage with the care system in the reporting country.

both women and men) or heterosexual transmission (41.7 years overall, 40.3 in women and 43.3 in men). For transgender people, the mean age at diagnosis was 33.5 years. The highest proportion of transgender peo-ple (41.7%) were diagnosed between the ages of 30−39 years, followed by 27.5% in the age group 25−29 years, 14.7% in the age group 40−49 years, 7.8% aged 20−24 years, 6.9% among those aged 50+ years, and 1.4% in the age group 15−19 years.

The age group 30−39 years accounted for the largest proportion of HIV diagnoses overall (31.3%), with 33.7% among men who have sex with men and 29.2% among those reporting heterosexual contact. In contrast, among people who inject drugs, most diagnoses (41.8%) were reported in the age group 40−49 years (Figure 1.3). One third (32.3%) of diagnoses attributed to sex between men were made before the age of 30, while over half of the HIV infections reported among men and women who had heterosexual contact (53.1%) and among those who acquired the infection through injecting drug use (62.9%) were diagnosed at 40 years or above.

The age distribution of HIV diagnoses varied across countries. In Romania (33.7%) and Cyprus (30.4%), approximately one-third of reported HIV diagnoses were among people aged under 30 years. By way of contrast, in Latvia (65.0%), Norway (54.9%), Italy (54.6%), Lithuania (54.1%), Luxembourg (53.5%), Slovakia (52.2%), Iceland (51.3%), Slovenia (50.9%), Croatia (50.6%) and Denmark (50.2%) over half of the HIV diagnoses were reported in people aged over 40 years (Figure 1.4; Table 9).

Data on transmission mode provide information on the groups most affected by HIV in the EU/EEA (Tables 4–8; Figure 1.5):

- Sex between men is the most reported transmission mode in the EU/EEA, accounting for 35.6% (8 614) of all HIV diagnoses in 2024. When cases with unknown transmission mode are excluded, this increases to 48.3% of diagnoses with a known mode (Figure 1.5; Table 4; Map 5) and accounts for more than 50% of the HIV diagnoses reported in six countries (Croatia, Hungary, Malta, Netherlands, Slovenia and Spain) (Figure 1.5). The majority (52.9%; 4 554) of people diagnosed with HIV attributed to sex between men were born in the reporting country. Among the 44.3% (3 816) of men who have sex with men diagnosed with HIV who were migrants, 48.3% (1 843) originated from Latin America and the Caribbean, 14.8% (565) origi-nated from Central or Eastern Europe, 10.4% (395) originated from Sub-Saharan Africa, 9.6% (365) origi-nated from Western Europe, 8.4% (320) originated from South and South-East Asia, 8.6% (328) origi-nated from other regions and for 6.4% (244) the origin was unknown (Table 11).

Figure 1.3: HIV diagnoses, by age group (in years) and transmission mode, EU/EEA, 2024 (n=16 948)



Note: Estonia, Latvia and Poland were excluded from the figure as more than 50% of their reported cases did not include information on the mode of transmission. Liechtenstein reported zero cases for 2024.

Figure 1.4: Percentage of HIV diagnoses, by country and age group, EU/EEA, 2024 (n = 24 019)





Note: unknown age is excluded from the proportions presented here. The figure is organised in descending order, from the lowest to highest percentage of diagnoses among people under 30 years. Liechtenstein reported zero cases for 2024.

Figure 1.5: Percentage of HIV diagnoses with known mode of transmission, by transmission route and country, EU/EEA, 2024 (n = 17 194)

Note: Estonia, Latvia and Poland were excluded from the figure as more than 50% of their reported cases did not include information on the mode of transmission. A total of 4 642 people with an unknown mode of transmission have been excluded from the proportions presented for the countries included in the figure. This figure is organised by proportion of diagnoses resulting from sex between men in descending order. Liechtenstein reported zero cases for 2024.

Figure 1.6: Percentage of HIV diagnoses among migrants out of all reported cases with known information on region of origin, by country of report, EU/EEA, 2024 (n = 19 595)



Note: Estonia, Latvia, Poland and Slovakia were excluded from the figure as more than 50% of their reported cases lacked information on the mode of transmission and/or region of origin. A total of 2 134 cases were reported with unknown region of origin, and 4 608 cases were reported with an unknown mode of transmission. The figure is organised from countries with the highest proportion of migrants to those with the lowest. Liechtenstein reported zero cases for 2024.

Figure 1.8: Percentage of people diagnosed late (CD4 cell count < 350 per mm$_3$) by demographic, EU/EEA, 2024 (n = 11 796)



Note: this figure excludes cases with an unknown CD4 cell count per mm$_3$, children under 15 years, previously positive diagnoses and cases reported by countries that did not report CD4 cell counts per mm$_3$. Cases classified as recent infections with CD4 < 350 cells/mm$_3$ are excluded from the numerator of the late-diagnosis indicator, but remain in the denominator. Liechtenstein reported zero cases for 2024.

Figure 1.9:Linkage to care after HIV diagnosis in the EU/EEA, individuals diagnosed with HIV 2023–2024 (n = 14 017).





Note: cases with no data or missing data on CD4 cell count or date of diagnosis, previous positive cases and those who died within 91 days of diagnosis are excluded from this figure. Liechtenstein reported zero cases for 2024.

Czechia, Denmark, Finland, France, Germany, Iceland, Ireland, Luxembourg, Malta, Netherlands, Norway, Portugal, Spain and Sweden.

For HIV diagnoses reported among transgender people in 2024, 85.4% (186) originated from a country other than the reporting country, 12.8% (28) were born in the reporting country, and in 1.8% of cases (4), the region of origin was unknown. Among those whose regions of origin were known and who were born abroad, 73.7% (137) were from Latin America and the Caribbean, 8.6% (16) from Central and Eastern Europe, 8.6% (16) from Sub-Saharan Africa, 3.8% (7) from South and South-East Asia, 2.7% (5) from other, and 2.7% (5) from Western Europe.

Information on CD4 cell count at the time of HIV diagnosis was available for 11 796 (63.9%) adults and children aged ≥15 years, diagnosed across 27 countries (Table 12). A total of 21 countries were able to provide CD4 cell counts for 50% or more of their reported cases, however Belgium, Germany, Greece, Ireland, Latvia, and Slovakia were unable to do so. Hungary and Poland did not provide CD4 cell counts for 2024.

To calculate late diagnoses, children under 15 years and previously positive diagnoses are excluded from both the numerator and the denominator. Cases classified as recent infection are excluded from the numerator of the late-diagnosis indicator of CD4 <350 cells/mm³, but remain in the denominator in Table 12, resulting in a final total of 11 796 cases. Almost half of these cases (48.0%) were considered to have been diagnosed several years after being infected, with a CD4 cell count below 350 cells/mm³. This included 30.6% of cases considered to have advanced HIV infection (CD4 cell count below 200 cells/mm³) (Table 12). The proportion diagnosed late (CD4 cell count below 350 cells/mm³) was above 60% in Croatia (68.3%), Sweden (66.7%), Bulgaria (63.1%) and Romania (62.3%).

Among all cases diagnosed in 2024 with available information on CD4 cell count (11 796) and excluding previous positive cases, 10.8% were diagnosed during recent infection[9] and 23.7% were diagnosed with CD4 cell count of 500 or over 500 cells/mm³. More specifically, among men who have sex with men diagnosed in 2024, 15.7% were reported as recent infections, and 26% had a CD4 cell count of 500 or over 500 cells/mm³ at diagnosis (Figure 1.7).

When analysing CD4 cell count, the highest proportions of people presenting at a later stage of HIV infection (CD4 less than 350 cells/mm³, excluding those previ-ously diagnosed or with evidence of recent infection) were among women (51.6%), older adults (61.3% in those over 50 years, 55.1% in the 40–49 age group), men or women who acquired the infection through hetero-sexual sex (59.9% and 52.6% respectively), people who

9 Recent infection status was reported by countries using one or more criteria for recent infection, including HIV negative test in the last six months, evidence of seroconversion illness, p24 antigen or an indication based on any other clinical or laboratory criteria.

acquired HIV through injecting drug use (52.4%), and migrants originating from Sub-Saharan Africa (53.8%) and South and South-East Asia (52.7%) (Figure 1.8).

The lowest proportions of late diagnosis (CD4 cell count below 350 cells/mm³) were observed among younger age groups (39.8% of those aged 20–24 years), men who acquired HIV through sex with another man (39.0%) and people from countries in Western Europe (42.5%) (Figure 1.8).

Information regarding CD4 cell count was available for 40.4% (n=88) of all transgender people reported (218). Of these, 31.8% (n=28) had a recent infection, 25% (n=22) had CD4 cell count of 500 or more than 500 cells/mm³ at diagnosis and 34.1% (n=30) presented at a late stage of HIV infection (CD4 cells/mm³ <350), with 14 (15.9%) considered to have advanced HIV infection at diagnosis (CD4 cells/mm³ <200).

Among cases diagnosed in recent years (2023−2024) where CD4 data and date of diagnosis were reported, the interval between the date of diagnosis and the date of the CD4 cell count was used as a proxy for time to link-age to care: 53.6% were linked to care within four days of HIV diagnosis and 97.0% were linked to care within three months (Figure 1.9).

1.2. Previous positive diagnoses

In 2024, previous positive diagnoses accounted for 14.7% (3 549) of the 24 164 HIV diagnoses reported, representing a 17.8% decrease compared with 2023, when the proportion was 16.9% (4 317 of 25 616). However, these figures are probably underestimated, as the variable identifying the HIV status as a previ-ous positive or first-time diagnosis had a completeness of 66.2%. Bulgaria, Finland, Hungary, Italy, Lithuania, Malta, Poland, Romania and Spain were excluded from this analysis, as more than half of their HIV diagnoses reported in 2024 did not have data on this variable (Figure 1.10).

If only the data from the 20 countries with sufficient reporting on this variable is considered, the proportion of previous positive diagnoses increases to 21.2% (3 192) of all HIV diagnoses reported by these countries in 2024 (Figure 1.10). In three countries, more than 50.0% of the HIV diagnoses reported in 2024 were previous positives: Iceland (61.5%), Norway (58.3%), Sweden (50.7%).

When comparing people with previous positive HIV diag-noses to those newly diagnosed, a higher proportion are women (36.3% versus 26.9%), and a higher proportion is over 30 years of age (79.9% versus 75.1%). In addition, a larger percentage of migrants is found among those with a previous positive diagnosis than among those newly diagnosed (86.5% versus 50.7%) and a higher propor-tion from Central and Eastern Europe (21.5% versus 14.7%) and Sub-Saharan Africa (33.1% versus 19.7%) (Figure 1.11).

In terms of transmission routes, among people with previous positive diagnoses, heterosexual contact was the primary route (39.1%), with a higher prevalence in women (27.1%) than in men (12.0%). Transmission through sexual contact between men is less common among those with previous positive diagnoses 34.3%. In addition, MTCT was reported at a higher rate among those with previous positive diagnoses (3.0%) than in newly diagnosed people (0.6%).

1.3. Trends in HIV diagnoses

Between 2015 and 2024, the trend in reported HIV diagnoses showed a decline, with the rate for EU/EEA countries dropping from 6.2 to 5.3 per 100 000 population, which represents a 14.5% decrease. Compared with 2023, the rate fell by 5.4%, from 5.6 to 5.3 per 100 000 population (Table 1).

When only new HIV diagnoses reported between 2015 and 2024 are considered (excluding previously reported positive cases from countries with sufficient data), the rate for 2024 is 3.8 per 100 000. This represents a 5.0% decrease compared with the 2023 rate (4.0 per 100 000) and a 22.4% decrease on the 2015 rate (4.9 per 100 000) (see Figure 1.12 and 1.13).

From 2015 to 2020, age-specific rates declined, followed by a plateau during the period 2020–2021, a marked increase in 2022 in most age groups for both women and men, and a subsequent decline in 2023–2024 (Figure 1.14a, Figure 1.14b).

HIV diagnoses among people born outside of the reporting country, excluding Latvia and Slovakia (where more than 50% of reported cases have an unknown region of origin), accounted for 33.1% of all diagnoses in 2015. This proportion has increased over time to 49.8% in 2023, and declined to 47.2% in 2024. When analys-ing data excluding cases with an unknown region of origin, the proportion of migrants among HIV diagno-ses increased from 38.3% in 2015 to 55.7% in 2024, representing a 45.4% rise over the period. However, compared to 2023, there was a decrease of 1.9%, down from 56.8%. In particular, there was a 9.2% decrease in diagnoses among people coming from Sub-Saharan Africa, declining from 4 041 reported diagnoses in 2023 to 3 670 in 2024. (Figure 1.15).

Since 2015, most of the EU/EEA countries have maintained consistent reporting on transmission routes. However, for the transmission mode analysis, HIV diagnoses reported by Estonia, Latvia and Poland were excluded due to incomplete reporting on transmission mode for some years of the previous decade. When

Figure 1.10:Percentage of previous positive diagnoses and newly HIV diagnoses by country of report, EU/EEA, 2024 (n = 14 745)



Note: countries with more than 50% unknown for the variable identifying the HIV status as a previous positive or new diagnosis are excluded from the figure.

Figure 1.11: Demographic and epidemiological characteristics of previous positive diagnoses and new HIV diagnoses by 20 EU/EEA countries, 2024 (n = 14 745)



Notes: MTCT: mother-to-child transmission.
The data for HIV cases reported in 2024 from the following EU/EEA countries have been included in this figure: Austria, Belgium, Croatia, Cyprus, Czechia, Denmark, Estonia, France, Germany, Greece, Iceland, Ireland, Latvia, Luxembourg, Netherlands, Norway, Portugal, Slovakia, Slovenia and Sweden.

Figure 1.12: Temporal trends in HIV diagnoses reported by 20 EU/EEA countries: comparison of trends including and excluding previous positive diagnoses, 2015–2024 (n = 176 219).





Note: this figure includes data on HIV cases reported between 2015 and 2024 from the following EU/EEA countries: Austria, Belgium, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Iceland, Ireland, Latvia, Luxembourg, Netherlands, Norway, Portugal, Slovakia, Slovenia and Sweden. Data from Bulgaria, Cyprus, Finland, Hungary, Italy, Liechtenstein, Lithuania, Malta, Poland, Romania and Spain were excluded as more than 50% of the HIV status variable data were classified as unknown.

Figure 1.13: People diagnosed with HIV, AIDS diagnosis and AIDS-related deaths reported per 100 000 population, EU/ EEA, 2015–2024



Note: rates exclude countries not reporting consistently over the period: Germany, Liechtenstein and Sweden (AIDS diagnosis and AIDS deaths). The newly diagnosed cases rate was calculated by removing previous positive cases from the 26 EU/EEA countries with sufficient reporting on this variable to exclude these cases (see Chapter 1.2 for more details). AIDS diagnosis and AIDS-related death rates were not affected by previous positive cases and these rates are not adjusted.

Figure 1.14a: Age-specific trends in HIV diagnoses in women, 2015–2024





Figure 1.14b: Age-specific trends in HIV diagnoses in men, 2015–2024




20
18
16
14
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Year of diagnosis

focusing on data from those countries that have consistently reported over the past decade (2015–2024) and analysing data with known routes of transmission, the following trends become evident:

- The proportion of HIV diagnoses with a known route of transmission attributed to sex between men decreased from 52.3% in 2015 to 48.3% in 2024. A slight decrease in reported HIV diagnoses among men who have sex with men was observed in 2022 (8 335 diagnoses), followed by an increase in 2023 (8 481 diagnoses), with the number remaining rela-tively stable in 2024 (8 307 diagnoses) (Figure 1.16a, Figure 1.16b). Among migrant men who have sex with men, HIV diagnoses increased by 25.5% from 3 019 in 2015 to 3 788 in 2024, but decreased 3.8% year on year from 3 936 in 2023 to 3 788 in 2024. Among men who have sex with men born in the reporting country, diagnoses increased by 1.7%, from 4 239 in 2023 to 4 312 in 2024 (Figure 1.17).
- The proportion of HIV diagnoses with a known mode of transmission attributed to heterosexual transmis-sion in both women and men increased from 40.9% in 2015 to 45.6% in 2024. Among men, this proportion showed a slight increase over the period, from 20.4% to 21.8%. In contrast, the increase among women was more pronounced, rising from 20.5% to 23.8% of HIV diagnoses with known transmission informa-tion (Figure 1.16b). A smaller increase (4.5%) was also observed among heterosexual migrants, with diagno-ses rising from 4 670 in 2015 to 4 878 in 2024. It is also worth noting that there was a 2.5% decrease in the number of reported diagnoses among heterosexual people born in the reporting country from 2023 (5 349 cases) to 2024 (4 878 cases) (Figure 1.17).
- The overall number of HIV diagnoses reported among people who inject drugs slightly decreased, from 1 291 cases in 2015 to 846 cases in 2024 (Figure 1.16a,

Figure 1.17, Table 5), although there was an increase in 2022 when the number was 1 092.

- The proportion of HIV diagnoses reported to be due to mother-to-child transmission of HIV increased from 0.9% to 1.1% between 2015 and 2024, although the number declined from 227 in 2023 to 196 in 2024 (Figure 1.16a, Table 7).

The trends for both late diagnoses and recent infections remained stable throughout the period (Figure 1.18). When analysing the trend in CD4 cell count data, a 14.7% decline was observed in the number of unknown CD4 cell count values, decreasing from 8 147 in 2015 to 6 934 in 2024.

1.4. AIDS cases, morbidity and mortality

Although there have been improvements in the early diagnosis of HIV, 2 215 diagnoses of AIDS were reported by 27 EU/EEA countries in 2024 – a crude rate of 0.7 AIDS diagnosis per 100 000 population (Table 13, Map 8). The highest rate was reported by Latvia (2.4 per 100 000 pop-ulation, 46 cases) followed by Portugal (1.8 per 100 000 population, 194 cases). The rate of AIDS diagnoses decreased by 12.5%, from 0.8 to 0.7 per 100 000 popula-tion between 2023 and 2024. The death rate remained stable at 0.2 per 100 000 over the same period.

The rate of reported AIDS cases has decreased by 30.0% over the past decade (excluding Cyprus, Germany, Liechtenstein, Spain and Sweden who did not report consistently over the period), representing a reduction compared with the 1.0 per 100 000 reported in 2015 (Table 13). This decline has been noted in both men and women, however, it is more pronounced in men. Among men, the rate decreased from 1.6 per 100 000 population in 2015 to 1.0 per 100 000 population in 2024, while among women, the decline was from 0.5 per 100 000 population in 2015 to 0.4 per 100 000 in 2024

Figure 1.17: HIV diagnoses, by year of diagnosis, transmission mode and migration status, EU/ EEA, 2015–2024



Note: Data from Estonia, Latvia, Poland and Slovakia were excluded from the figure due to over 50% of their reported cases having either an unknown region of origin or an unknown mode of transmission during a period of the previous decade.

(Tables 14−15). Moreover, a decrease has been observed across all cases with a known mode of transmission (Figure 1.19).

The most common AIDS-indicative conditions diagnosed in 2024 in the EU/EEA were Pneumocystis jirovecii pneumonia (22.4% of all AIDS-indicative diseases), wasting syndrome due to HIV (12.9%) and oesophageal candidiasis (12.1%) (Table 16). Combined pulmonary and/ or extrapulmonary tuberculosis (TB) made up 11.7% of AIDS-indicative diseases.

Twenty-seven EU/EEA countries (all but Germany, Liechtenstein and Sweden) reported data on deaths of those diagnosed with AIDS. Overall, 579 people were reported to have died due to AIDS-related causes dur-ing 2024 (Table 17), although these data are affected by under-reporting due to the challenges for many countries in linking to death registries. AIDS-related death reports have declined by 62.9% since 2015, when there were 1 562 deaths. However, delays in reporting affect the lat-est figures and under-reporting also had an impact on the reporting of AIDS deaths throughout the previous decade. From the beginning of the HIV epidemic to the end of 2024, the cumulative total of people diagnosed with AIDS in the EU/EEA was 353 234 (Table 13). The cumulative total of cases reported as known to have died from AIDS-related causes by the end of 2024 was 180 757 (Table 17).

1.5. HIV testing

Thirteen countries — Belgium, Czechia, Denmark, Estonia, France, Greece, Ireland, Latvia, Lithuania, Poland, Portugal, Romania, Slovenia — consistently reported data on HIV tests performed from 2015 to 2024, excluding unlinked anonymous testing and blood donation testing. Poland also reported data but was unable to exclude unlinked anonymous testing from its figures. The number of tests performed in the countries consistently reporting testing activity has increased by 15.4% compared to 2022 and 8.5% compared to 2023 (Table 18). It is important to note that the numbers provided are collected in a heterogeneous manner and therefore comparisons between country testing rates should be undertaken with caution. However, these data can indicate large changes in overall testing policy or be used to support the interpretation of HIV cases notified.

1.6. Conclusions

In 2024, 30 EU/EEA countries reported a total of 24 164 HIV diagnoses, corresponding to a reporting rate of 5.3 per 100 000 population—14.1% lower than 2015 (6.2 per 100 000) and 5.4% lower than 2023 (5.6 per 100 000), indicating a sustained decline. If previously known positive cases are excluded to better capture recent infections, the 2024 rate was 3.8 per 100 000, a 22.4% decrease compared with 2015 (4.9 per 100 000) and a 5.0% decrease on 2023 (4.0 per 100 000). This sug-gests that the lack of classification between new and previously known HIV-positive diagnoses might lead to

an overestimation of the number of reported HIV cases, while underestimating the magnitude of the long-term decline. However, this decrease should be interpreted with caution, as it may reflect a reporting artefact rather than a true epidemiological reduction. Standard report-ing-delay adjustments were not applied, so residual delays and improved timeliness after COVID-19 may have led to an increase in reported cases immediately after the pandemic, which in turn affects the counts currently being observed. At the same time, the downward trajec-tory could be also compatible with a genuine reduction in transmission, plausibly driven by expanded antiretro-viral therapy (ART) coverage, supporting ‘undetectable = untransmittable’ (U=U); wider implementation of test-and-treat initiatives; greater pre-exposure prophylaxis (PrEP) uptake and coverage; more frequent testing among key populations; harm-reduction services for people who inject drugs [1], and the post-COVID restora-tion of prevention and care services [2].

AIDS and AIDS-related death rates in the EU/EEA have declined substantially over the past decade. Reported AIDS cases fell by 30.0%, with the largest reductions observed among men and decreases evident across all transmission categories. Over the same period, AIDS-related deaths declined by 62.9%, indicating fewer progressions to AIDS and fewer fatalities — probably reflecting earlier diagnosis, faster initiation of ART, and improved long-term HIV care and viral suppres-sion. However, these trends should be interpreted with caution, given the under-reporting of both AIDS and AIDS-related deaths.

In 2024, sex between men was the most frequently reported mode of transmission in the EU/EEA, compris-ing 48.3% of cases with a known transmission route. The high proportion of men who have sex with men among the reported diagnoses, underscores the importance of reinforcing and tailoring HIV prevention and testing pro-grammes for this group. Tailored programmes should prioritise regular, accessible HIV testing with immediate linkage to care upon diagnosis, distribution of condoms, and access to PrEP for people at higher risk of acquiring HIV, as part of comprehensive sexual health services. These programmes have demonstrated success in achieving higher rates of viral suppression and reducing HIV transmission [3,4]. Expanding PrEP access remains critical, particularly in countries where its implementa-tion is limited or absent, despite rising HIV rates among men who have sex with men [4,5]. For men who have sex with men with poor adherence to daily oral PrEP, long-acting injectable PrEP (LA-PrEP) may address key barriers such as reducing the stigma associated with pill-taking, simplifying dosing, and improving adherence through bi-monthly injections [6,7]. This underscores the need to first build robust, equitable oral PrEP pro-grammes (access, counselling, monitoring, and linkage), and then consider LA-PrEP as an additional PrEP option to expand choice and support adherence among men who have sex with men [8].

In 2024, heterosexual transmission accounted for 45.7% of diagnoses with a known transmission route and was the predominant mode of transmission (≥50% of cases) in 13 EU/EEA countries. The share was higher among women (52.1%) than men (47.9%). With regard to origin, 35.3% of heterosexual diagnoses were among peo-ple born in the reporting country, whereas 61.4% were among migrants — primarily from Sub-Saharan Africa, Central and Eastern Europe, and Latin America and the Caribbean. For 3.3%, the region of origin was unknown. It is important to highlight that 59.9% of heterosexual men and 52.6% of women were diagnosed at a later stage of HIV infection than men who have sex with men (39.0%). This disparity may be shaped by the persistent misconception — often echoed by healthcare profes-sionals — that heterosexual people are at lower risk of HIV [9]. In addition, implicit biases rooted in cultural stereotypes can shape clinicians' risk assessments and testing practices, leading to differential access. Gender is particularly susceptible to such bias, with docu-mented effects on clinician–patient interactions and downstream care indicating that women are often less likely to be offered or receive HIV testing [10]. It is essen-tial to improve the testing offered by healthcare workers by strengthening provider education and training, and making targeted efforts to address such inequities.

In 2024, migrants (people born outside the reporting country) accounted for 55.7% of cases with known ori-gin. From 2015 to 2024, the proportion of diagnoses among migrants increased by 45.4%. Given this bur-den, countries should develop, implement, and scale up strategies to improve access to HIV testing and ensure rapid linkage to care for migrants. Evidence indicates that many migrants — including those from high-preva-lence regions — acquire HIV after arrival in the EU/EEA [11-14]. This highlights the importance of targeted, non-stigmatising prevention and information campaigns at or soon after arrival; offering HIV testing as part of routine health assessments for new arrivals [13], and provid-ing ongoing, culturally and linguistically-tailored sexual health services (including self-testing, community/out-reach testing, and same-day or rapid ART initiation, irrespective of insurance or legal status). Futhermore, a systematic review and meta-analysis have shown that, even though their mortality risk is similar, compared with non-migrant populations in Europe, migrants are at higher risk of AIDS-defining conditions, treatment dis-continuation, loss to follow-up, and virological failure. These disparities are most pronounced among migrants from the African region [15]. Persistent data gaps, espe-cially for migrants in precarious circumstances [16, 17], highlight the urgent need for migrant-sensitive HIV care pathways and strengthened monitoring to mitigate these risks and improve outcomes. To effectively reach migrant men who have sex with men, community-based and culturally-tailored interventions – such as peer-to-peer involvement, cultural and language mediation and cul-tural sensitivity training – are essential for improving HIV testing uptake. The offering of self-testing kits, removal of healthcare access barriers, and the employment of targeted social marketing campaigns can all further

enhance privacy, convenience and awareness which help to increase testing rates in this key population (18).

HIV transmission among people who inject drugs remains at consistently low levels in most EU/EEA countries, with a further decrease observed in 2024. This decline is probably attributable to the presence of well-established and effective harm-reduction programmes, as well as to changes in drug-use behaviour in many countries. However, a few countries still report a relatively high number of cases among injecting drug users. In these countries, harm reduction coverage should be reviewed and potentially strengthened. These findings underscore the critical importance of maintaining sufficient scale and coverage of harm-reduction services, as trends can rapidly reverse in the absence of robust prevention efforts delivered on a large scale [19,20]. In addition to HIV prevention, expanding access to testing for other bloodborne infections, such as hepatitis B and C, is an essential and integrated strategy for this population. Addressing these infections, which are highly prevalent among injecting drug users, is crucial to the achievement of the Sustainable Development Goals (SDG) for this key population by 2030 [21].

In 2024, 218 transgender people (0.9% of all diagno-ses) were diagnosed and reported by eight EU/EEA countries. Of these, 85.4% were migrants, primar-ily originating from Latin America and the Caribbean. Among those with available CD4 cell count data, 31.8% had a recent infection and 34.1% were diagnosed at a late stage. Despite these insights, it remains difficult to draw comprehensive conclusions about HIV prevention and control for transgender populations due to limited data. Many EU/EEA countries still do not collect specific data on transgender people. Improving data collection is crucial to gaining a clearer understanding of this population's epidemiological profile and developing more targeted prevention strategies. Despite the scarcity of data, research indicates that engaging transgender communities through trans-led organisations and integrating HIV services with gender-affirming care has been effective in enhancing care engagement and reten-tion [22]. Furthermore, gender-affirming programmes that also include the provision of PrEP along with inte-grated healthcare services have been shown to increase PrEP adherence and reduce HIV risk among transgender people [22,23].

In the 26 countries with data, it is estimated that about 625 368 people are living with HIV in the EU/EEA, of which around 576 550 (92%) have been diagnosed [1]. While a comparison of modelled data on HIV infections with the number of people diagnosed with HIV appears to indicate that, over time, fewer people are living with undiagnosed HIV in the EU/EEA, around one in nine peo-ple living with HIV in the EU/EEA are still unaware of their status [1]. In addition to the clinical and personal benefits for the person diagnosed, early diagnosis and effective antiretroviral treatment (ART) can also help sexual and injecting partners by preventing onward HIV transmission [24].

Among newly diagnosed individuals with no evidence of recent infection and no previously known HIV diag-nosis, 48.0% had a CD4 count <350 cells/mm³, including 30.6% with advanced HIV infection (CD4 <200 cells/ mm³). Although the number of people diagnosed late declined by 33.9% from 8 016 (2015) to 5 300 (2024), these figures should be interpreted cautiously. Three countries do not report CD4 cell counts, and among the reporting countries the completeness is 60.7%, which could underestimate the absolute number of late diagnoses. Conversely, limited identification of recent infections may overestimate the proportion of late diag-noses — an issue highlighted in recent methodological updates to late-diagnosis definitions [25,26]. Despite these nuances, the proportion of people diagnosed late remains high, indicating that people have been infected for many years. This suggests problems with access to, and uptake of HIV testing for some segments of the population, and indicates the need to improve testing programmes to diagnose people living with HIV at an earlier stage. To reduce the high proportion of people diagnosed late, it is essential to diversify HIV testing by increasing routine testing for health condi-tions associated with HIV (indicator condition-guided testing), increasing HIV testing during screening for other sexually transmitted infections, and continuing to expand community-based testing, self-testing/home-sampling and partner notification. The development of European Standards of HIV Care and European guidance on setting-based approaches for HIV and viral hepatitis testing, including best practices for effective implemen-tation, can promote more uniform and improved care quality across the Region, and can help countries seek-ing to implement more effective testing programmes [27]. Testing not only provides a gateway to HIV treat-ment for people found to be positive but can also serve as an entry point for high-risk HIV-negative people to effective prevention, including PrEP.

Despite clear evidence of the health benefits for HIV-positive people of introducing ART early [28] and the fact that this should serve as an incentive for people to know their HIV status, many continue to be diagnosed with HIV years after becoming infected, at an advanced stage of illness. Overall, more than 95% of AIDS diagno-ses were reported to have been made within 90 days of the HIV diagnosis, indicating that most AIDS cases in the EU/EEA are due to late diagnosis of HIV infection. Stigma towards people living with HIV and members of key population groups disproportionately affected by HIV is a documented contributing factor to delayed HIV test-seeking [29]. Stigma reduction efforts within healthcare and community settings could increase care seeking and reduce late diagnosis.

Once tested, rapid linkage to high-quality care (includ-ing ART) is essential. In recent years, around 97.0% of those diagnosed who had evidence of linkage to care were linked to care within three months of HIV diagnosis. Timely linkage to care following HIV diagnosis is crucial, as delayed access can result in poor patient outcomes [21]. Once linked to care, there is evidence that high

proportions of people diagnosed with HIV in the EU/EEA have access to ART and achieve viral suppression [21].

The changing epidemiology of HIV infections observed in the EU/EEA in recent years indicates that it is crucial to sustain, and in some places strengthen, evidence-based HIV prevention measures tailored to the local epidemiological context and targeting those most at risk. The European Centre for Disease Prevention and Control (ECDC) will continue to support EU/EEA countries in their efforts to accelerate progress towards reaching the SDG for HIV through dedicated workshops, webi-nars, guidance and other technical support focused on high-impact surveillance, monitoring and prevention activities.

Tailored prevention for key populations in the EU/EEA remains essential. Priorities include women, migrants, transgender people, and men who have sex with men, supported by a core package of expanded ART (U=U), test-and-treat, condoms, and PrEP — with equitable access to oral PrEP as the mainstay and long-acting PrEP as a complementary option. Case-finding should combine indicator-condition testing, community out-reach, self-testing/home sampling, assisted partner notification, and rapid linkage to care. Migrants require culturally and linguistically-tailored services, test-ing at or soon after arrival, removal of access barriers, and swift ART initiation; therefore migrant-sensitive pathways and strengthened monitoring are crucial. For transgender people, trans-led engagement and gender-affirming care (including PrEP) can improve uptake and retention. As heterosexual diagnoses rise, sexual-health services should expand with accessible, non-stigmatis-ing models and prompt testing. For people who inject drugs and their partners, harm-reduction services (nee-dle/syringe programmes and opioid agonist therapy) must be maintained and scaled, with integrated HBV/ HCV testing and care. Across all groups, reducing stigma and improving adherence to European testing and care standards is critical to achieving equitable impact.

The 2024 HIV analysis of surveillance data is con-strained by substantial data incompleteness — 26.2% missing transmission route, 40.0% missing CD4 cell count, and 33.8% missing HIV diagnosis status (newly diagnosed people versus previously known positive cases). However, surveillance data quality has improved over the last year as 26 countries now distinguish newly diagnosed from previously known positive cases, with 66.2% completeness for this variable. This enhancement reduces misclassification bias and overestimation of newly diagnosed cases. Among countries with sufficient reporting on this variable, previous positives accounted for 21.0% of all HIV diagnoses in 2024, and in three countries, more than half of the HIV diagnoses reported were previously known positive cases, underscoring the importance of capturing this information accurately. All countries should therefore implement this distinction within their surveillance systems, and those already reporting should improve completeness to strengthen internal validity, enhance cross-country comparabil-ity, and improve the interpretability of temporal trends.

Accurate transmission data are essential for targeting prevention and planning programmes, while CD4 cell count and prior-diagnosis status are critical for monitoring late diagnosis and interpreting trends. Improving collaboration with clinicians, establishing routine follow-up with data providers, and standardising the collection of previously known diagnosed cases across EU/EEA countries would significantly enhance data quality. Strengthening these practices will provide more robust epidemiological insights and support better-targeted prevention strategies.

References[10]

1. European Centre for Disease Prevention and Control (ECDC). Progress towards reaching the Sustainable Development Goals related to HIV, viral hepatitis, sexually transmitted infections and tuberculosis in the EU/EEA: 2024 progress report. Stockholm: ECDC; 2025. Available at: https://www.ecdc.europa.eu/en/publications-data/hiv-tb-hepatitis-progress-sustainable-development-goal-2025

2. European Centre for Disease Prevention and Control (ECDC). The impact of the COVID-19 pandemic on the HIV response in Europe and Central Asia: Monitoring implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia. Stockholm: ECDC; 2024. Available at: https://www.ecdc.europa.eu/en/publications-data/impact-covid-19-pandemic-hiv-response-europe-and-central-asia-monitoring.

3. Brown AE, Mohammed H, Ogaz D, Kirwan PD, Yung M, Nash SG, Fall in new HIV diagnoses among men who have sex with men (MSM) at selected London sexual health clinics since early 2015: testing or treatment or pre-exposure prophylaxis (PrEP)? Euro Surveill. 2017;22(25):30553. Available at: https://doi.org/10.2807/1560-7917.ES.2017.22.25.30553

4. Nwokolo N, Whitlock G, MacOwan A. Not just PrEP: other reasons for London's HIV decline. Lancet HIV. 2017;4(4):e153. Available at: https://doi.org/10.1016/S2352-3018(17)30044-9

5. European Centre for Disease Prevention and Control (ECDC). Evidence Brief: Pre-exposure prophylaxis for HIV prevention in Europe. Stockholm: ECDC; 2023. Available at: https://www.ecdc.europa.eu/en/publications-data/ecdc-evidence-brief-pre-expo-sure-prophylaxis-hiv-prevention-europe

6. Keddem S, Thatipelli S, Caceres O, Roder N, Momplaisir F, Cronholm P. Barriers and facilitators to long-acting injectable HIV pre-exposure prophylaxis implementation in primary care since its approval in the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2024 Apr 1;95(4):370-6. Available at: https://doi.org/10.1097/QAI.0000000000003370

7. Wang H, Lozano AA, Kolstee J, Zimmermann HM, Tosh J, Schroeder M, et al. Oral PrEP use and intention to use long-acting PrEP regimens among MSM accessing PrEP via governmental and non-governmental provision pathways - 20 European countries, October 2023 to April 2024. Eurosurveillance. 2025 Aug 28;30(34):2500122. Available at: https://doi.org/10.2807/1560-7917.ES.2025.30.34.2500122

8. World Health Organization (WHO). Guidelines on long-acting injectable cabotegravir for HIV prevention. Geneva: WHO; 2022. Available at: https://www.who.int/publications/i/item/9789240054097

9. Martinez V, Ormel H, Op de Coul ELM. Barriers and enablers that influence the uptake of HIV testing among heterosexual migrants in the Netherlands. PLoS One. 2024;19(10):e0311114. Available at: https://doi.org/10.1371/journal.pone.0311114

10. Agustí C, Cunillera O, Mascort J, Carrillo R, Casabona J. Implicit bias in HIV testing based on indicator conditions in primary care: a population-based study in Catalonia, Spain, 2017 to 2021. Eurosurveillance. 2025 Jun 19;30(24):2400585. Available at: https://doi.org/10.2807/1560-7917.ES.2025.30.24.2400585

11. Rice BD, Elford J, Yin Z, Delpech VC. A new method to assign country of HIV infection among heterosexuals born abroad and diagnosed with HIV. AIDS. 2012;26(15):1961–6. Available at: https://doi.org/10.1097/QAD.0b013e3283578b80

12. Pantazis N, Rosinska M, van Sighem A, Quinten C, Noori T, Burns F, et al. Discriminating Between Premigration and Postmigration HIV Acquisition Using Surveillance Data. J Acquir Immune Defic Syndr. 2021;88(2):117–124. Available at: https://doi.org/10.1097/QAI.0000000000002745

13. European Centre for Disease Prevention and Control (ECDC). Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants in the EU/EEA. Stockholm: ECDC;

10 All references were accessed 11 October 2025.

2019. Available at: https://www.ecdc.europa.eu/en/publications-data/public-health-guidance-screening-and-vaccination-infectious-diseases-newly

14. European Centre for Disease Prevention and Control (ECDC). HIV and migrants - Monitoring the implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia: 2022 progress report. Stockholm: ECDC; 2022. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/HIV_and_migrants_0.pdf
15. Shobowale O, Schmidt AJ, Meireles P, Rojas Castro D, Detandt S, Stuttenheim SE, et al. Determinants of HIV Testing Among Migrant Men Who Have Sex with Men from Sub-Saharan Africa and Other Regions Residing in 10 European Countries. AIDS Behav. 2024;28:488–506. Available at: https://doi.org/10.1007/s10461-023-04239-1
16. Nöstlinger C, Cosaert T, Van Landeghem E, Vanhamel J, Jones G, Zenner D, et al. HIV among migrants in precarious circumstances in the EU and European Economic Area. The Lancet HIV. 2022 Jun 1;9(6):e428-37. Available at: https://doi.org/10.1016/S2352-3018(22)00032-7
17. Segala FV, Di Gennaro F, Frallonardo L, De Vita E, Petralia V, Sabienza V, et al. HIV-related outcomes among migrants living in Europe compared with the general population: a systematic review and meta-analysis. The Lancet HIV. 2024 Dec 1;11(12):e833-42. Available at: https://doi.org/10.1016/S2352-3018(24)00210-8
18. Kamenshchikova A, Peters CM, Nöstlinger C, Rice B, Ford N, Ravasi G, et al. Interventions to ensure access to and continuity of HIV care for international migrants: an evidence synthesis. The Lancet HIV. 2024 Dec 1;11(12):e873-84. Available at: https://doi.org/10.1016/S2352-3018(24)00175-9
19. European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Technical guidance on prevention and control of infectious diseases among people who inject drugs. Stockholm: ECDC/EMCDDA; 2012. Available at: www.ecdc.europa.eu/en/publications-data/ecdc-and-emcdda-technical-guidance-prevention-and-control-infectious-diseases-0
20. European Centre for Disease Prevention and Control (ECDC) and European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Prevention and control of infectious diseases among people who inject drugs - 2023 update. Stockholm: ECDC/EMCDDA; 2023. Available at: https://www.ecdc.europa.eu/en/publications-data/prevention-and-control-infectious-diseases-among-people-who-inject-drugs-2023
21. European Centre for Disease Prevention and Control (ECDC). Continuum of HIV care - Monitoring implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia: 2022 progress report. Stockholm: ECDC; 2023. Available at: https://www.ecdc.europa.eu/en/publications-data/continuum-hiv-care-monitoring-implementation-dublin-declaration-partnership-0
22. Restar A, Minalga BJ, Quilantang MI, Adamson T, Dusic E, van der Merwe LA, et al. Mapping Community-Engaged Implementation Strategies with Transgender Scientists, Stakeholders, and Trans-Led Community Organizations. Curr HIV/AIDS Rep. 2023;20(3):160-169. Available at: https://doi.org/10.1007/s11904-023-00656-y
23. Downing J, Yee K, Sevelius JM. PrEP Use and Adherence Among Transgender Patients. AIDS Behav. 2022;26(4):1251–1259. Available at: https://doi.org/10.1007/s10461-021-03482-8
24. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: WHO; 2016. Available at: https://iris.who.int/handle/10665/208825
25. Croxford S, Stengaard AR, Brännström J, Combs L, Dedes N, Girardi E, et al. Late diagnosis of HIV: an updated consensus definition. HIV medicine. 2022 Dec;23(11):1202-8. Available at: https://doi.org/10.1111/hiv.13425
26. Suligoi B, Regine V, Pugliese L, Galli C. Recent HIV Infections in Italy: Data from the HIV National Surveillance System, 2012–2023. Pathogens. 2025 Aug 22;14(9):835. Available at: https://doi.org/10.3390/pathogens14090835
27. European Centre for Disease Prevention and Control (ECDC). European Standards of HIV prevention and care: Module on HIV testing. Stockholm: ECDC; 2025. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/European-Standards-of-HIV-prevention-and-Care-Module-on-HIV-testing.pdf
28. INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795–807. Available at: https://doi.org/10.1056/NEJMoa1506816
29. Earnshaw VA, Smith LR, Chaudoir SR, Lee IC, Copenhaver MM. Stereotypes about people living with HIV: implications for perceptions of HIV risk and testing frequency among at-risk populations. AIDS Educ Prev. 2012;24:574–581. Available at: https://doi.org/10.1521/aeap.2012.24.6.574

2. HIV and AIDS in the WHO European Region

2.1. HIV and AIDS diagnoses in the WHO European Region

2.1.1. HIV diagnoses

In 2024, 105 922 people in the WHO European Region were diagnosed with HIV, corresponding to a rate of 11.8 per 100 000 population (see Table A, Table 1). This number includes HIV diagnoses reported by 49 countries[11] to the joint ECDC and WHO Regional Office for Europe surveillance system. It brings the cumulative number of reported HIV diagnoses in the Region to 2 683 039 since reporting began in the 1980s. As in previous years, most (66%) of the people diagnosed with HIV in 2024 were from the East of the Region (69 292)[12], 25% (26 124) were from the West, and 10% (10 506) were from the Centre. The rate was also highest in the East (27.2 per 100 000 population), five times higher than in the West (5.9 per 100 000) and in the Centre (5.3 per 100 000) (see Table A, Table 1). For men, the average rate across the Region was 15.8 per 100 000 population (Table 2), and for women, 8.0 per 100 000 population (Table 3).

Rates of HIV diagnoses varied widely across countries in the WHO European Region in 2024. The highest rates per 100 000 population (more than 15.0) were observed in the Russian Federation (33.5), followed by Ukraine (26.5), Moldova (26.4), Malta (20.6), Kazakhstan (20.2), Malta (20.6), Armenia (19.6), Ireland (18.8), Georgia (16.5), and Kyrgyzstan (15.4). The lowest rates (3.0 and under) were reported by Sweden (2.8), Slovenia (2.6), North Macedonia (2.5), Croatia (2.4), Austria (2.2), Hungary (2.2), Serbia (2.2), Slovakia (2.1), and Bosnia and Herzegovina (1.3).

The largest age groups diagnosed in the 49 report-ing countries were 30–39 years and 40–49 years (32% each), while 5.9% were young people aged 15–24 years, and 20.1% were 50 years or above at diagnosis (Fig 2.1; see Table A, Table 9).

The male-to-female ratio was 1.9, lowest in the East (1.6), higher in the West (2.3), and highest in the Centre (4.6). The highest male-to-female ratios (more than 10.0) at country level among countries with more than 10 cases were observed in North Macedonia (16.7) Serbia (15.0) and Malta (11.8), and the lowest in Iceland (1.1), Estonia (1.2) the United Kingdom and the Russian Federation (1.4 each), Finland, Moldova, and Ireland (1.5 each).

11 No data were received from Andorra, Monaco, San Marino, Turkmenistan or Uzbekistan. Liechtenstein is an EEA Member State but not a WHO Member State, so its data are included in the totals for the EU/EEA, but not for the WHO European Region.

12 Figure A1.1 in Annex 1 illustrates the division of countries into West, Centre and East of the WHO European Region.

Data on transmission mode, which was available for 49 countries (Fig 2.2; see Table A, Tables 4–8) provide information on risk exposure among people diagnosed with HIV. The data for 2024 indicate the following:

WHO European Region

- Heterosexual contact was still the main reported mode of HIV transmission in the WHO European Region, accounting for 62% (65 275) of people diagnosed in 2024 and 70% of HIV diagnoses in 2024 with a known mode of transmission (Table 6). Among these diagnoses, 14% originated from countries with generalised epidemics (data not shown).
- Sex between men was the second most common transmission mode, accounting for 13% (13 633) of HIV diagnoses and 15% of HIV diagnoses with a known mode of transmission (Table 5).
- Injecting drug use accounted for 12% (13 194) of diagnoses overall and 14% of HIV diagnoses with a known mode of transmission (Table 4).
- Less than one percent (0.6%, 611) of cases were infected through MTCT (0.7% of those with a known mode of transmission) (Table 7) and 0.1% (114) through other transmission routes (nosocomial infection, transfusion or use of other blood products) (Table 8).
- Transmission mode was reported as unknown or missing for 12% (12 983 cases) (Table 8). Reporting completeness regarding transmission mode varies greatly across the Region, with information lacking for 2% of HIV diagnoses in the East, 57% in the Centre, and 20% in the West.

East

- In total, 75% of those diagnosed in 2024 and 77% of diagnoses with a known mode of transmission (52 279) were infected heterosexually, making this the main route of transmission reported in all countries in the East (Table 6).
- Overall, 18% of those diagnosed in 2024, as well as those with known route of transmission (12 266) were infected through injecting drug use (Table 5), with transmission through injecting drug use account-ing for more than 18% of diagnoses with a known transmission mode in Ukraine (19%) and the Russian Federation (20%).
- In total, 4% (2 814) of those diagnosed were infected through sex between men (Table 4). However, Armenia, Azerbaijan, Estonia, Kazakhstan, Kyrgyzstan, Georgia, Latvia, and Lithuania reported that sex between men accounted for 10% or more of HIV diagnoses with a known transmission mode.

Figure 2.1: Percentage of HIV diagnoses, by country and age group, WHO European Region, 2024 (n=105 772)

Note: the graph organises countries in order of the proportion of the population <30 years. San Marino reported zero cases for 2024 and is not included in the graph. Unknown age is excluded from the proportions presented here.

Figure 2.2: Percentage of HIV diagnoses with known mode of transmission, by transmission route and country, WHO European Region 2024 (n=92 858)



Note: the graph organises countries in order of increasing proportion of heterosexual mode of transmission. No data from Andorra, Monaco, Turkmenistan, or Uzbekistan. San Marino reported zero cases.

Figure 2.4: HIV diagnoses, by CD4 cell count per mm3 at diagnosis and transmission mode, WHO European Region, 2024





Note: children under 15 years of age and individuals with previously positive diagnoses are excluded from both the numerator and denominator. Cases classified as recent infections are excluded from the numerator of the late-diagnosis indicator if CD4< 350 cells/mm³ but remain included in the denominator. Data on CD4 cell counts reported from the Russian Federation do not include information on previous or recent infection, or disaggregation by mode of transmission, and are therefore excluded from subregional and regional totals. No data were reported from Andorra, Monaco, Turkmenistan, or Uzbekistan. San Marino reported zero cases.

Forty-six countries provided information on the country of birth, country of nationality, or region of origin for 93.3% (53 786) of HIV diagnoses in 2024 (Table 10)[13]. In the WHO European Region, 29.6% of the total HIV diagnoses and 31.7% of those with known informa-tion on region of origin (17 073) were reported among people originating from outside the reporting country. This is slightly less than for 2023 (33.2%), driven by the decrease in diagnoses among people of foreign origin in the West and the Centre of the Region (from 66.1% to 64.5% and from 21.8% to 16.8%, respectively). There was no change observed in the East, which remains at 2.0%.

Most of the diagnoses (>80% of all diagnoses with known foreign origin) originated from three regions: Sub-Saharan Africa; Latin America and the Caribbean; and Central and Eastern Europe, with the share of diagnoses among those originating from Sub-Saharan Africa being the largest (40.3%). Of 6 874 HIV diagnoses originating from this subregion in 2024, 97.0% (6 666) were diag-nosed in the EU/EEA countries and the United Kingdom.

Forty-one countries provided information on CD4 cell count at the time of HIV diagnosis in 2024[14]. Information was reported for 27 871 people aged over 15 years at diagnosis (covering 66.2% of all HIV diagnoses in the reporting countries) (Table 12). More than half (54.2%) of all individuals diagnosed in 2024, where a CD4 cell count at diagnosis was reported, were considered to have been diagnosed late, with a CD4 cell count < 350 cells per mm^3, including 33.6% of cases considered to have advanced HIV infection (CD4 cell count < 200 cells per mm^3). This is comparable to the results from previous years, albeit with a slight increase. However, the regional average excludes data from the Russian Federation, where a CD4 cell count at diagnosis was reported for 98.2% of HIV diagnoses, which means that only 32.1% of cases are considered to be diagnosed late (CD4 cell count < 350 cells per mm^3) and 16.9% to have advanced HIV infection (CD4 cell count < 200 cells per mm^3). The percentage of those diagnosed late (CD4 cell count < 350 cells per mm^3) varied across the countries. Those countries with the highest percentages of late diagnoses (60% or more, in countries with more than five cases) were Bosnia and Herzegovina (80.6%), North Macedonia (74.5%), Croatia (68.3%), Sweden (66.7%), Albania (66.7%), Moldova (66.1%), Ukraine (64.7%), Bulgaria (63.1%), Romania (62.3%) and Serbia (62.1%). Those with the lowest percentages (40% or less) were Finland (26.9%) and Cyprus (40.7%).

The percentage of late diagnoses also varied across transmission categories and was highest for people with reported heterosexual transmission (61%; 62% for men and 59% for women) and as a result of injecting drug use

13 Aggregated data reported from the Russian Federation did not include information on the country of birth, country of nationality or region of origin and is not included in the denominator.

14 Data on CD4 cell count reported from the Russian Federation did not include disaggregation by mode of transmission, and data from Armenia, Azerbaijan, Kazakhstan and Tajikistan labelled all HIV diagnoses as previously positive. Therefore data from these countries were excluded from subregional and regional analysis.

(57%) and lowest for men infected through sex with men (41%) (see Figure B, Figure 2.4; Table 12). Late diagnosis was more common in the East (62%) than in the Centre (57%) and the West (47%). In the Centre and East, the high proportion of late diagnoses is mainly driven by the high proportion of people infected through heterosexual contact.

The percentage of people diagnosed with a CD4 cell count < 350 cells per mm^3 increased with age, ranging from 33% among people aged 20–24 years at diagnosis to 66% among people aged 50 years or above. Overall, the percentage of late diagnoses by gender was 58% among women and 53% among men, but this is confounded by transmission mode and, for men, it conceals the difference between men who have sex with men (who tend to be diagnosed earlier) and men with reported het-erosexual transmission (who tend to be diagnosed later) (see Figure B).

2.1.2. Trends in HIV diagnoses

The rate of HIV diagnoses in the WHO European Region showed a slight downward trend between 2015 and 2019, decreasing from 18.3 to 15.9 per 100 000 population. In 2020, the rate dropped sharply to 12.2 per 100 000 (Figure 2.5). A modest annual increase was then observed, reaching 12.8 per 100 000 in 2023, before declining again to 11.8 per 100 000 in 2024. The marked decline in 2020 was probably due, in part, to reduced case detection resulting from the public health and social measures implemented by countries in response to the COVID-19 pandemic. The slight increase in the subsequent years may reflect a rebound in HIV testing and case detection as these measures were lifted, along with increased population movement within and into the Region. The year 2024 marked the first decrease in HIV diagnoses since the post-pandemic rise. Year-to-year declines were observed in all subregions except the Centre, where the rate increased from 4.3 to 5.3 per 100 000 population. This increase was driven primarily by Türkiye, which reported a 67% rise in new HIV diagnoses in 2024. According to the national focal point, this sharp rise was largely due to strengthened surveil-lance and expanded testing capacity rather than a true increase in transmission. Overall, 11 of 49 countries reported an increase in HIV diagnoses in 2024 against 2023. However, as regional trends are strongly influenced by the largest countries, the findings presented in this chapter should be interpreted with caution.

In 2024, the number of diagnosed women and men decreased by 34% in the WHO European Region, from 55 580 in 2015 to 36 835 and from 104 237 to 68 639, respectively (Tables 2 and 3). The overall trend largely reflects the situation in the Russian Federation, which accounts for the vast majority of HIV diagnoses reported in 2024, where reported diagnoses have decreased by 40% since 2019. Other countries have seen significant variations, with 11 countries reporting an increase in HIV diagnoses in 2024 compared to 2023. For example, the number of women diagnosed in Czechia and Iceland was over six times higher in 2024 than in 2015. A large

(over 100%) increase between 2015 and 2024 was also observed in Iceland, Ireland, Bosnia and Herzegovina, North Macedonia, and Türkiye in both males and females. Conversely, a large (over 40%) decrease among males was observed in Albania, Austria, Belarus, Estonia, Latvia, Portugal, and Switzerland. Among females, the largest decrease between 2015 and 2024 was observed in Belarus, Estonia, Latvia, Luxembourg, Malta, and Sweden.

Forty-three countries consistently reported data on transmission mode for the period 2015–2024 (Figure 2.6−2.9) and the HIV diagnoses with known mode of transmission indicate the following (Figure 2.6−2.9):

WHO European Region

- The number of HIV diagnoses in people with reported heterosexual transmission increased from 26 403 in 2015 to 27 514 in 2024. The proportion of all HIV

diagnoses attributed to heterosexual contact also increased from 52% of cases in 2015 to 64% in 2024.

- The number of all HIV diagnoses attributed to sex between men decreased by 29% from 15 935 in 2015 to 11 286 in 2024 and the proportion compared to other transmission modes also decreased from 32% to 26% over the same period. Overall, the number of HIV diag-noses reported among men who have sex with men in countries reporting consistently has remained sta-ble at around 11 000 (26% of all known transmission modes) since 2019.
- While the number of diagnoses in people infected through injecting drug use has shown a stable decline since 2015, it increased by 13% in 2020 compared to 2019, with a reversal in 2021. The decreasing trend continued in 2023 and in 2024, reaching 3 798 or 9% of all diagnoses with known modes of transmission versus 7 417 and 15% proportion in 2015.

Figure 2.5: HIV diagnoses per 100 000 population, by year of diagnosis, WHO European Region, 2015–2024



Note: includes data from 49 countries. Data from Andorra, Monaco, Turkmenistan and Uzbekistan are excluded due to inconsistent reporting during the period.

Figure 2.6: HIV diagnoses, by transmission mode and year of diagnosis, WHO European Region, 2015–2024



Note: Data from Andorra, Iceland, Malta, Monaco, the Russian Federation, San Marino, Turkmenistan and Uzbekistan are excluded due to inconsistent reporting during the period. HIV diagnoses reported by Poland and Türkiye were excluded due to incomplete reporting on transmission mode during a portion of the previous decade.

Figure 2.7: HIV diagnoses, by transmission mode and year of diagnosis, East, 2015–2024



Note: data from the Russian Federation, Turkmenistan, and Uzbekistan are excluded due to inconsistent reporting during the period.

Figure 2.8: HIV diagnoses, by transmission mode and year of diagnosis, Centre, 2015–2024



HIV diagnoses reported by Poland and Turkiye were excluded due to incomplete reporting on transmission mode during a portion of the previous decade.

Figure 2.9: HIV diagnoses, by transmission mode and year of diagnosis, West, 2015–2024

Note: data from Andorra, Iceland, Malta, Monaco, and San Marino, are excluded due to inconsistent reporting during the period.

- The number HIV diagnoses among children infected through have remained relatively stable over the past decade, with approximately 500 cases reported annually. The proportion has been fluctuating between 0.8% and 1.2%, with no clear trend to indicate either an increase or decrease.
- The number of diagnoses in people infected by other means, such as through nosocomial infection or blood transfusion, remains stable, with around 100 diagnoses and a 0.3% share of all transmission modes. Most cases originate outside of the WHO European Region (65%).

East

- The number of HIV diagnoses in people with reported heterosexual transmission increased slightly (6%), from 15 019 in 2015 to 15 959 in 2024. At the same time, the percentage of all HIV diagnoses attributed to heterosexual contact increased from 68% of cases in 2015 to 79% in 2024.
- The number of diagnoses in people infected through injecting drug use decreased by 52%, from 6 118 in 2015 to 2 924 in 2024. The percentage of all HIV diagnoses attributed to injecting drug use decreased from 28% in 2015 to 14% in 2024.
- The number of diagnoses in people infected through sex between men increased from 833 in 2015 to 1 265 in 2024. Yet despite this increase, the percentage of all HIV diagnoses attributed to sex between men has remained low, at 4% in 2015 and 6% in 2024.
- The number of children infected through MTCT transmission decreased by 50%, from 272 in 2015 to 137 in 2024, representing 1.2% of HIV diagnoses in 2015 and 0.7% in 2024.
- The number of diagnoses in people infected by other means, such as nosocomial infection or blood transfusion, is very low, with only a few cases reported annually.

Centre

- Since the general decline in reported HIV cases in 2020, the number of HIV diagnoses in those infected through heterosexual transmission has increased. In 2024, it remained high, resulting in a 39% increase between 2015 and 2024 (from 838 to 1 164). The per-centage of HIV diagnoses attributed to heterosexual transmission was 39% in 2015 and 47% in 2024.
- During the same reporting period, the number of diagnoses in those infected as a result of sex between men remained stable. However, the percentage of HIV diagnoses attributed to sex between men decreased from 48% in 2015 to 39% in 2024. This was the predominant mode of transmission in the Centre until 2021, when heterosexual transmission became more common. However, in eight out of fifteen countries it was still the predominant transmission mode for the Centre in 2024.

- The number of HIV diagnoses in those infected as a result of injecting drug use was 248 in 2015 and 111 in 2024. The percentage of HIV diagnoses attributed to injecting drug use was 12% in 2015 and 4% in 2024.
- The number of HIV diagnoses as a result of MTCT transmission was 24 in 2015 and 33 in 2024, representing 0.5% of all diagnoses in 2024 (a percentage which has ranged between 0.7 and 1.9% over the last decade).
- The number of diagnoses in people infected due to nosocomial infection or blood transfusion is very low, with under ten cases reported annually.

West

- HIV diagnoses of people with reported heterosexual transmission slightly decreased from 10 546 to 10 387. The percentage of HIV diagnoses attributed to heterosexual contact increased from 41% of cases in 2015 to 50% in 2024. The proportion of people infected through heterosexual transmission originating outside the reporting country remained high (73%) in 2024. The share of previously diagnosed individuals has slightly decreased, from 35% in 2023 to 31% in 2024.
- HIV diagnoses of people infected through sex between men decreased by 38%, from 14 061 in 2015 to 9 043 in 2024. The percentage of HIV diagnoses attributed to sex between men decreased from 54% in 2015 to 44% in 2024.
- HIV diagnoses of people infected through injecting drug use decreased by 27%, from 1 051 in 2015 to 763 in 2024, representing 4% of HIV diagnoses in both 2015 and 2024.
- Diagnoses of children infected through MTCT decreased consistently between 2015 and 2021 (from 226 to 168) before increasing dramatically in 2022 to reach 326 cases by 2024. This may be due to the increasing trend among previous positive individuals, which remained high in 2024 (61%).

The number of people infected due to nosocomial infection or blood transfusion remained stable over the decade, with 98 cases in 2015 and 106 in 2024. Of 106 cases with known origin in 2024, 88% originated from outside the reporting country.

2.1.3. AIDS cases, morbidity and mortality

In 2023, 7 161 people in 43 countries of the WHO European Region[15] were diagnosed with AIDS, corresponding to a rate of 1.2 per 100 000 population (Table 13). Of the 7 161 people who received a diagnosis of AIDS in 2024, 63% (4 505) were diagnosed in the East, 24% (1 718) in the West and 13% (938) in the Centre of the Region. The rate was also highest in the East (4.4 per 100 000 popula-tion), seven times higher than that in the West (0.6 per

15 No data were reported from Andorra, Bosnia and Herzegovina, Germany, Monaco, North Macedonia, the Russian Federation, Sweden, Turkmenistan or Uzbekistan. Data from Portugal not published at the country's request.

100 000) and nine times higher than in the Centre (0.5 per 100 000 population).

The rate of AIDS diagnoses varied widely among the countries, with the highest rates (3.0 or above) reported in Moldova (8.9), Ukraine (8.2), Georgia (6.8) and Armenia (4.2), and the lowest rates (under 0.3) reported in Israel (0.2) and Slovakia (0.1).

Tuberculosis represented 16% of all reported AIDS-defining illness events in 2024, ranging from 9% of reports in the West, to 13% in the Centre, and 15% in the East.

In the 39 countries with consistent AIDS data[16], the overall rate of AIDS diagnoses in the Region decreased by 53% between 2015 and 2024, from 2.5 per 100 000 population (14 756 cases) to 1.2 per 100 000 (7 119 cases) (Figure 2.10).

AIDS trends varied across the three subregions. In the East, the rate fluctuated between 4.3 and 4.9 over the past three years, but still represented a 56% decrease in 2024 compared with 2015. In the Centre, no substantial change was observed, with the rate remaining around 0.5. In the West, the steady downward trend contin-ued, with a 47% decline from 0.9 in 2015 to 0.6 in 2024 (Figure 2.10).

A total of 43 countries in the Region[17] provided information on AIDS-related deaths or deaths among people

16 Data from Andorra, Belarus, Bosnia and Herzegovina, Cyprus, Germany, Malta, Monaco, North Macedonia, the Russian Federation, San Marino, Spain, Sweden, Turkmenistan and Uzbekistan are not reported, or excluded due to inconsistent reporting during the period.

17 No data were received from Andorra, Bosnia and Herzegovina, Germany, North Macedonia, Monaco, the Russian Federation, Sweden, Turkmenistan or Uzbekistan. Data from Portugal not published at country request.

previously diagnosed with AIDS[18], with 2 503 people reported to have died during 2024. This represents a 47% decrease compared with the 4 759 deaths reported for the same countries in 2015. Of the 2 503 deaths in 2024, 72% were reported from the east of the Region, 19% from the West and 9% from the Centre (Table 17). It is important to note that delays in reporting and under-reporting have a significant impact on these numbers at the European level, particularly when the death occurs long after the HIV or AIDS diagnosis. The numbers presented here should therefore not be interpreted as representative of the true burden of mortality due to AIDS in the European Region.

2.2. HIV testing

Data on the number of HIV tests can support the interpretation of trends in diagnosed HIV infections. However, it is worth noting that the numbers provided are collected in a heterogeneous manner, and compari-sons between country testing rates should be made with caution. In 2024, a total of 89 971 809 HIV tests were reported by 29 countries (13 in the East, nine in the Centre, and seven in the West). These tests do not include unlinked anonymous testing and all countries except the Russian Federation also exclude the HIV tests performed as part of blood-donor screening. In 2024, the Russian Federation reported a total of 54 360 488 HIV tests, accounting for 63% of all HIV tests reported in the Region for that year. Countries in the East tended to report higher testing rates than those in the West and Centre, but rates varied greatly across countries from all parts of the Region, and more data were available from countries in the East than the Centre and the West (Table 18).

18 In countries and years for which cause of death (AIDS or non-AIDS related) was unknown or could not be reported, deaths among people (ever) diagnosed with AIDS were included.

Figure 2.10: New AIDS diagnoses per 100 000 population, by geographical area and year of diagnosis, WHO European Region, 2015–2024



Note: includes data from 39 countries. Data from Andorra, Belarus, Bosnia and Herzegovina, Cyprus, Germany, Malta, Monaco, North Macedonia, the Russian Federation, San Marino, Spain, Sweden, Turkmenistan, and Uzbekistan are excluded due to inconsistent reporting during the period.

The overall number of tests performed in the Region increased by 62%, from 53 681 202 in 2015 in the 29 coun-tries with data available in 2015 and 2024 (Table 18). Increases in large countries with high numbers tested, such as Belarus, France, Kazakhstan, the Russian Federation and Türkiye, have had a considerable impact on the overall increase since 2015. The number of tests have more than doubled in a few countries, although information on testing yield or coverage among key pop-ulations at higher risk of HIV infection was not collected.

2.3. Conclusions

The 2024 HIV surveillance data indicate a wide varia-tion in epidemic patterns and trends across the WHO European Region. Overall, after three years of consecu-tive increase (2021−2023), HIV diagnoses decreased in the WHO European Region in 2024, with a rate of 11.8 per 100 000 population, a 7.8% decrease compared with the 2023 rate. Nevertheless, the overall trend masks very different movements across the Region. The trend largely reflects the situation in the Russian Federation, which accounts for the vast majority of HIV diagnoses reported in 2024, where diagnoses have decreased since 2019 by 40% (although 11 out of 49 countries did report an increase in HIV diagnoses in 2024 compared to 2023).

When comparing the number of HIV diagnoses with the estimated number of new HIV infections over the past decade, it becomes clear that more people are acquiring HIV than are being diagnosed. This suggests an increas-ing number of people living with undiagnosed HIV in the Region. The widening gap between estimated new infections and reported diagnoses highlights the need to further scale up targeted and differentiated testing efforts, particularly in the eastern part of the Region, where case detection remains lower.

Previously positive individuals have had a considerable impact on the epidemiological profile and the trends reported in 2024, specifically for the EU/EEA countries from the West and the Centre of the Region. A sub-anal-ysis of the previous positive diagnoses shows that they include a higher proportion of women in older age groups, originating mainly from central and eastern Europe and Sub-Saharan Africa, who were primarily infected through heterosexual contact. Transmission through sexual con-tact between men is less common among those with previous positive diagnoses, while MTCT was reported at a higher rate among this group compared to newly diag-nosed people. Consequently, trends in reported modes of transmission from EU/EEA countries and from the West should be interpreted with caution.

Heterosexual transmission remains the main transmis-sion route in the East, with an increasing trend over time, and reported transmission through sex between men remains low in absolute terms in the East of the Region. This trend in reported mode of transmission does not explain a rising male-to-female ratio over time. In the regions where HIV infections are predominantly attrib-uted to heterosexual transmission, such as sub-Saharan

Africa [1], women outnumber men among people living with HIV, resulting in a male-to-female ratio lower than 1.0 [2]. There is also some evidence to suggest that a proportion of men reported as heterosexually infected may, in fact, be men who have sex with men or people with a history of injecting drugs, who may have been misclassified as heterosexually infected [3-5].

Despite the increasing trend in heterosexual transmis-sion due to the factors described above, eight of the 15 countries in the Centre reported sex between men as the predominant mode of transmission. Drug-injection-related transmission remains low, but past outbreaks [6–10] suggest that HIV prevention services for people who inject drugs continue to be important, and must be maintained with sufficient coverage to prevent further outbreaks. The percentage of young people among the new diagnoses is also higher in this part of the Region than elsewhere, with almost every third person diag-nosed with HIV under 30 years of age. HIV prevention, diagnostics and treatment interventions should accom-modate the needs of key populations, particularly men who have sex with men, with relevant evidence-based interventions. These interventions include condom and lubricant programming; diversified HIV testing services; assisted voluntary partner notification, PrEP; prevention and management of co-infections (particularly sexually transmitted infections) and rapid HIV treatment initia-tion. Services should be patient-centred and provided in a friendly environment, preferably with the involvement of civil society along the entire HIV continuum of ser-vices, ranging from HIV prevention to adherence to ART.

In all, 23.3% of the diagnoses reported in the West in 2024 were previously positive. However, the number of previous positives is probably underestimated, as the variable identifying them had a completeness of 80.6% in 2024. This category includes individuals who had previously received an HIV diagnosis, either in another country or within a different setting in the reporting country, before the current reporting year. Most of these infections were probably acquired abroad and may not reflect a rise in transmission in the reporting countries. Almost two-thirds of HIV diagnoses in the West origi-nated from outside the reporting country. In countries where migration is common and takes various forms, the public health challenge of ensuring access to health services for migrant populations, including HIV services and promoting cross-border collaboration and data shar-ing, remains essential to a robust and people-centred public health response. The influx of people living with HIV, particularly from Eastern Europe and Latin America and the Caribbean, has introduced new challenges to HIV care, as this population may have different needs for mental health and social support. For example, people from Ukraine require special consideration when transi-tioning to new ART regimens (many were on treatment regimens that are not available in EU/EEA countries) [11]. In addition, individuals who are aware of their HIV-positive status may hesitate to seek care in the health system due to challenges to access or concerns related to stigma and discrimination [12].

More than half of HIV diagnoses have a CD4 cell count < 350 cells per mm^3, including one third of cases with advanced HIV infection (CD4 cell count < 200 cells per mm^3). Once again, it is significant that the 2024 data provide information on variations in late diagnoses according to geography, transmission mode and age. The data also suggest problems with access to and uptake of HIV testing for some populations, indicating the need to improve testing programmes and address structural barriers to diagnose people living with HIV at an earlier stage. The data also confirm that the pro-portion diagnosed at a late stage of infection is highest among people infected heterosexually (particularly men), or as a result of injecting drug use, and among those in the older age groups.

Late diagnosis reflects insufficient access to and uptake of appropriate HIV testing and counselling by those at greater risk of acquiring HIV, as a result of a number of personal, system-related and structural fac-tors. HIV testing strategies must be reconsidered and diversified to include innovative approaches involving community-based organisations and focusing on key population groups. Multiple entry points to HIV testing should be available through HIV self-testing, HIV test-ing performed by trained lay providers and civil society, social-network based strategies, home sampling, rou-tine indicator condition-guided HIV testing offered in the health system, and assisted partner notifications. HIV testing should also be available in settings such as prisons, drug-dependence treatment programmes, sex-ual and reproductive health clinics, and migrant health services, depending on the local context. Support for timely linkage to HIV treatment and care is essential to reduce late diagnosis and ensure progress towards the Joint United Nations Programme on HIV/AIDS and WHO 95–95–95 targets, improving treatment outcomes and reducing HIV transmission.

It is estimated that around 3 200 000 (95% confidence interval: 2 800 000–3 400 000) people are living with HIV in the WHO European Region, around 63% of whom are on ART [13].

Similar to the 2023 data, 2024 HIV data reveals a sig-nificant issue with data quality, completeness and lack of standardisation for the variable ‘HIV status’, differ-entiating new HIV diagnoses from previous positives. A total of 16 countries did not have any information on this variable at all. Achieving consensus among countries in the Region on the collection, recording and reporting of previous positive cases is critical, due to the different epidemiological profiles and healthcare needs of previ-ously diagnosed individuals. Overall, 13 of 49 reporting countries had less than 50% coverage with CD4 cell count at the time of diagnosis. This complicates the 2024 data interpretation. Improving data recording and reporting standards within surveillance systems will ensure accuracy and help with the planning of tailored prevention strategies.

Since the adoption of the ‘Regional action plans 2022–2030 for ending AIDS and the epidemics of viral

hepatitis and sexually transmitted infections' [14], WHO and partners have been working with Member States on their national adoption and implementation of the action plans, with a particular focus on strengthening HIV surveillance; reporting and analytical capacity; alignment and uptake of HIV testing and treatment guidance; innovative combination HIV prevention approaches in key populations; efforts to eliminate MTCT of HIV, viral hepatitis B and syphilis, and other key priorities, as highlighted within the plans.

To support implementation of the 'Regional action plans 2022–2030 for ending AIDS and the epidemics of viral hepatitis and sexually-transmitted infections', in a year marked by significant funding reductions and evolving global health architecture, the WHO Regional Office for Europe has prioritised maintaining visibility of the communicable diseases agenda at policy level.

At the regional level, efforts focused on strengthening surveillance and global reporting, including the first-ever publication on sexually-transmitted infection (STI) surveillance in non-EU countries. A series of regional events was convened to disseminate WHO guidelines and foster political engagement across the European Region.

Despite substantial funding constraints, the WHO Regional Office for Europe has continued to provide technical support to Member States. This included programme reviews, assessments of Global Fund funding requests, and reviews of national clinical guidelines and strategic plans for HIV, viral hepatitis, and STIs. Technical support was also provided to modernise testing strate-gies, implement WHO guidance on PrEP, conduct studies on late diagnosis, and improve surveillance and cascade analysis for key populations. The Regional Validation Secretariat team supported countries in preparing and submitting validation and maintenance dossiers for the elimination of vertical transmission of HIV and syphilis.

WHO Regional Office of Europe, with ECDC and other partners, will continue to support Member States in their efforts to accelerate progress toward reaching the Sustainable Development Goals for HIV through dedicated guidance, workshops, webinars and other technical support focused on high-impact surveillance, monitoring, treatment and prevention activities.

References[19]

1.

2.

3.

19 All references were accessed on 14 November 2024.

Ukraine. AIDS Behav. 2015;19:1938–40. Available at: https://doi.org/10.1007/s10461-015-1112-0

4. Dumchev K, Kornilova M, Kulchynska R, Azarskova M, Vitek C. Improved ascertainment of modes of HIV transmission in Ukraine indicates importance of drug injecting and homosexual risk. BMC Public Health 2020;20(1):1288. Available at: https://doi.org/10.1186/s12889-020-09373-2
5. Dumchev K, Stepanovich-Falke A, Lunchenkov N, Ronde A, Danshyna A, Bekbolotov A, et al. Comparison of registered and survey-based modes of HIV transmission in 2021-2023: Cross-sectional study in the Kyrgyz Republic. PLoS One. 2025 Aug 19;20(8). Available at: https://www.doi.org/10.1371/journal.pone.0330210
6. Hedrich D, Kalamara E, Sfetcu O, Pharris A, Noor A, Wiessing L, et al. Human immunodeficiency virus among people who inject drugs: is risk increasing in Europe? Euro Surveill. 2013;18(48). Available at: https://doi.org/10.2807/1560-7917
7. Giese C, Igoe D, Gibbons Z, Hurley C, Stokes S, McNamara S, et al. Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2016. Euro Surveill. 2016;20(40). Available at: https://doi.org/10.2807/1560-7917
8. European Centre for Disease Prevention and Control (ECDC)/ European Monitoring Centre for Drugs and Drug Addiction (EMCDD). HIV in people who inject drugs – Joint technical mission to Luxembourg. Stockholm: ECDC/EMCDDA; 2018. Available at: https://sante.public.lu/fr/publications/h/hiv-joint-technical-mission.html
9. McAuley A, Palmateer NE, Goldberg DJ, Trayner KMA, Shepherd SJ, Gunson RN, et al. Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis. Lancet HIV. 2019;6(5):e315–24. Available at: https://doi.org/10.1016/S2352-3018(19)30036-0
10. Des Jarlais DC, Sypsa V, Feelemyer J, Abagiu AO, Arendt V, Broz D, et al. HIV outbreaks among people who inject drugs in Europe, North America, and Israel. Lancet HIV. 2020;7(6):e434–42. Available at: https://doi.org/10.1016/S2352-3018(20)30082-5
11. Massmann R, Groh T, Jilich D, Bartková D, Bartovská Z, Chmelař J, et al. HIV-positive Ukrainian refugees in the Czech Republic. AIDS. 2023 Oct 1;37(12):1811–1818. Available at: https://doi.org/10.1097/QAD.0000000000003633
12. World Health Organization (WHO) Regional Office for Europe. Standardized protocol for clinical management and medical data-sharing for people living with HIV among refugees from Ukraine. Copenhagen: WHO Regional Office for Europe; 2022. Available at: https://iris.who.int/handle/10665/353083
13. Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDS crisis and the power to transform: UNAIDS Global AIDS Update 2025. Geneva: UNAIDS; 2025. Available at: https://www.unaids.org/en/resources/documents/2025/2025-global-aids-update
14. World Health Organization (WHO) Regional Office for Europe. Regional action plans for ending AIDS and the epidemics of viral hepatitis and sexually transmitted infections 2022–2030. Copenhagen: WHO Regional Office for Europe; 2023. Available at: https://iris.who.int/handle/10665/369243.

Tables

Table 1: HIV diagnoses and rates per 100 000 population, by country and year of diagnosis (2015–2024) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area	Country, territory or area[a]	Year of start of reporting	2015		2016		2017		2018		2019		
			N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	
EU/EEA													
West	Austria[c]	1980	346	4.0	321	3.7	337	3.8	236	2.7			
West	Belgium	1985	1109	9.9	1006	8.9	963	8.5	957	8.4			
Centre			277	3.2	202	2.9	241	3.5	311	4.6			
Centre			1178	2.8	110	2.7	106	2.6	105	2.6			
Centre		1986	0266	9.3	80	9.3	85	9.8	78	8.9			
				2.5	286	2.7	254	2.4	208	2.0			
	Bulgaria	1985											
	Croatia	1986											
	Cyprus	1985											
	Czechia												
West	Denmark	1990	277	4.9	244	4.3	242	4.2	219	3.8			
East	Estonia	1988	270	20.5	229	17.4	219	16.6	190	14.4			
West			174	3.2	180	3.3	158	2.9	153	2.8			
	Finland	1980											
West	France	2003	5 335	8.0	5 448	8.2	5 395	8.1	5 116	7.6			
West	Germany[d]	1993	3656	4.5	3400	4.1	3180	3.9	2899	3.5			
West				7.2		6.1		6.0		6.8			
Centre				2.8	656	2.3	650	2.3	728	2.4			
	Greece	1984	783										
					228		223		229				
	Hungary	1985	271										
West	Iceland	1983	12	3.6	28	8.4	24	7.1	38	10.9			
West	Ireland	1985	4873	10.4	5023	10.6	4883	10.2	5233	10.8			
West			6314	6.0	7303	6.2	6223	6.0	6433	5.1			
East			100	20.6	75	19.0	82	19.6	60	17.4			
West			157	0.0	214	5.3	263	5.3	336	0.0			
East			162	5.4	169	7.4	140	9.2	0	5.7			
West			61	28.8	63	29.3	45	23.7	160	19.9			
West			1	13.9	9	14.0	1	9.8	120	15.4			
West		1985	1051	6.2	961	5.7	1012	5.9	73	5.6			
Centre			2211	4.3	2201	4.2	2131	4.1	960	3.6			
West	I			3.4		3.5		3.8	191	3.2			
Centre				17.2	1318	17.0	1621	16.2	1	14.5			
				4.7		4.2		4.3	216	4.0			

Centre	taly	1987	279	1.6	1	1.6	427	1.3	1
Centre			1	2.3	766	3.0	1	2.0	501
West			784	9.3	822	9.5	678	9.4	782
West			931	4.6	88	4.4	853	4.3	102
			86	**6.2**	62	**6.1**	72	**6.0**	42
			48		4		42		4
			4		421		4		114
			332		429		351		481
			447		**27**		434		**25**
			28		**560**		**27**		**111**
			010				**101**		

Last column: 1.9, 2.0, 8.8, 4.8, **5.6**

Latvia	1985
Liechtenstein	1988
Lithuania	1983
Luxembourg	2001
Malta	1980
Netherlands	1984
Norway	1985
Poland	1985
Portugal	1987
Romania	1985
Slovakia	1985
Slovenia	2003
Spai	1983

	n										
	Sweden										
	Total EU/EEA										
Non-EU/EEA											
Centre	Albania	1993	96	3.3	127	4.4	94	3.3	102	3.5
West			3	4.2	3	4.1	6	8.1	12	16.0
East			2	10.2	303	10.6	358	12.6	429	15.1
East			94	7.4	556	5.6	567	5.6	656	6.5
East		2004	727	23.8	2 391	24.6	2 468	25.4	2 386	24.6
			2305							
	Andorra	1988								
	Armenia	1987								
	Azerbaijan	1981								
	Belarus									
Centre	Bosnia and Herzegovina	1986	15	0.4	24	0.7	15	0.4	24	0.7
East	Georgia	1989	717 413 2 474 619 818	19.0 5.2 13.9 10.5 25.0 2.7	718 363 2 898 748 832	19.0 4.4 16.0 12.4 25.8 0.0	631 403 3 008 836 835	16.7 4.9 16.4 13.7 26.3 8.1	672 434 3 212 866 905	17.8 5.1 17.3 13.9 28.8 0.0
West			1	3.0	0	5.4	3	4.1	0	3.6
Centre			19	1.2	34	1.4	26	2.1	23	2.1
Centre	Israel	1981	25	69.3	30	59.9	44	59.0	45	59.0
East			100	6.0	86	5.9	85	2.9	85	8.8
West			220	2.1	855	2.0	802	2.1	995	2.1
Centre			2	2.5	2	2.3	1	2.5	3	2.6
Centre			192	0.2	186	0.6	191	0.2	198	0.4
West			188	6.6	176	6.5	188	5.5	190	5.2
East	Kazakhstan	1987	4 550	13.5 2.6	10 545	11.9 3.0	3 465	13.5 3.5	8 444	15.6 3.9
Centre			1	-	1	-	1	-	1	-
East			149	30.4	038	33.4	205	36.8	421	37.1
East			2	9.6	2	8.3	2	7.4	3	7.2
West			107		437		844		248	
	Kyrgyzstan	1987	- 13 000 6 253		- 14 229 5 455		- 15 604 4 896		- 15 648 4 791	
	Moldova	1987								
	Monaco	1993								
	Montenegro	1987								
	N	20								

	North Macedonia	1990	1985							
	Russian Federation	1984	1984							
	San Marino	1999	1985							
	Serbia[f]	1991	1985							
	excluding Kosovo[g]	1990								
	Kosovo[g]	1987								
	Switzerland	1981								
	Tajikistan									
	Türkiye									
	Turkmenistan									
	Ukraine									
	United Kingdom									
East	Uzbekistan	1981	-	-	-	-	-	-	-	-
Total non-EU/EEA WHO European Region			**131 999 090**	**30.8**	**119 774 759**	**27.7**	**120 302 178**	**27.7**	**121 514 876**	**27.9**
West			5	48.2	123	43.5	112	43.7	112	43.8
Centre				**18.2**	160	**16.7**	**147**	**16.7**	**146**	**16.5**
East					111		112		112	
Total WHO European Region					386		178		876	
					147 334		**147 403**		**146 625**	

[a] Country/territory/area specific comments are in Annex 5.
[b] Cumulative total is the total number of cases reported by the country since the start of reporting.
[c] Austria uses study cohort data.
[d] The cumulative figure for Germany differs from the country's own reported total because of variations in the counting methodology used.
[e] The numbers displayed here may not fully align with the numbers in the country's national statistics as these are presented by the 'date of notification' instead of the 'date of diagnosis' as here.
[f] Due to discrepancies in the methodology used for calculating the population rates by the Russian Federal Statistics Service and the United Nations Population Division, rates on overall HIV diagnoses, as well as data disaggregated by sex, presented in Tables 1, 2 and 3 and elsewhere in the report may differ from the data presented in national statistics.
[g] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

2020		2021		2022		2023		2024		Cumulative total[b]	Country, territory or area[a]
N	Rate	N	Rate	N	Rate	N	Rate	N	Rate		
											EU/EEA
183	2.1	205	2.3	207	2.3	206	2.3	204	2.2	11 618	
	6.7	79	6.9	1 061	9.1	113	9.7	113	9.6	39 232	Austria[c]
	3.0	6	3.6		5.1	7	3.9	6	4.4	4 617	
	1.9		2.0	328	2.9	25	2.5	28	2.4	2 201	Belgium
	11.7	23	16.6		24.1	3	17.2	4	12.9	2 093	
	2.3	7	2.2	113	8.3	97	3.7	91	3.7	5 744	
						16		12			Bulgaria
		78		218		3		5			
						40		39			
				870		2		8			
		149									
											Croatia
		233									
161	2.8	139	2.4	258	4.4	227	3.8	199	3.3	8 984	
	11.1	12	9.4	25	18.8	18	13.4	13	9.7	10 917	
	2.4	5	2.6	0	4.7	3	4.5	3	4.0		Cyprus
		14		26		25		22		5 224	
		4		0		1		6			
3 593	5.3	3 688	5.4	4 269	6.3	5 050	7.4	4 716	6.9	115 599	
2 624 201	3 476 05.8 2.1	226 67 579 226	2.7 5.4 2.3	3 281 583 224	3.9 5.6 2.3	3 332 680 228	4.0 6.5 2.4	3 259 646 210	3.9 6.2 2.2	86 177 19 055 123	Czechia
34	9.3	20	5.4	40	10.6	44	11.3	39	10.2	628	
	8.7	39	7.8	87	17.1	90	17.2	100	18.8	13 499	Denmark
	2.5	51	3.3	92	3.7	72	4.2	82	4.0	60 573	
	13.5	92	11.2	164	12.2	507	10.0	379	9.6	9 100	
	2.6	82	2.6	229	2.5	188	2.5	180	0.0	73	Estonia
	4.9	12	4.3	91	9.0	81	9.3	0	6.8	4 298	
	11.2	110	15.8	252	12.7	267	11.0	19	6.4	3 777	
	15.9	45	8.7	82		73	19.4	6	20.6	993	Finland
	4.1	72	4.2	60	11.5	105	5.0	43	4.7	32	
	2.6	61	1.9	102		89	6.0	11	4.8	587	
	2.5	02	4.0	72	5.8	33	6.5	6	5.5	7 734	France
	11.0	14	12.3	45	4.5	22	10.6	84	9.4	35	
	2.8	61	3.4	26	7.1	40	3.9	3	4.0	168	
	1.9	10	2.1	14	10.7	21	2.7	26	2.1	70	
	1.7	27	1.8	11		11	2.1	4	2.6	884	Germany[d]
	6.4	96	6.7	10	3.7	17	7.0	3	6.6	28	
	3.5	01	3.4	70	3.7	35	2.9	26	2.8	898	
	4.1	15	**4.3**	82	2.7	14	**5.6**	4	**5.3**	1 755	
		39		03	7.0	44		2		1 149	
		31		57	4.3	3		00		75	
		92		33	**5.6**	35		9		247	
		35		74		03		99		15	
		2		6		4		7		257	
		19		**25**		**25**		77		**678**	
		61		**37**		**61**		1		**204**	
		9		**6**		**6**		11			
								3			
								55			
								3			
								22			
								8			
								29			
								6			
								24			
								16			
								4			
	3.3	10	3.6	98	3.4	12	4.3	12	4.4	1 848	
	-	4	-	-	-	3	-	3	-	96	
	13.2	-	15.2	53	19.2	-	18.0	-	19.6	6 158	
	5.4	42		57		50		54	11.2	12	
	14.8	56	6.7	66	7.4	09	8.8	4	13.0	226	
		90	15.6	1	17.2	1	15.4	1		36	
		1		64		46		17		325	
		49		4		3		1			
		6						1			
								22			
								8			
17	0.5	36	1.1	57	1.8	29	0.9	40	1.3	515	
	14.1	53	14.1	61	16.5	61	16.4	61	16.5	11 006	
	4.1	0		7		2		5	3.4	12	
	18.3	39	4.4	45	5.1	40	4.4	31	20.2	320	
	10.5	0	18.7	7	20.6	6	20.6	7	15.4	58	
	22.0	3		4		4		3	26.4	443	
	-	58	12.9	00	16.5	03	15.6	99	-	14	
	2.4	6		3		9		9	5.9	342	
	1.4	84	25.9	1	28.4	1	27.0	1	2.5	17	
	40.	1	-	09	-	05	-	05	33.5	888	
		79	2.1	1	6.4	4	8.6	3	0.0	40	
		2		92		92		88	2.2	462	
		-		9		8		0	2.2	486	
		13		-		-		-	1.9		

Greece	Hungary	Iceland	Ireland	Italy	Latvia	Liechtenstein	Lithuania	Luxembourg	Malta	Netherlands	Norway	Poland	Portugal	Romania
9	43	2.0	40	2.0	54	2.4	37	3.6	1 157					
0.0	58	40.2	41	38.4	51	37.9	53	9.7	711					
1.5	34		55		54		48	7.0	94					
1.9	0 0		57	3.0	68	0.0	25	-	5 195					
0.1		0.0	3	2.2	9	2.3	3	26.5	4 981					
3.4	19	2.1	1	2.4	0	2.6	0	8.7	214					
11.	0	2.5	19	1.2	20	1.1	19		38					
3	18	0.5	6	4.1	5	4.1	2		612					
2.5	1	3.8	17	10.4	18	10.8	15		17					
-	9	9.5	5		5		8		131					
37.	32	3.4	21	4.5	20	4.2	34		40					
1	7	-	35	-	35	-	31		886					
5.1	92	37.0	8	29.7	7	31.5	7		2					
	2		1		1		1		358					
	2	5.3	03	7.0	10	10.1	00		840					
	92		7		0		2		190					
	0		3		3		6		191					
	-		82		59		00							
	15		4		5		5							
	33		-		-		-							
	3		12		11		10							
	3		18		56		03							
	57		3		4		8							
	8		4		6		5							
			71		82		89							
			6		7		1							
-	-	-	-	-	-	-	-	-	24 018					
90 339	**20.6**	**90 556**	**20.6**	**88 166**	**20.0**	**88 515**	**20.3**	**81 758**	**18.6**	**2 004 835**				
	4.5	20	4.7	24	5.7	28	6.4	26	5.9	808 494				
	2.4	253.6	3.3	842.9	4.8	100	4.3	124	5.3	136 140				
	32.7	509	32.4	591	30.7		30.6	10	27.2	1 738				
	12.2	83	**12.4**	79	**12.7**	8	**12.8**	506	**11.8**	405 **2 683 039**				
		413		109		525		69						
		110 175		**113 542**		77 506		292 **105 922**						
						114 131								

Slovakia
Slovenia
Spain
Sweden
Total EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Moldova
Monaco
Montenegro
North Macedonia
Russian Federation
San Marino
Serbia
Serbia excluding Kosovo
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA
WHO European Region

West
Centre
East
Total WHO European Region

Table 2: HIV diagnoses in males and rates per 100 000 population, by country and year of diagnosis (2015–2024) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area	Country, territory or area[a]	2015		2 016		2 017		2 018		2 019		
		N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	
EU/EEA												
West	Austria[c]	296	7.0	264	6.2	278	6.4	192	4.4			
West	Belgium	764	13.8	714	12.8	650	11.6	658	11.7			
Centre			5.7		5.0		6.6		8.5			
Centre			5.5	169	5.3	218	5.2	276	5.0			
Centre			17.2		15.4		15.3		15.2			
Centre			4.8	105	5.1	101	4.4	97	3.6			
West			7.3		6.7		6.7	65	5.9			
East		194	27.2	65	22.5	65	23.6	186	21.1			
West			4.9	262	4.5	230	3.7		3.8			
	Bulgaria	111		191		192		170				
				139		146		131				
				121		101		104				
	Croatia	72										
	Cyprus	248										
	Czechia	205										
	Denmark	167										
	Estonia	131										
	Finland											
West	France	3 569	11.1	3 587	11.1	3 513	10.9	3 272	10.1			
West	Germany[d]	2	7.3	2 668	6.6	2	6.2	2	5.5			
West			13.1		10.3	511	10.2	248	11.2			
Centre			4.2	540	3.7	535	3.2	581	4.2			
West		889	6.1	171	13.2	149	12.3	195	13.5			
West			16.1	22	16.7	21	15.6	24	17.1			
West			9.6	390	9.8	371	9.4	411	8.2			
East			30.1	2 868	26.1	2	27.7	2	25.6			
West			0.0		10.7	750	10.7	386	0.0			
East			8.5		12.4	248	16.7	228	9.0			
West	Greece	690	43.6	236	45.3	2	35.4	0	28.4			
West			24.0	2	22.5	220	15.1	117	25.8			
West			10.2	165	9.6	105	10.0	86	9.1			
West			5.6	131	6.0	35	5.9	62	4.6			
Centre			5.9	51	6.3	846	6.9	776	5.7			
West			26.8	806	26.1	155	24.9	122	22.2			
Centre			7.0	157	6.3	1	6.6	1	6.1			
Centre		196	2.9	1 150	3.1	262	2.5	052	3.5			
Centre			4.0		5.7	1	3.9	1	3.9			
West	Hungary		16.2	1 284	16.4	223	16.2	087	15.4			
West			5.7		5.5	637	5.4	586	6.0			
			9.8		**9.6**	66	**9.4**	94	**8.7**			
						40		40				
						3		3				
		10		605		688		514				
				81		273		306				
				58		**20**		**19**				
				3 734		**631**		**066**				
				269								

21 005

Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg[e]
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slova

373
2 815
274
0
115
123
53
853
145
1 084
1 322
684
76
41
3 701
276
21 477

	kia												
	Slovenia												
	Spain												
	Sweden												
	Total EU/EEA												
Non-EU/EEA													
Centre	Albania		67	4.6	104	7.2	69	4.8	768	5.3
West				8.3	3	8.2		8.0	29	21.0
East				15.6	212	16.3	3	19.5	3	22.8
East			3	10.2	355	7.2	253	7.2	437	8.7
							359			
	Andorra		205							
			495							
	Armenia									
	Azerbaijan									
East	Belarus	1 395		31.1	1 490	33.2	1 540	34.3	1 499	33.5
Centre	Bosnia and Herzegovina	14		0.8	22	1.3	15	0.9	22	1.3
East	Georgia	545		30.7	552	31.1	492	27.7	506	28.5
West				7.3	253	6.2	285	6.9	288	6.8
East				16.9	1 684	19.5	1	20.7	2	22.5
East				11.8		14.7	815	16.3	004	17.5
East				29.6	434	30.7	490	30.9	535	35.9
West				5.5	471	0.0	468	16.5	537	0.0
Centre			290	5.5	0	10.4	3	7.8	0	6.8
Centre				2.3	32	2.7	24	4.2	21	4.3
East				92.6	28	79.8	44	78.8	45	78.0
West				12.2	53	12.2	53	6.0	52	12.0
	Israel		1		6892		2091		7202	
			442							
	Kazakhstan		342							
			462							
	Kyrgyzstan		1							
			17							
	Mo		24							

		Republic of Moldova	Monaco	Montenegro	North Macedonia	Russian Federation: San Marino				
Centre	Serbia	186	4.1	170	3.8	180	4.0	183	4.1	
Centre	Serbia excluding Kosovo[9]	183	5.1	160	4.5	177	4.9	176	4.9	
Centre	Kosovo[9]	3	0.3	10	1.1	3	0.3	7	0.8	
West	Switzerland	423	10.3	425	10.2	357	8.5	342	8.1	
East	Tajikistan		15.9	621	14.2	735	16.4	874	19.0	
Centre	Türkiye		4.4	2 065	5.1	2	5.8	2	6.5	
East	Turkmenistan		-	-	-	389	-	717	-	
East	Ukraine		32.7	8 366	42.4	-	47.3	-	48.6	
West	United Kingdom		14.8		12.8	9	11.1	9	10.8	
East	Uzbekistan	680	-	4 146	-	297	-	512	-	
Total non-EU/EEA			**39.6**		**36.2**	3 604	**36.3**	3 529	**36.3**	
WHO European Region				**75 124**		- **75 632**		- **76 150**		
West		1 770								
Centre		- 7 519								
East		4 760 - **8 2**								
Total WHO European Region		**7 60**								
		23 6	11.4 5.0 61.8 **24.4**	22 628 5 087 68 414	10.8 5.2 57.1 **22.5**	21 502 5 489 69 272 **96 263**	10.2 5.6 57.6 **22.5**	20 168 5 655 69 393	9.5 5.8 57.5 **22.2**	

9 4	**96** **129**	**95** **216**
4		
7 8 4		
7 5		
7 5 9		
1 **0** **4**		
2 **3** **7**		

[a] Country/territory/area specific comments are in Annex 5.
[b] Cumulative total is the total number of cases reported by the country since the start of reporting.
[c] Austria uses study cohort data.
[d] The cumulative figure for Germany differs from the country's own reported total because of variations in the counting methodology used.
[e] The numbers displayed here may not fully align with the numbers in the country's national statistics as these are presented by the 'date of notification' instead of the 'date of diagnosis' as here.
[f] Due to discrepancies in the methodology used for calculating the population rates by the Russian Federal Statistics Service and the United Nations Population Division, rates on overall HIV diagnoses, as well as data disaggregated by sex, presented in Tables 1, 2 and 3 and elsewhere in the report may differ from the data presented in national statistics.
[g] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

2 020		2 021		2 022		2 023		2024		Cumulative total[b]	Country, territory or area[a]
N	Rate	N	Rate	N	Rate	N	Rate	N	Rate		
											EU/EEA
150	3.4	172	3.9	168	3.8	168	3.7	159			
533	9.4	586	10.3	689	12.0	772	13.3	735			Austria[c]
168	5.3	205	6.5	215	6.9	206	6.6	222			Belgium
66	3.5	72	3.8	90	4.8	83	4.5	75			
87	19.6	115	26.3	154	34.9	122	26.2	99			
203	3.9	200	3.9	435	8.4	269	5.1	291			Bulgaria
133	4.6	115	4.0	149	5.1	154	5.2	136			
88	14.0	80	12.7	130	20.5	109	16.8	73			
96	3.5	110	4.0	162	5.9	151	5.5	136			
2 417	7.4	2 457	7.5	2 757	8.4	3 142	9.5	3 056			Croatia
1 903	4.6	1 787	4.4	2 253	5.5	2 334	5.7	2 341			
499	9.6	468	9.0	463	9.1	522	10.2	501			Cyprus
166	3.6	182	3.9	179	3.9	178	3.8	169			
28	15.0	14	7.4	30	15.5	33	16.5	20			
343	13.8	305	12.2	576	22.6	586	22.5	606			Czechia
1 169	4.0	1 533	5.3	1 710	5.9	1 916	6.6	1 884			
162	18.4	136	15.5	154	17.7	131	15.0	116			
1	5.2	1	5.2	1	5.1	1	5.1	0			Denmark
97	7.5	93	7.1	152	11.6	178	13.3	134			
50	15.9	74	23.2	53	16.3	52	15.6	32			
67	25.1	41	15.3	55	20.3	99	34.8	106			Estonia
562	6.5	590	6.8	733	8.4	700	7.9	655			
91	3.4	64	2.4	136	5.0	205	7.4	171			
804	4.4	1 208	6.7	1 756	9.8	1 783	10.0	1 532			Finland
838	17.0	918	18.6	821	16.5	773	15.4	709			
407	4.3	510	5.4	564	6.1	575	6.2	582			
90	3.4	100	3.8	122	4.6	108	4.1	89			
30	2.9	32	3.0	45	4.3	41	3.9	44			
2 571	11.1	2 697	11.6	2 833	12.2	2 853	12.1	2 739			France
226	4.3	232	4.4	265	5.0	196	3.7	194			
14 045	**6.3**	**15 097**	**6.8**	**17 850**	**8.1**	**18 440**	**8.3**	**17 606**			
70	4.9	73	5.1	71	5.0	95	6.7	94			Germany[d]
25	19.8	29	23.6	39	31.2	34	27.7	39			
1	7.6	7	9.3	0	10.3	6	12.7	6			
38		47		52		65		85			
6		2		4		1		0			
899	20.2	926	21.0	1 028	23.4	886	20.3	749			
14	0.9	34	2.1	52	3.3	26	1.6	36			
403	22.7	403	22.8	454	25.8	471	26.9	470			
258	5.9	278	6.3	300	6.7	274	6.0	222			
2 292		2 342		2 686		2 770		2 711			
383	25.1	513	25.4	658	28.8	651	29.3	649			
398	12.1	455	16.0	537	20.2	561	19.7	531			
14	27.2	12	31.3	34	34.5	40	34.2	33			
29	4.6	41	3.9	35	11.1	47	13.1	50			
36	2.8	33	3.9	33	3.4	32	4.5	28			
659 0		543 0		396 1		187 0		249 0			

Greece	Hungary	Iceland	Ireland	Italy	Latvia	Liechtenstein	Lithuania	Luxembourg	Malta	Netherlands	Norway	Poland	Portu
54.2	49.8	49.7	48.0										
0.0	0.0	6.1	0.0										
129	2.9	183	4.2	182	4.2	187	4.4	180					
128	3.6	175	5.0	162	4.7	167	4.9	149					
1	0.1	8	0.9	20	2.3	20	2.3	31					
230 643	5.4	244 574	5.7	251 665	5.8	250 693	5.7	231 622					
1 763 - 9 810	13.4	2 445 - 9 796	11.7	3 181 - 8 078	13.3	2 997 - 7 497	13.6	5 089 - 6 572					
2 517 - **57 148**	4.2 - 43.8 7.6 - **26.7**	2 537 - **55 168**	5.8 - 51.0 7.6 - **26.1**	2 982 - **55 505**	7.4 - 42.5 8.9 - **26.2**	3 710 - **54 339**	7.0 - 44.7 11.1 - **25.9**	3 402 - **51 136**					
14 682 4 040 52 471 **71 193**	6.9 4.1 42.3 **16.4**	15 223 5 412 49 630 **70 265**	7.1 5.5 41.1 **16.3**	17 388 7 115 48 852 **73 355**	8.1 7.3 40.5 **17.0**	18 891 6 757 47 131 **72 779**	8.8 6.9 39.7 **16.9**	18 035 8 585 42 122 **68 742**					

gal

Romania

Slovakia

Slovenia

Spain

Sweden

Total EU/EEA

Albania

Andorra

Armenia

Azerbaijan

Belarus

Bosnia and Herze

govina

Georgia

Israel

Kazakhstan

Kyrgyzstan

Moldova

Monaco

Montenegro

North

Macedonia

Russian

Federation

San

Marino

Serbia

Serbia excluding Kosovo[g]

Kosovo[g]

Switzerland

Tajikistan

Türkiye

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Total

non-EU/EEA West Centre East **Total WHO European Region**

Table 3: HIV diagnoses in females and rates per 100 000 population, by country and year of diagnosis (2015–2024) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area	Country, territory or area[a]	2015		2 016		2 017		2 018		2 019		
		N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	
EU/EEA												
West	Austria[c]	48	1.1	57	1.3	57	1.3	42	0.9			
West	Belgium	33	5.9	29	5.1	31	5.4	29	5.1			
Centre		38	0.9	2	0.9	0	0.7	3	1.0			
Centre			0.3	33	0.2	23	0.2	35	0.3			
Centre			1.8		3.4		4.5		2.9			
Centre			0.3	5	0.4	5	0.4	7	0.4			
West			2.5	15	1.8	20	1.7	13	1.7			
East			14.7		12.9		10.5		8.5			
West		33	1.5		2.1		2.0		1.8			
	Bulgaria			24		24		22				
		6		53		50		49				
				90		73		59				
		8		59		57		49				
	Croatia	18										
		72										
	Cyprus	103										
		43										
	Czechia											
	Denmark											
	Estonia											
	Finland											
West	France	1 725	5.0	1 814	5.3	1 814	5.3	1 768	5.1			
West	Germany[d]	755	1.8	720	1.7	654	1.6	639	1.5			
West			1.7	11	2.1	11	2.0	9	2.6			
Centre			0.5	4	0.4	0	0.4	14	0.2			
West			1.2	21	3.6	18	1.8	2	8.2			
West			4.8		4.7		4.7	8	4.3			
West			2.6		2.8		2.8	14	2.1			
East			12.7		13.1		12.7		10.3			
	Greece	93		61		31		106				
				12		15		65				
				86		87		7				
				2		2		10				
		26		13		13		8				
				9		4						
	Hungary	2										
		113										
	Iceland	81										

	Iceland	6							
	Ireland	136							
	Italy								
	Latvia								
West	Liechtenstein	0	0.0	0	0.0	0	0.0	0	0.0
East	Lithuania	42	2.7	49	3.1	43	2.8	43	2.8
West			13.9	38	13.2	35	11.9	34	11.4
West			3.7	11	4.9	10	4.4	11	4.7
West			2.0	142	1.7	143	1.7	154	1.8
West			3.0	63	2.4	58	2.2	69	2.6
Centre			0.9	141	0.7	162	0.8	154	0.8
West		39	8.4	482	8.8	453	8.3	412	7.6
Centre			2.4	217	2.1	216	2.2	196	2.0
Centre			0.4	7	0.3	6	0.2	8	0.3
Centre			0.7	4	0.4	2	0.2	2	0.2
West			2.6	673	2.9	645	2.7	586	2.5
West		8	3.5	160	3.3	161	3.2	175	3.5
			2.8	**6**	**2.8**	**6**	**2.7**	**5**	**2.5**
				403		**273**		**855**	
	Luxembourg	174							
	Malta	76							
	Netherlands	176							
	Norway	461							
	Poland	247							
	Portugal	10							
	Romania	7							
	Slovakia	623							
	Slovenia	171							
	Sp	**6**							
		369							

		a l n											
		S w e d e n											
		T o t a l											
		E U / E E A											
Non-EU/EEA													
Centre		A l b a n i a	29	2.0	23	1.6	25	1.7	26	1.8
West				0.0		0.0		8.2		10.8
East				5.7	0	5.8	3	6.7	4	8.8
East				4.6	91	4.0	10	4.1	13	4.3
East			0	17.4		17.3	5	17.8	6	17.0
					20		20		21	
					1		8		9	
					90		92		88	
					1		8		7	
		A n d o r r a	89							
		A r m e n i a	910							
		A z e r b a i j a n								
		B e l a r u s								
Centre		Bosnia and Herzegovina	1	0.1	2	0.1	0	0.0	2	0.1
East		G e o r g i a	172	8.6	166	8.3	139	7.0	166	8.3
West				3.0	106	2.6	116	2.8	144	3.4
East				11.1	1	12.9	1	12.5	1	12.5
East				9.2	214	10.2	190	11.1	208	10.4
East				20.7	314	21.3	346	22.0	331	22.3
West				0.0	361	0.0	367	0.0	368	0.0
Centre			121	0.6	0	0.6	0	0.3	0	0.6
Centre				0.1	2	0.1	1	0.0	2	0.0
					1		0		0	
		I s r a e l	1							
			032							
		K a z a k h s t a n	277							
			356							
		K y r g y z s t a n	0							
			2							
			1							
		M o l d o v a								
		M o n								

East	Russian Federation[f]	38 102	49.1	33 166	42.6	32 593	41.8	33 275	42.6
West	San Marino	0	0.0	0	0.0	0	0.0	1	5.7
Centre	Serbia	6	0.1	16	0.3	11	0.2	15	0.3
Centre	Serbia excluding Kosovo[g]	5	0.1	16	0.4	11	0.3	14	0.4
Centre	Kosovo[g]	1	2.9	-	-	-	-	1	0.1
West	Switzerland	2	11.0	113	2.7	102	2.4	97	2.3
East	Tajikistan	1	0.8	417	9.6	470	10.6	547	12.1
Centre	Türkiye	4	27.7	372	0.9	455	1.1	531	1.3
East	Turkmenistan	6	4.5	-	-	-	-	-	-
East	Ukraine	9	-	5	25.6	6	27.7	6	27.1
West	United Kingdom	0	22.4	863	3.8	307	3.7	136	3.7
East	Uzbekistan	7	-	1	-	1	-	1	-
Total non-EU/EEA				280	**20.0**	254	**20.1**	242	**20.1**
WHO European Region				-		-		-	
West				**44**		**44**		**45**	
Centre				**609**		**620**		**337**	
East									
Total WHO European Region									

[a] Country/territory/area specific comments are in Annex 5.
[b] Cumulative total is the total number of cases reported by the country since the start of reporting.
[c] Austria uses study cohort data.
[d] The cumulative figure for Germany differs from the country's own reported total because of variations in the counting methodology used.
[e] The numbers displayed here may not fully align with the numbers in the country's national statistics as these are presented by the 'date of notification' instead of the 'date of diagnosis' as here.

[1] Due to discrepancies in the methodology used for calculating the population rates by the Russian Federal Statistics Service and the United Nations Population Division, rates on overall HIV diagnoses, as well as data disaggregated by sex, presented in Tables 1, 2 and 3 and elsewhere in the report may differ from the data presented in national statistics.

[2] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

2 020		2 021		2 022		2 023		2024		Cumulative total[b]	Country, territory or area[a]
N	Rate	N	Rate	N	Rate	N	Rate	N	Rate		
											EU/EEA
32	0.7	33	0.7	38	0.8	38	0.8	45			
225	3.9	198	3.4	334	5.7	342	5.8	370			Austria[c]
319	0.9	326	0.9				1.4				
194	0.4	346	0.3				0.7				
828	4.1	334	7.4	113	3.4	47	8.1	62			Belgium
285	0.9	245	0.6			14	2.4	16			
959	1.0	345	0.8	23	1.1	39	2.4	26			
35	8.4	34	6.4	64		133	10.3	107			
	1.3		1.2	435	13.8	73	3.6	63			
				109	8.2	74		60			Bulgaria
				120	3.7	100		90			
				98	17.2						Croatia
					3.5						
1 098	3.2	1 138	3.3	1 408	4.0	1 773	5.0	1 553			Cyprus
560	1.3	459	1.1	100	2.4	984	2.3	884			
122	2.2	110	2.0	6	2.2	15	2.9	14			
156	0.3	195	0.4	11	0.5	5	0.8	1			Czechia
863	3.4	825	2.8	8	5.5	38	5.9	28			
306	3.4	395	3.2	26	11.4	11	11.7	19			
95	1.0	76	1.3	10	1.5	312	2.0	391			Denmark
	9.3		7.5	296	7.5	591	5.6	495			
				454		157		564			
0	0.0	0	0.0	0	0.0	0	0.0	0			Estonia
42	2.8	28	1.9	100	6.7	89	5.8	62			
18	5.8	26	8.2	29	9.1	21	6.4	11			
15	6.0	4	1.6	5	2.0	5	1.9	9			
125	1.4	111	1.3	26	3.0	159	1.8	158			Finland
46	1.7	38	1.4	7	4.1	127	4.7	93			
15	0.8	238	1.2	10	4.4	600	3.2	441			
3	5.5	358	6.6	9	5.3	335	6.1	283			France
298	1.3	150	1.5	83	1.5	160	1.6	189			
128	0.4	14	0.5	9	2.8	36	1.3	24			
115	0.5	6	0.6	28	1.0	3	0.3	11			Germany[d]
5 420	1.7	465	1.9	8	2.0	474	1.9	463			
134	2.6	119	2.3	14	3.5	108	2.1	102			
4 169	**1.8**	**4 280**	**1.9**	4	**3.1**	**6 898**	**3.0**	**6 260**			
				78							
				11							
				481							
				1							
				18							
				1							
				7 259							
26	1.8	31	2.2	27	1.9	28	2.0	29			Greece
11	7.7	12	8.3	14	9.5	15	10.1	14			
8		8		5		4		8			
173	3.3	218	4.2	242	4.6	268	5.1	321			Hungary
52		57		61		57		147			
8	10.2	0	11.0	6	12.0	7	11.3	9			
3	0.2	2	0.1	5	0.3	3	0.2	4			Iceland
127	6.4	127	6.4	163	8.2	141	7.1	145			
104	2.4	112	2.5	156	3.4	131	2.9	90			
1		1		1		1		1			Ireland
173	11.9	243	12.5	317	13.1	269	12.5	287			
29	8.9	32	9.9	43	12.8	40	11.8	40			
128	17.4	337	21.0	39	22.9	36	20.4	34			Italy
2	-	-	-	2	-	7	-	9			

1 0	- 0.3 0.0	1 2	- 0.3 0.2	6 4	1.9 0.4	13 4	4.0 0.4	3
22 939	29.4	24 797	31.9	22 177	28.6	22 502	29.1	20 004
0 10 9 1 60 438 313 - 5 668	0.0 0.2 0.2 0.1	0 7 6 1 78 348 475 - 5 537	0.0 0.1 0.2 0.1	0 14 13 1 104 372 643 - 4 105	0.0 0.3 0.3 0.1	0 18 18 - 102 407 592 - 4 067	0.0 0.4 0.5 - 2.3	0 12 9 3 83 380 916 - 3 466
916 - **33** **170**	1.4 9.2	1 025 - **35** **366**	1.8 7.2	1 708 - **32** **629**	2.4 7.5	3 096 - **34** **142**	8.1 1.4 -	2 460 - **30** **584**
	0.7 - 29. 3 2.7 - **14.** **8**		1.1 - 24. 9 3.0 - **15.** **5**		1.5 - 18. 7 5.0 - **14.** **3**		20. 3 9.0 - **15.** **1**	
4 634	2.1	4 814	2.2	7 199	3.2	8 937	4.0	7 803
772 31 933 **37** **339**	0.8 23. 8 **8.2**	1 050 33 782 **39** **646**	1.0 24. 7 **8.6**	2 432 30 257 **39** **888**	2.4 22. 1 **8.7**	1 728 30 375 **41** **040**	1.7 22. 5 **9.0**	1 872 27 169 **36** **844**

Greece

Hungary

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portu

	Portugal	Romania	Slovakia	Slovenia	Spain	Sweden	**Total EU/EEA**
Non-EU/EEA							
Albania							
Andorra							
Armenia							
Azerbaijan							
Belarus							
Bosnia and Herzegovina							
Georgia							
Israel							
Kazakhstan							
Kyrgyzstan							
Moldova							
Monaco							
Montenegro							
North Macedonia							
Russian Federation							
San Marino							
Serbia							
Serbia excluding Kosovo							
Switzerland							
Tajikistan							
Türkiye							
Turkmenistan							
Ukraine							
United Kingdom							
Uzbekistan							
Total non-EU/EEA							
WHO European Region							

	West	Centre	East	**Total**
Non-EU/EEA				
Albania				
Andorra				
Armenia				
Azerbaijan				
Belarus				
Bosnia and Herzegovina				
Georgia				
Israel				
Kazakhstan				
Kyrgyzstan				
Moldova				
Monaco				
Montenegro				
North Macedonia				
Russian Federation				
San Marino				
Serbia				
Serbia excluding Kosovo				
Switzerland				
Tajikistan				
Türkiye				
Turkmenistan				
Ukraine				
United Kingdom				
Uzbekistan				
Total non-EU/EEA				
WHO European Region				

Table 4: HIV diagnoses in men infected through sex with men, by country and year of diagnosis (2015–2024) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area	Country, territory or area[a]	Year of diagnosis 2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	Cumulative total[b]
EU/ EEA West West Centre Centre Centre Centre West East West	Austria[c] Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland	1 8 0 4 6 1 1 1 1 9 9 5 1 2 1 1 1 2 6 1 8 5 3	180 428 96 96 47 213 121 9 48	205 372 120 97 47 182 123 16 32	132 375 170 89 44 138 110 11 38	148 367 122 83 41 150 99 16 37	88 274 96 57 62 145 80 8 37	10 7 32 0 11 1 63 80 14 5 60 9 37	11 1 36 3 10 6 70 84 18 0 71 11 51	10 3 43 3 98 64 61 14 3 68 8 44	83 38 1 76 60 56 16 3 49 7 52	4 764 11 624 1 528 1 502 933 3 218 3 700 222 1 503
West	France	1 484	1 353	1 436	1 511	1 512	1 194	1 168	1 245	1 410	1 416	31 093
West West Centre West West West East West East West West West West Centre West Centre Centre Centre West West	Germany[d] Greece Hungary	1 8 9 7 4 6 7 1 3 4 0	1 739 326 119 8 274 1 422 24 0 29 62 38 618 87 414	1 631 317 112 4 261 1 391 24 1 21 46 23 633 88 396	1 434 307 146 15 296 1 196 20 0 19 54 38 582 73 314 621 172 60 31 2 431 158 **10 585**	1 463 291 168 15 268 1 123 18 0 20 43 0 555 61 354 624 191 51 26 2 410 152 **10 408**	1 015 282 128 19 217 658 11 0 18 26 30 415 63 204	1 00 2 26 2 14 4 10 18 7 75 9 11 1 21 46 20 41 2 36 23 9 52 7 20 6 49	1 06 3 26 7 11 2 19 36 1 88 9 9 0 29 25 30 47 7 59 22 2 49 6 20 4 48	1 04 0 25 1 11 0 23 32 0 96 5 9 1 42 21 45 48 3 71 30 7 46 1 21 5 31	1 13 4 20 0 12 2 10 27 5 98 9 10 0 30 16 85 47	39 840 9 835 2 966 228 4 804 21 890 484 6 438 1 454 432 18 705 2 508 5 536 15 855 2 701

Iceland	25	730	690	511	24	32	29	7	877
	51				1	1	1	64	729
Ireland		155	181	150	74	81	85		38
	1	60	52		8	6	1	29	967
Italy		48	28	50	11	12	98	0	4
	46	2	2	20	9	7	**8**	41	956
Latvia	0	533	534	1	**7**	**8**	**80**	2	**233**
		136		721	**92**	**57**	**5**	23	**298**
Liechtenstein	34		128	116	**3**	**7**		2	
		11						24	
Lithuania	0	**413**	**11**	**7**					
			191	**695**				26	
Luxembourg	29							1	
								77	
Malta	56							7	
								98	
Netherlands	45								
								8	
Norway	639							**61**	
								4	
Poland	70								
Portugal	358								
Romania	758								
Slo	148								
	55								
	34								
	2								
	465								
	118								
	11								
	812								

	Slovakia	Slovenia	Spain	Sweden	**Total EU/EEA**
Non-EU/EEA					
Centre Albania	13	11	6	8	29
West Andorra		3	2	4	-
East Armenia		17	17	41	50
East Azerbaijan		17	42	45	50
East Belarus		71	72	103	82
Centre Bosnia and Herzegovina	2	18	12		22
East Georgia		131	130	14	97
West Israel				154	12
East Kazakhstan	12	130	147		2
East Kyrgyzstan				131	20
East Moldova		121	145		5
West Monaco				163	38
Centre Montenegro		37	45		29
Centre North Macedonia	35	18	29	47	-
East Russian Federation		0	2	32	15
West San Marino		25	22	0	48
Centre Serbia	58	18	34	16	0
Centre Serbia excluding Kosovo[1]		0	0	37	0
Centre Kosovo[1]		0	0	0	18
West Switzerland		120	126	145	5
East Tajikistan					18
Centre Türkiye	10	117	126	15	2
East Turkmenistan			-	5	3
East Ukraine		3	174	11	15
West United Kingdom		235		143	5
East Uzbekistan	16		13		11
Total non-EU/EEA	61	11	494	2	53
WHO European Region		403	-	164	9
West West	14	-	490		-
Centre Centre		435		24	46
East East	2		2	540	7
Total WHO European Region		2	310	-	1
	82	693	-	506	94
		-	**4**		2
	23	**4**	**312**	2	-
		514		181	**4**
	10			-	**08**
				4	**6**
	1			**355**	
	14				
	21				
	0				
	0				
	140				
	1				

	Total EU/EEA
Non-EU/EEA	
Centre Albania	289
West Andorra	38
East Armenia	436
East Azerbaijan	723
East Belarus	933
Centre Bosnia and Herzegovina	246
East Georgia	1
West Israel	511
East Kazakhstan	3
East Kyrgyzstan	373
East Moldova	2
West Monaco	528
Centre Montenegro	659
Centre North Macedonia	256
East Russian Federation	18
West San Marino	247
Centre Serbia	344
Centre Serbia excluding Kosovo[1]	7
Centre Kosovo[1]	687
West Switzerland	21
East Tajikistan	2
Centre Türkiye	341
East Turkmenistan	2
East Ukraine	273
West United Kingdom	68
East Uzbekistan	6
Total non-EU/EEA	236
WHO European Region	174
West West	5
Centre Centre	023
East East	0
Total WHO European Region	5
	182
	82
	312
	29
	120 606

38										
2										
212										
3										
350										
-										
368										
3										
222										
-										
4										
879										
14	13 164 1 843 920	12 550 1 909 1 044	11 851 1 924 1 165	11 387 2 024 1 083 **14 494**	8 278 1 388 2 494 **12 160**	8 430 1 637 2 562 **12 629**	9 125	9 543	9 138 1 703 2 814 **13 655**	304 162 28 480
109	**15 927**	**15 503**	**14 940**				1 719	1 551		21 262
							2 920	2 653		**353 904**
							13 764	**13 747**		
1										
749										
833										
16										
691										

[a] Country/territory/area specific comments are in Annex 5.
[b] Cumulative total is the total number of cases reported by the country since the start of reporting.
[c] Austria uses study cohort data.
[d] The cumulative figure for Germany differs from the country's own reported total because of variations in the counting methodology used.
[e] The numbers displayed here may not fully align with the numbers in the country's national statistics as these are presented by the 'date of notification' instead of the 'date of diagnosis' as here.
[f] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

Table 5: HIV diagnoses in people infected through injecting drug use, by country and year of diagnosis (2015–2024) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area	Country, territory or area[a]	Year of diagnosis										Cumulative total[b]
		2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	
EU/EEA												
West	Austria[c]	35	20	214	17	22	164	193	161	239	20	2
West	Belgium	54		33			153	141	118	24		242
Centre		29	1	00	8	6	33	15	32	26	4	345
Centre	Bulgaria	21	22	56	34		141	57	61	24	36	738
Centre		58	0	15	1	37	10	10	18	7	0	78
West	Croatia	55	2	10	1	1	4	5	5	4	0	35
East	Cyprus	7	7		8	3		12	24		17	266
West	Czechia		9		6	9					7	606
	Denmark		3		2	4					4	64
	Estonia		1		4	20					13	243
	Finland		6		6	8						492
West	France	80	70	75	78	91	60	58	94	90	73	2 615
West	Germany[d]	14	13	12	15	168	177	125	290	276	24	5
West		49	8	0	4						8	562
Centre			10	96	12	90	88	95	67	88	97	2
West			2	1	3	1	1	0	3	2		355
West			3	3	1	2	0	1	1	1	1	39
West			9	18	2	19	11	8	38	31	4	76
East			20	10	14	102	55	88	98	85	9	1
West		99	11	3	11		41	27	35	22	91	783
East			2	81	6	46	0	0	0	0		3
West			63	0	77	0	32	30	32	44	13	166
West			0	14	0	51	5	5	13	6		3
West			88	3	55	5	0	0	0	0	13	623
West		2	33	16	13	0	6	8	39	21		5
Centre	Greece		1	0	0	7	8	4	24	31	0	2
West			6	11	7	6	14	13	33	37	20	077
Centre			8	7	30	22	34	32	28	24		427
Centre			39	30	43	38	44	60	51	61	3	10
Centre		0	52	43	10	86	0	1	9	3	0	911
West			14	10	4	1	1	4	3	3	13	735
West			2	4	0	1	64	56	64	63		6
			1	0	0	1	13	3	12	15		534
	Hungary	51	1	12	12	5	2	**694**	1	1	20	19
			14	0	12	23	97		**092**	**023**		677
			1	3	3		21				29	2
			26	20	20	**1**	**970**					094
			115	**108**	**1**	**047**						32
												35

3 **8**

20 4
164
45 1
361
66
326
1
1
50
7
84
6

Iceland 121
94
0
Ireland 46
25
Italy 0
5
Latvia 8
51
Liechtenstein 67
201
Lithuania 3
1
Luxembourg[e] 127
15
Malta **1**
291
Netherlands
Norway
Poland
Portugal
Romania
Slo

	Slovakia	Slovenia	Spain	Sweden	**Total EU/EEA**
Non-EU/EEA					
Centre Albania	0	0	0	0	11
West Andorra		0	0	-	-
East Armenia		35	39	35	11
East Azerbaijan		16	10	10	868
East Belarus		3	2	8	3
Centre Bosnia and Herzegovina	0	60	48	39	705
East Georgia		0	5	1	10
West Israel		0	0	0	615
East Kazakhstan	3	20	15	96	19
East Kyrgyzstan	7	5	0	35	3
East Moldova		25	33	92	399
West Monaco		90	89	0	1
Centre		0	8	14	411
		21	20	2	22
	1	0	5	59	773
	8	40	42	0	4
Montenegro	5	0	0	0	067
Centre North Macedonia		0	1	0	3
East Russian Federation		0	0	0	088
West San Marino		0	0	0	8
Centre Serbia	7	1	4	2	27
Centre Serbia excluding Kosovo[1]	9	1	4	2	2
Centre Kosovo[1]	0	-	-	-	62
West Switzerland		14	20	13	796
East Tajikistan		20	25	19	11
Centre Türkiye		2	2	9	999
East Turkmenistan		8	14	24	997
East Ukraine		-	-	-	2
West United Kingdom	1	3	2	3	2
East Uzbekistan	8	-	-	-	873
Total non-EU/EEA	7	3	3	73	4
WHO European Region	3	68	97	0	032
West West		9	4	11	263
Centre Centre		14	14	2	0
East East		7	2	-	148
Total WHO European Region	1	-	-	5	734
	8	**6**	**6**	**86**	6
	7	**23**	**36**	**6**	139
		9	**1**		11
					390
					287
	3				**241**
	9				
	8				
	2				
	6				
	1				
	6				
	2				
	3				
	8				
	0				
	0				
	0				
	0				
	0				
	4				
	4				
	-				

	Centre Albania	West Andorra	East Armenia	East Azerbaijan	East Belarus	Centre Bosnia and Herzegovina	East Georgia	West Israel	East Kazakhstan	East Kyrgyzstan	East Moldova	West Monaco	Centre			Montenegro	Centre North Macedonia	East Russian Federation	West San Marino	Centre Serbia	Centre Serbia excluding Kosovo[1]	Centre Kosovo[1]	West Switzerland	East Tajikistan	Centre Türkiye	East Turkmenistan	East Ukraine	West United Kingdom	East Uzbekistan	**Total non-EU/EEA**	**WHO European Region**	West West	Centre Centre	East East	**Total WHO European Region**
Non-EU/EEA																																			
Centre Albania	0	0	0	0	0	0	1	2	1	2	11																								
West Andorra		0	0	-	-	-	-	-	-	-	-																								
East Armenia		35	39	35	38	22	26	32	20	32	868																								
East Azerbaijan		16	10	10	102	87	97	71	68	72	3																								
East Belarus		3	2	8		222	221	287	211	156	705																								
Centre Bosnia and Herzegovina	0	60	48	39	363	0	0	0	0	0	10																								
East Georgia		0	5	1		62	69	80	53	67	615																								
West Israel		0	0	0	0	21	12	29	16	18	19																								
East Kazakhstan	3	20	15	96	115	1 062	851	812	720	551	3																								
East Kyrgyzstan	7	5	0	35		47	37	26	25	19	399																								
East Moldova		25	33	92	19	17	29	35	37	35	1																								
West Monaco		90	89	0	1	-	-	-	-	-	411																								
Centre		0	8	14	219	1	0	2	13	5	22																								
		21	20	2		0	0	0	0	0	773																								
	1	0	5	59		15	16	11	10	9	4																								
	8	40	42	0		203	702	416	133	342	067																								
Montenegro	5	0	0	0	106	0	0	0	0	0	3																								
Centre North Macedonia		0	1	0		-	3	3	5	3	088																								
East Russian Federation		0	0	0		0	-	3	-	3	8																								
West San Marino		0	0	0	39	-	5	-	5	-	27																								
Centre Serbia	7	1	4	2	-	4	76	8	43	6	2																								
Centre Serbia excluding Kosovo[1]	9	1	4	2	-	83	11	82	21	35	62																								
Centre Kosovo[1]	0	-	-	-	0	14	-	17	-	22	796																								
West Switzerland		14	20	13	0	-	5 312	-	2 885	-	11																								
East Tajikistan		20	25	19	0	5 905	92	3 812	84	1	999																								
Centre Türkiye		2	2	9	0	84	-	82	-	920	997																								
East Turkmenistan		8	14	24	3	-	**23**	-	**14**	64	2																								
East Ukraine		-	-	-	3	**22**	**544**	**16**	**340**	-	2																								
West United Kingdom	1	3	3	73	11	**834**		**796**		**12**	873																								
East Uzbekistan	8	-	-	0	135					**349**	4																								
Total non-EU/EEA	7	3	3	11							032																								
WHO European Region	3	68	97	0	10						263																								
West West		9	4	11	-						0																								
Centre Centre		14	14	2	4						148																								
East East		7	2	-	173						734																								
Total WHO European Region	1	-	-	5	117						6																								
	8	**6**	**6**	**86**	-						139																								
	7	**23**	**36**	**6**	**6**						11																								
		9	**1**		**450**						390																								
											287																								
	3										**241**																								
	9																																		
	8																																		
	2																																		
	6																																		
	1																																		
	6																																		
	2																																		
	3																																		
	8																																		
	0																																		
	0																																		
	0																																		
	0																																		
	4																																		
	4																																		
	-																																		

9										
2										
4										
9										
1										
3										
-										
3										
4										
4										
9										
2										
0										
2										
-										
6										
1										
9										
0										
1	940	87	89	848	655	636	956	896	76	56
	226	1	6		110	120	207		7	985
	6 226	19	18		22	23	16		16	11
0		2	1	165	793	482	725	202	2	172
5		6	5		**23**	**24**	**17**		12	285
1	**7 392**	38	83	6	**558**	**238**	**888**	14	26	410
		6	6	407				265	6	**353**
		7	**6**					**15**	**13**	**567**
		44	**91**					**363**	**19**	
3		**9**	**3**	**7**					**5**	
1				**420**						
2										
6										
1										
1										
8										
7										
4										
8										
1										

[a] Country/territory/area specific comments are in Annex 5.
[b] Cumulative total is the total number of cases reported by the country since the start of reporting.
[c] Austria uses study cohort data.
[d] The cumulative figure for Germany differs from the country's own reported total because of variations in the counting methodology used.
[e] The numbers displayed here may not fully align with the numbers in the country's national statistics as these are presented by the 'date of notification' instead of the 'date of diagnosis' as here.
[f] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

Table 6: HIV diagnoses in people infected through heterosexual contact, by country and year of diagnosis (2015–2024) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area	Country, territory or area[a]	Year of diagnosis										Cumulative total[b]
		2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	
EU/EEA												
West	Austria	109	95	96	69	84	67	67	64	56	71	3
West	Belgium[c]	381	366	374	349	380	272	257	394	401		672
Centre	Bulgaria	86						110	199	130	40	15
Centre	Croatia	132	84	85	104	98	84	12	27	25	2	230
Centre	Cyprus	64	13	8		13	11	59	125	89	16	2
Centre	Czechia	61	27	32	11	50	38	69	451	184	8	253
West	Denmark	261	54	59	31	57	82	48	116	108	19	501
East	Estonia	46	100	93	55	87	65	34	98	44		1
West	Finland	126		89	91	79	72	40	91	101	62	020
		14	116	70	67	44	44					1
		47			55						17	840
		79	83								9	3
											10	962
											4	1
											35	997
												2
											84	051
West	France	1 806	1 670	1 740	1 982	1 933	1 304	1 373	1 610	1 939	1 662	46 210
West	Germany[d]	975	887	797	761	778	537	450	1 067	1 042	959	20 776
West	Greece		148	156	179	195	134	127	130	112	104	4 339
West	Hungary	129	289	232	1315	286	2610	227	437	527	428	702
West			143	168	167	167	102	789	1313	1760		202 4
West			1769	1659	1253	1101	628	856	317	360	23	862
West							108	670	927	1200	365	27 415
West			145	137	113	112		057	96	56	109	2 673
Centre		22	171	072	067	059	1683	4377	0152	0140	463	14
West			6421	6217	5014	540	3214	184	3412	3120	084	1 332
Centre			241	239	222	258	192	584	295	239	19	1
Centre							66	847				547
Centre		0	120	115	101	100	6954	346	138	153	25	1 274
West							1					9
West		132	111	105	75	100			217			525 4 026 2 699 32 645 10

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slo

1 643 157 0 66 61 15 285 138 114 896 498 23 8 1 072 211 **9 261**

924 509 18 12 1 111 202 **9 142**

887 547 15 11 1 156 212 **9 026**

783 507 19 8 1 073 213 **8 447**

780 498 28 12 1 116 204 **8 421**

326 16 11 725 148 **5 793**

22 10 833 133 **6 111**

531 352 61 17 830 199 **8 606**

189 550 449 45 9 883 113 **8 737**

21 9 90 16 7 49 6 47 9 53 19 93 0 11 2 **8 11 5**

382 451 227 22 554 6 779 **232 160**

	Slovakia	Slovenia	Spain	Sweden	**Total EU/EEA**
Non-EU/EEA					
Centre Albania	77	115	87	80	71
West Andorra		0	2	7	-
East Armenia			290	341	352
East Azerbaijan		244	377	477	540
East Belarus			1 868	1 861	1 659
Centre Bosnia and Herzegovina	0	344	2 342	10 411	10 445
East Georgia			195	245	202
West Israel		1	1 867	2 060	2 127
East Kazakhstan	23	671	491	549	569
East Kyrgyzstan			561	617	683
East Moldova	6	6	1	0	-
West Monaco			3	5	5
Centre Montenegro		371	8	6	17
Centre North Macedonia	48	192	0	0	0
East Russian Federation			0	0	0
West San Marino		1	31	35	27
Centre Serbia		751	29	30	23
Centre Serbia excluding Kosovo[f]	1	428	2	5	4
Centre Kosovo[f]			146	156	136
West Switzerland		547	807	1 051	971
East Tajikistan	41		775	951	806
Centre Türkiye	16	0	-	-	-
East Turkmenistan		9	11	11	11
East Ukraine		10	024	313	489 1
West United Kingdom		0	1 758	1 795	757
East Uzbekistan	4	35	-	-	-
Total non-EU/EEA		30 5	**20 635**	**21 970**	**21 866**
WHO European Region		169			
West West	357	703			
Centre Centre					
East East		646			
Total WHO European Region		- 10 004			
	214	1 953			
		- **19 198**			
	1				
	438				
	385				
	578				
	0				
	3				
	4				
	0				
	0				

Non-EU/EEA									
Centre Albania	73	79	51	74	86	1 424			
West Andorra	-	-	-	-	-	30			
East Armenia	303	351	435	415	448	4			
East Azerbaijan	407	513	595	708	931	672			
East Belarus	1 098	1 159	1 240	1 150	977	7			
Centre Bosnia and Herzegovina	6	2	6	2	10	110			
East Georgia	351	339	415	429	395	23			
West Israel	169	197	239	210	146	376			
East Kazakhstan	2 036	2 288	2 687	2 807	2	164			
East Kyrgyzstan	478	612	879	851	861	5			
East Moldova	404	460	650	778	817	804			
West Monaco	-	-	-	-	723	-			
Centre Montenegro	2	2	11	17	-	6			
Centre North Macedonia	3	5	11	20	6	375			
East Russian Federation	38	38	41	42	16	30			
West San Marino	937 0	381 0	119	326 0	36	604			
Centre Serbia	15	12	0	55	320	8			
Centre Serbia excluding Kosovo[f]	14	12	39	46	0	061			
Centre Kosovo[f]	1	-	27	9	43	11			
West Switzerland	92	101	12	110	25	710			
East Tajikistan	881	752	112	951	18	13			
Centre Türkiye	536	666	863	723	91	130			
East Turkmenistan	-	-	789	-	869	121			
East Ukraine	9 080	9 524	-	8 325	1	197			
West United Kingdom	1 271	1 381	8 032	4 032	234	083			
East Uzbekistan	-	-	2 226	-	-	23			
Total non-EU/EEA	**56 142**	**56 824**	- **60 399**	**63 983**	7	1			
WHO European Region					756	074			
West West					3	967			
Centre Centre					439	107			
East East					-	7			
Total WHO European Region					**57 168**	784			
						11			
						258			
						11			
						324			
						0			
						196			
						750			
						84			
						209			
						4			
						711			
						613 810			

28										
28										
-										
183										
751										
583										
-										
9										
043										
2										
106										
-										
17										
854										
10	10	9 945	9 580 1	9 382	6 414 1	6 898 1	9 345 2	11 677	10	304
0	268 1	1 791	910 18	1 820	298 54	500 54	399 57	2 063	435 2	517
	677	17	927 **30**	19	223 **61**	537 **62**	261 **69**	58 980	569	34
	16	925	**417**	085	**935**	**935**	**005**	**72 720**	52	312
56	395	**29**		**30**					279	507
1	**28**	**661**		**287**					**65**	141
	340								**283**	**845**
										970
1										
535										
15										
019										
27										
115										

[a] Country/territory/area specific comments are in Annex 5.
[b] Cumulative total is the total number of cases reported by the country since the start of reporting.
[c] Austria uses study cohort data.
[d] The cumulative figure for Germany differs from the country's own reported total because of variations in the counting methodology used.
[e] The numbers displayed here may not fully align with the numbers in the country's national statistics as these are presented by the 'date of notification' instead of the 'date of diagnosis' as here.
[f] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

Table 7: HIV diagnoses in people infected through mother-to-child transmission, by country and year of diagnosis (2015–2024) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area	Country, territory or area[a]	Year of diagnosis										Cumulative total[b]
		2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	
EU/EEA												
West	Austria[c]	0	2	1	1	0	0	2	0	0	3	79
West	Belgium	1	1		6	7	8		16	1	1	53
Centre	Bulgaria	4	0	4	3	1	4	6		1	4	8
Centre	Croatia	1	1		0	0	1		5	0	1	44
Centre	Cyprus	0	2	3	1	1	0	2	13	1	4	18
Centre	Czechia	4	1	0	0	0	0	0	26	3	4	18
West	Denmark	1	0	5	0	0	2			4	1	42
East	Estonia	0	2	0	2	0	3	4	7	3	0	13
West	Finland	3	0	0	0	0	1	1	2	4	7	0
West	France	48	31	28	40	56	26	38	50	64	59	71
West	Germany[d]	29	24	18	20	14	11	11	61	39	22	907
West	Greece	0	4	1	1	4	3	1	6	3	2	623
West	Hungary	2	1	2	0	0	0	3	1	0	2	84
West	Ireland	0	0	0	2	1	2	0	0	0	0	23
West	Italy	5	3	0	4	3	6	4	17	7	1	4
West	Luxembourg	1	1	0	1	0	5	2	10	6	2	152
West	Malta	0	0	0	0	0	0	1	0	0	1	244
West	Netherlands	1	0	0	0	0	1	0	2	0	0	93
West	Norway	6	6	3	5	2	1	1	0	3	2	1
West	Portugal	0	0	0	0	0	1	0	1	1	1	28
West	Spain	2	1	1	2	0	1	1	5	0	0	37
West	Sweden	1	0	0	0	0	0	0	0	0	0	5
West	United Kingdom	16	10	0	0	0	0	0	8	0	0	441
Centre	Hungary	5	11	15	15	11	10	12	20	12	5	120
West	Iceland	0	0	0	0	0	0	0	0	0	0	274
Centre	Latvia	2	0	2	2	2	0	0	5	1	1	601
Centre	Lithuania	1	1	3	0	0	3	0	25	0	0	819
Centre	Poland	6	7	10	15	13	10	12	6	7	5	4
West	Slovenia	0	0	0	0	0	0	0	8	1	1	9
West	Switzerland	0	0	0	0	0	0	0	8	0	0	167
West	United Kingdom	16	10	0	12	12	**7**	**8**	8	9	**6**	325
												5 953

4
14
15
8
15
1
2
1
4
13
22
7
15
3
14
5
31
3

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slo

3
0
0
1
0
22
2
8
8
18
0
0
3
15
204

v a k i a

S l o v e n i a

S p a i n

S w e d e n

T o t a l

E U / E E A

Non-EU/EEA

Centre Albania
West Andorra
East Armenia
East Azerbaijan
East Belarus
Centre Bosnia and Herzegovina
East Georgia
West Israel
East Kazakhstan
East Kyrgyzstan
East Moldova
West Monaco
Centre Montenegro
Centre North Macedonia
East Russian Federation
West San Marino
Centre Serbia
Centre Serbia excluding Kosovo[f]
Centre Kosovo[f]
West Switzerland
East Tajikistan
Centre Türkiye
East Turkmenistan
East Ukraine
West United Kingdom
East Uzbekistan
Total non-EU/EEA
WHO European Region
West
Centre
East
Total WHO European Region

1 0 4 1 6 2 6 0 6 4 2 5 2 3 1 4 0 0 0 0 0 1 0 1 4

1 0 1 10 20 0 4 4 24 16 10 0 0 0 0 0 0 2 2 - 4 54 15 - 77 49 - **29 1**

1 0 5 12 13 0 3 5 34 16 11 0 0 0 0 0 - 0 - 0 - 4 61 12 - 86 64 - **32 7**

2 0 6 9 4 0 6 8 24 22 13 0 0 0 0 0 1 0 1 2 53 13 - 71 66 - **30 0**

1 - 3 4 10 0 3 2 26 21 19 - 0 0 0 0 2 2 - 0 47 15 - 79 75 - **30 7**

1 - 9 2 5 0 3 3 23 12 12 - 0 0 16 2 0 - 0 - 1 43 12 - 67 30 - **38 5**

3 - 3 7 5 0 2 9 30 25 14 - 0 0 15 3 0 2 1 1 0 33 15 - 48 55 - **40 4**

2 - 3 12 4 1 6 6 22 20 12 - 0 0 12 9 0 - 0 - 3 30 11 - 35 86 - **38 2**

2 - 5 5 7 2 2 2 22 13 10 - 0 0 98 0 - 0 - 6 24 4 - 38 17 3 - **41 3**

5 - 3 1 1 3 0 3 4 1 5 2 0 5 - 0 0 9 6 0 - 0 - 3 2 5 1 6 - 5 0 1 5 6 - **4 1 5**

49 1 76 171 341 4 124 299 508 331 262 1 4 2 638 1 56 50 6 195 635 240 0 2 538 3 402 363 **10 241**

56										
23										
-										
98										
48										
-										
349										
226	191	191	214	206	117	168	312	372	326	8 409
	130	136	31	38	29	38	86	35	52	1 606
	223	245		214	346	326	297	233	233	6 179
	444	**472**	213	**458**	**492**	**532**	**695**	**640**	**611**	**16 194**
55			**458**							
272										
553										

[a] Country/territory/area specific comments are in Annex 5.
[b] Cumulative total is the total number of cases reported by the country since the start of reporting.
[c] Austria uses study cohort data.
[d] The cumulative figure for Germany differs from the country's own reported total because of variations in the counting methodology used.
[e] The numbers displayed here may not fully align with the numbers in the country's national statistics as these are presented by the 'date of notification' instead of the date of diagnosis as here.
[f] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

Table 8: HIV diagnoses in 2024, by country of report, transmission mode and sex, in EU/EEA and other countries of the WHO European Region

Area	Country, territory or area[a]	Sex between men			Injecting drug users			Heterosexual				Mother to child transmission			
		Male		Total[c]	Female		Total[c]	Female	Male	Trans. gender[b]	Total[c]	Female		Total[c]	
EU/EEA															
West	Austria[d]	83		0	83	6	14	0	20	30	41	0	71	0	3
West	Belgium	381		0	176	0	428	0	436	253	149	0	402	8	
Central				0	60	8	80	0	60	54	114	0	168	0	
Central				0			013	0	017	14	5	0	19		
Central				0	56	0	32	0	74	24	38	0	62	1	
West				0	163		11	0	13	88	91	0	179		
East	Bulgaria	76		0	49	0		0		46	114	0	104	2	
West				0	7	0		0		21	5	0	35		
		60		0	52			0		53	38	0	84	1	
	Croatia	56				4					91			2	
						4					58				
		163									14			1	
	Cyprus	49				2					31			0	
		7				2								0	
	Czechia	52												4	
	Denmark														
	Estonia														
	Finland														
West	France	1 416		0	1 416	8	63	2	73	976	686	0	1 662	29	29
West	Germany[e]	1105		29	1134	59	189	0	248	661	296	1	958	112	11
West		197		3	4200	20	97	0	97	64	96	0	1042	1210	0
West				0	122		77	0	149	20	40	0	282	1310	1
West				0	10	0	1	0	91	18	8	0	233	1001	0
East	Greece	122		0	275	12	3	0	13	244	5	4	365	1004	8
West				0	989	21	7	0		430	117	0	651	422	2
West				0	10		70	0	20	29	76	0	1094	2600	0
Central		270		0	30	0	13	0	30	04	64	0	630	026	0
West				0		0		0		40	34	0	841	1002	1
Central	Hungary	989		0	16	0	16	0	13	99	0	0	419	1003	1
Central				0	85	0	3	0	20	13	4	0	252	1004	0
West				0		0		0		057	44			2606	3
West				0	47	0	0	0	29					1000	2
				42		169									

Iceland	Ireland	Italy	Latvia	Liechtenstein	Lithuania	Luxembourg	Malta	Netherlands	Norway	Poland	Portugal	Romania	Sl
10	0	30	16	84	47	764	290	408	232	24	26	1759	98	**8554**
764	2902	4122	2322	24	26	1759	98	**8596**					
8	15	26	18	38	11	43	7	**674**					
0	0	0	0	0	0	0	0	**2**					
20	45	1	149	7	**845**								
83	25	117	417	835	368	**4224**							
10	16	89	33	83	245	305	36	11	577	44	**3**	**884**	
0	0	0	0	0	0	0	0	**5**					
19901649647953193012	**8113**												
136103	**95**												

		Slovakia	Slovenia	Spain	Sweden	**Total EU/EEA**	**Non-EU/EEA**	Albania	Andorra	Armenia	Azerbaijan	Belarus	Bosnia and Herzegovina
Centre													25
East	Georgia												110
West	Israel												
East	Kazakhstan												
East	Kyrgyzstan												
East	Moldova												94
West	Monaco												
Centre	Montenegro												411
Centre	North Macedonia												
East	Russian Federation												116
West	San Marino												
Centre	Serbia												
Centre	Serbia excluding Kosovo[g]												12
Centre	Kosovo[g]												-18
West	Switzerland												
East	Tajikistan												
Centre	Türkiye												36
East	Turkmenistan												
East	Ukraine												154
West	United Kingdom												49
East	Uzbekistan												
	Total non-EU/EEA												0
Centre													0
East	Georgia												031
West	Israel												00-
East	Kazakhstan												0000
East	Kyrgyzstan												0-00
East	Moldova												0000
West	Monaco												0-00
Centre	Montenegro												00-4
Centre	North Macedonia												
East	Russian Federation												
West	San Marino												
Centre	Serbia												
Centre	Serbia excluding Kosovo[g]												
Centre	Kosovo[g]												
West	Switzerland												
East	Tajikistan												
Centre	Türkiye												
East	Turkmenistan												
East	Ukraine												
West	United Kingdom												
East	Uzbekistan												
	Total non-EU/EEA												
Centre													0
East	Georgia												11
West	Israel												097
East	Kazakhstan												
East	Kyrgyzstan												412
East	Moldova												116
West	Monaco												12
Centre	Montenegro												
Centre	North Macedonia												018
East	Russian Federation												
West	San Marino												36
Centre	Serbia												
Centre	Serbia excluding Kosovo[g]												1549
Centre	Kosovo[g]												012
West	Switzerland												010
East	Tajikistan												5
Centre	Türkiye												15
East	Turkmenistan												
East	Ukraine												105
West	United Kingdom												27
East	Uzbekistan												
	Total non-EU/EEA												435 0
Centre													0
East	Georgia												38
West	Israel												80
East	Kazakhstan												
East	Kyrgyzstan												44
East	Moldova												-0
West	Monaco												01
Centre	Montenegro												156
Centre	North Macedonia												20
East	Russian Federation												11
West	San Marino												-10
Centre	Serbia												1-
Centre	Serbia excluding Kosovo[g]												01
Centre	Kosovo[g]												-283
West	Switzerland												11
East	Tajikistan												-**1995**
Centre	Türkiye												
East	Turkmenistan												
East	Ukraine												
West	United Kingdom												
East	Uzbekistan												
	Total non-EU/EEA												
Centre													0
East	Georgia												64
West	Israel												10
East	Kazakhstan												47
East	Kyrgyzstan												1
East	Moldova												15
West	Monaco												31
Centre	Montenegro												-5
Centre	North Macedonia												07
East	Russian Federation												78
West	San Marino												00
Centre	Serbia												22
Centre	Serbia excluding Kosovo[g]												-5
Centre	Kosovo[g]												35
West	Switzerland												21
East	Tajikistan												-1
Centre	Türkiye												63
East	Turkmenistan												7
East	Ukraine												53
West	United Kingdom												-**10354**
East	Uzbekistan												
	Total non-EU/EEA												
Centre													0
East	Georgia												00
West	Israel												00
East	Kazakhstan												00
East	Kyrgyzstan												00
East	Moldova												00
West	Monaco												00
Centre	Montenegro												00
Centre	North Macedonia												00
East	Russian Federation												00
West	San Marino												00
Centre	Serbia												00
Centre	Serbia excluding Kosovo[g]												00
Centre	Kosovo[g]												00
West	Switzerland												00
East	Tajikistan												00
Centre	Türkiye												00
East	Turkmenistan												00
East	Ukraine												00
West	United Kingdom												00
East	Uzbekistan												00
	Total non-EU/EEA												**0**
Centre													4
East	Georgia												133
West	Israel												69
East	Kazakhstan												1
East	Kyrgyzstan												148
East	Moldova												359
West	Monaco												304
Centre	Montenegro												-3
Centre	North Macedonia												3
East	Russian Federation												18
West	San Marino												035
Centre	Serbia												0
Centre	Serbia excluding Kosovo[g]												9
Centre	Kosovo[g]												7
West	Switzerland												2
East	Tajikistan												43
Centre	Türkiye												340
East	Turkmenistan												228
East	Ukraine												-3
West	United Kingdom												151
East	Uzbekistan												2
	Total non-EU/EEA												020
													-**26755**
Centre													6
East	Georgia												26
West	Israel												2
East	Kazakhstan												75
East	Kyrgyzstan												1
East	Moldova												71
West	Monaco												3
Centre	Montenegro												45
Centre	North Macedonia												8
East	Russian Federation												41
West	San Marino												9
Centre	Serbia												-3
Centre	Serbia excluding Kosovo[g]												13
Centre	Kosovo[g]												18
West	Switzerland												28
East	Tajikistan												5 0
Centre	Türkiye												
East	Turkmenistan												34
East	Ukraine												18
West	United Kingdom												16
East	Uzbekistan												48
	Total non-EU/EEA												52
													9
													1
													006
													-4
													60
													5
													1
													41
													4
													-**3040**
Centre													0
East	Georgia												0
West	Israel												10
East	Kazakhstan												0
East	Kyrgyzstan												0
East	Moldova												0
West	Monaco												0
Centre	Montenegro												0
Centre	North Macedonia												0
East	Russian Federation												0
West	San Marino												0
Centre	Serbia												0
Centre	Serbia excluding Kosovo[g]												0
Centre	Kosovo[g]												0
West	Switzerland												0
East	Tajikistan												0
Centre	Türkiye												0
East	Turkmenistan												0
East	Ukraine												0
West	United Kingdom												0
East	Uzbekistan												0
	Total non-EU/EEA												**1**
Centre													10
East	Georgia												395
West	Israel												
East	Kazakhstan												145
East	Kyrgyzstan												2
East	Moldova												861
West	Monaco												
Centre	Montenegro												817
Centre	North Macedonia												
East	Russian Federation												723
West	San Marino												
Centre	Serbia												0
Centre	Serbia excluding Kosovo[g]												6
Centre	Kosovo[g]												16
West	Switzerland												36
East	Tajikistan												320
Centre	Türkiye												0
East	Turkmenistan												43
East	Ukraine												25
West	United Kingdom												18
East	Uzbekistan												91
	Total non-EU/EEA												869
													1
													234
													0
													7
													756
													3
Centre													0
East	Georgia												2
West	Israel												3
East	Kazakhstan												9
East	Kyrgyzstan												3
East	Moldova												-0
West	Monaco												4
Centre	Montenegro												5
Centre	North Macedonia												0
East	Russian Federation												-1
West	San Marino												1
Centre	Serbia												4
Centre	Serbia excluding Kosovo[g]												5
Centre	Kosovo[g]												-2
West	Switzerland												1
East	Tajikistan												1
Centre	Türkiye												0
East	Turkmenistan												1
East	Ukraine												-**224**
West	United Kingdom												
East	Uzbekistan												
	Total non-EU/EEA												
Centre													0
East	Georgia												1
West	Israel												1
East	Kazakhstan												6
East	Kyrgyzstan												1
East	Moldova												1
West	Monaco												2
Centre	Montenegro												
Centre	North Macedonia												-0
East	Russian Federation												0
West	San Marino												5
Centre	Serbia												1
Centre	Serbia excluding Kosovo[g]												0
Centre	Kosovo[g]												-0
West	Switzerland												2
East	Tajikistan												1
Centre	Türkiye												1
East	Turkmenistan												1
East	Ukraine												1
West	United Kingdom												-0
East	Uzbekistan												-2
	Total non-EU/EEA												1
													1
													1
													1
													-

WHO European Region	120	283					**6**	434	29			
West		1										
Centre		41						0	5			
East	105	4						**57**	5			
Total WHO European Region	**15**	**0 5037**						**162**	**-1911**			
	105											
	27											
	4355-2833											
	14144-50333											

907	45	9	161	60	2	766	5	4	6	10	1	13
711		116	24	3		162	784	63		428	9	43
170	0	1	1	13	0	12	756	8	0	2	1	3
328	1	703	979	8		266	24	1		568	1	1
13	**46**	2	**2**	10	0	**13**	439	81	0	52	9	1
13587		814	**164**	28		**194**	**30**	2		279	1	1
		13		7	**2**		**979**	27	**6**	**65**	1	9
		633		**11**				84		**275**	4	**28**
				028				0			**324**	**6**
								34				
								290				

[a] Country/territory/area specific comments are in Annex 5.
[b] The mode of transmission among transgender people should be classified according to the gender at the time of diagnosis. However, there are discrepancies across countries in how the mode of transmission for transgender individuals is classified. Therefore, comparisons between countries should be made with caution. [c] Cumulative total is the total number of cases reported by the country since the start of reporting.
[d] Austria uses study cohort data.
[e] The cumulative figure for Germany differs from the country's own reported total because of variations in the counting methodology used.
[f] The numbers displayed here may not fully align with the numbers in the country's national statistics as these are presented by the 'date of notification' instead of the 'date of diagnosis' as here.
[g] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

	Nosocomial				Haemophiliac/transfusion		Unknown				Total c	Country, territory or area a
	Female	Male	Transgender b	Total c	Female		Total c	Female	Male	Transgender b	Total c		

0 1 0 1 0 0 0 0 9 17 0 26 204

0 0 0 0 0 0 0 0 1

0 0 0 0 1 0 0 1

0 0 0 0 0 0 0 0

0 0 0 0 1 0 0 2

4 0 0 0 0 1 0 2

0 0 0 1 0 0 0 1

0 0 0 0 0 0 0 0

4 0 0 1 0 1 0 3

10 5 0 1 0 14 12 37 28

1 9 7 0 1 0 2 2 0 2 5 5 0 3 7

2 8 0 0 0 0 0 0 0

33 0 0 11 2 34 37 87 65

1 133 284 91 125 398 199 133 226

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany e
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg f
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Total EU/EEA

0 0 0 0 10 2 0 12 530 860 104 1 494 4 716

0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 **3**

0 0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 **6**

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 1 0 0 0 0 0 0 0 0 2 2 0 0 0 0 0 0 0 **9**

0 0 0 0 0 0 0 0 0 0 0 0 7 1 1 0 0 0 3 2 **31**

0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 2 3 **11**

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 0 0 0 0 0 0 0 0 0 0 8 1 2 0 0 0 5 5 **42**

15 3 55 7 0 13 2 43 35 0 17 2 0 18 19 35 2 27 2 7 3 99 26 **1 733**

740 187 36 2 204 159 59 0 43 2 6 77 55 1 132 34 1 27 6 355 39 **4 382**

3 1 0 0 1 0 0 0 0 0 0 30 0 0 1 0 0 0 0 0 **168**

89 6 24 3 43 2 33 7 20 2 94 0 60 4 6 12 5 74 1 48 4 62 3 34 9 45 4 65 **6 283**

3 258 646 197 39 1 007 2 379 180 0 196 43 116 843 264 1 973 997 771 113 55 3 202 296 **24 084**

Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Moldova
Monaco
Montenegro
North Macedonia
Russian Federation
San Marino
Serbia
Serbia excluding Kosovo
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA
WHO European Region

West

Centre

East			0 0 0 **0**				0 0 0 **0**						
Total WHO European Region		0 - 0 0 0	0 - 0 0 0	0 0 0 0 0	0 - 0 0 0	0 - 0 0 0	0 - 0 0 0	0 0 0 0 0	1 - 1 11 10	9 - 2 5 2 3	0 - 0 0 0	1 0 0 3 1 6 3 3	123 0 544 1 171 1 228
	0	0	0	0	0	0	0	0	0	5	0	5	40
		0 0 0 0 0 - 0 0 0 0 - 0 - 0 0 0 - 2 7 - **9**	0 0 0 0 0 - 0 0 0 0 - 0 - 0 0 0 - 0 0 - **0**	0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 2 1 4 0 **1 7**	0 0 0 0 0 - 0 0 0 0 - 0 - 0 0 0 - 0 2 3 - **2 3**	1 1 0 0 0 - 0 0 0 0 - 0 - 0 0 0 - 0 2 1 - **2 3**	0 0 0 0 0 - 0 0 0 0 - 0 - 0 0 0 - 0 0 - **0**	1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 4 0 **4 6**	7 10 50 31 38 - 1 0 36 2 0 2 1 1 38 26 68 2 - 11 29 8 - **1 57 9**	3 2 4 1 1 1 0 4 9 6 7 - 7 1 5 8 4 0 2 4 2 4 - 7 1 2 0 3 6 1 6 - 1 6 4 3 8 - **5 1 2 0**	0 0 0 0 0 - 0 0 0 0 - 0 - 1 0 0 - 0 0 - **1**	39 51 16 0 80 10 5 0 8 1 94 6 0 26 25 1 11 0 46 4 29 8 0 27 73 6 0 **6 70 0**	615 316 3 999 1 053 880 0 37 53 48 253 0 192 158 34 315 1 002 6 005 0 10 038 5 862 0 **81 726**
		1 1 2 2 **1 5**	0 0 0 **0**	2 1 2 3 **2 6**	5 3 1 0 **5 4**	3 2 1 1 **3 4**	0 0 0 **0**	8 5 2 1 **8 8**	1 604 1 072 636 **3 312**	3 5 4 6 4 8 9 6 1 0 6 0 **9 5 0 2**	16 9 0 0 **16 9**	5 319 5 968 1 696 **12 983**	26 061 10 457 69 292 **105 810**

Table 9: HIV diagnoses in 2024, by country of report, age and sex, in EU/EEA and other countries of the WHO European Region

Area	Country, territory or area[a]	<15 years			15–19 years				20–24 years				25–29 years				
		Female	Male	Total[b]	Female	Male	Trans-gender[c]	Total[b]	Female	Male	Trans-gender[c]	Total[b]	Female	Male	Trans-gender[c]	Total[b]	
EU/EEA																	
West	Austria[d]	0	3	3	3	3		3	0	6	3	8	0	11	4	16	
West	Belgium	3	2	5	5			1	0	1	1	5 8	3	80 30 2 9	3	12 7	
Centre														20 5 7 10			
Centre		0	4	4	2				0			2 3	0			25	
Centre																15	
West		1	0	1	0				0				0			21	
East	Bulgaria	1	2	3	0				0			2	0			41	
West												7				21	
		1	1	2	2				0				0			5	
	Croatia	0	1	1	0				0			1 5	0			16	
		3	0	3	1				0				0				
	Cyprus	4	0	4	3				0			5	0				
												5					
	Czechia											8					
	Denmark																
	Estonia																
	Finland																
West	France	19	16	35	61	72	0		133	124	285	7	416	183	486		
West	Germany[e]	3	9	12	18	26	2		46	47	17	3	226	9	30		
West			21		51		0				76	0	56	0	09		
Centre			03	2	07	4	0		92	18		0	19	2			
West		0	20		61		0		0		38	0	0	3	54		
West			01	3	01	1	0		14	1		0	42	2			
West			00		00		0			0	18	0	118	1	24		
East	Greece	2	14	0	06	7	0		21	14		0	5	3			
West			36		25		0				0	0	0	5	45		
West			20	6	00	15	0		3	28	28	0	7	5			
West			03		13		0		0			0	4	9	5		
West		0	1	3	1	2	0		0	20	90	0	66	1	92		
Centre			67		14		0		0	11		0	12	0			
West				0	9	0	0		0	10	0	0	149	2	22		
Centre							0		18			0	91	1	44		
Centre		3		0		2	0			10	3	0	101	0	40		
Centre						0	0		2			0	12	3	13		
Centre	Hungary			1		0	0		35	7	0	0	7	3			
West		1			1	0	0		6	17	6	0	265	3	0		
West					49	11	0		23	21	3	17	15	4	13		
													1 792	1			

	Slovakia													
	Slovenia													
	Spain													
	Sweden													
	Total EU/EEA													
Non-EU/EEA														
Centre West East East East	Albania Andorra Armenia Azerbaijan Belarus	1 - 2 5 3	4 - 2 10 1	5 - 4 1 5 4	1 - 3 7 8	3 - 4 1 6 6	0 - 0 0 0	4 - 7 23 14	2 - 9 32 22	1 0 - 1 4 8 6 1 9	0 - 0 0 0	12 - 23 11 8 41	0 - 1 2 4 3 2 4	2 1 - 3 9 1 7 8 5 1
Centre	Bosnia and Herzegovina	0	0	0	0	0	0	0	0	2	0	2	1	6
East Georgia West Israel East Kazakhstan East Kyrgyzstan East Moldova West Monaco Centre Montenegro Centre North Macedonia East Russian Federation West San Marino Centre Serbia Centre Serbia excluding Kosovo[g] Centre Kosovo[g] West Switzerland East Tajikistan Centre Türkiye East Turkmenistan East Ukraine West United Kingdom East Uzbekistan **Total non-**		2 2 1 3 1 0 3 - 0 0 1 7 2 0 - 0 - 0 2 2	1 1 7 1 3 3 - 0 0 1 7 4 0 - 0 - 1 2 2 1 2 - 3 2 1 5 - **2 9 8**	3 3 2 0 2 3 6 - 0 0 3 4 6 0 0 0 0	3 1 2 1 1 7 1 3 - 0 0 1 7 9 0 - 0 - 2 2 3 8 - 3 8 4 0 - **3 6 4**	8 1 4 3 1 3 6 - 0 0 1 0 2 0 4 2 2 2 1 6	0 0 0 0 0 - 0 0 0 0 - 0 - 0 0 0 - 0 0 - **0**	11 2 64 30 19 - 0 0 28 1 0 4 2 2 4 39 75 - 65 83 - **72 5**	11 2 73 21 25 - 0 1 721 0 2 2 - 2 28 84 - 95 116 - **1 246**	41 8 19 1 57 16 - 3 6 60 1 0 11 8 3 17 40 59 2 - 12 8 22 4 - **2 06 6**	0 2 0 0 0 - 0 0 0 0 - 0 - 0 0 0 - 0 0 - **2**	52 12 264 78 41 - 3 7 1 322 0 13 10 3 19 68 676 - 223 342 - **3 316**	8 6 9 0 3 3 2 8 - 0 0 1 2 7 2 0 1 0 1 5 4 3 1 1 4 - 2 2 3 2 8 0 - **2 1**	7 5 2 4 3 4 4 1 0 1 3 7 - 2 7 1 3 4 9 0 4 1

EU/EEA **WHO European Region** West Centre East **Total WHO European Region**	6 - 2 4 1 9 - **2** **8** **4**	1 4 4 1 8 - 5 6 3 4 - **5** **8** **2**	6 7 - 2 7 4 2 - **3** **6** **0**	**8** **3**	3 1 1 0 2 0 7 9 9 1 7 - 3 4 4 4 7 6 - **4** **1** **1** **1**

6 1 2 2 2 5 9 **3** **4** **2**	63 36 266 **365**	1 2 4 5 8 5 2 5 **7** **0** **7**	173 25 315 **513**	2 6 2 1 2 6 2 4 6 **6** **3** **4**	3 0 0 **3**	439 151 561 **1** **151**	44 1 14 6 1 04 2 **1** **62** **9**	1 3 2 9 9 1 6 1 2 0 7 **3** **4** **5** **2**	19 0 0 **19**	1 79 7 1 06 2 2 24 9 **5** **10** **8**	856 209 1 785 **2** **850**	2 7 1 5 1 4 7 8 2 6 1 9 **6** **8** **1** **2**

[a] Country/territory/area specific comments are in Annex 5.
[b] Cumulative total is the total number of cases reported by the country since the start of reporting.
[c] The mode of transmission among transgender people should be classified according to the gender at the time of diagnosis. However, there are discrepancies across countries in how the mode of transmission for transgender individuals is classified. Therefore, comparisons between countries should be made with caution.
[d] Austria uses study cohort data.
[e] The cumulative figure for Germany differs from the country's own reported total because of variations in the counting methodology used.
[f] The numbers displayed here may not fully align with the numbers in the country's national statistics as these are presented by the 'date of notification' instead of the 'date of diagnosis' as here.
[g] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

	30–39 years				40–49 years				50+ years				Unknown age			Total	Country, territory or area[a]
	Female	Male	Trans-gender[c]	Total[b]	Female	Male	Trans-gender[c]	Total[b]	Female	Male	Trans-gender[c]	Total[b]	Female		Total[b]	Total[b]	

Block	Col 1	Col 2	Col 3	Col 4	Col 5	Col 6	Col 7	Col 8	Col 9	Col 10	Col 11	Col 12	Col 13	Col 14	Country, territory or area
1	15	51 2	0 15 0 0 0 0 0 0 0	66 370 91 25 34 123 66 45 80	11 95 20 3 4 49 25 14 28	49 173 57 21 16 98 29 28 35	0 3 0 0 0 0 0 0 0	60 271 77 24 20 147 54 42 63	9 77 9 5 4 13 12 15 17	29 142 38 17 29 39 34 8 24	0 2 0 0 0 0 0 0 0	38 221 47 22 33 52 46 23 41	0 2 0 0 0 0 0 0 0	0 1 0 0 0 0 0 0 0	EU/EEA Austria[d] Belgium Bulgaria Croatia Cyprus Czechia
2	448	859 6 9 2 1 3 3 5 3 6 2 2 1 5 0 9 **1 898** 3 4 0 4 6 1 2 4 9 2 2 3 5 7 5 1 1 2 1 0 1 9 7 2 6 8 8 9 9 4 9 **5 397**	43 15 3 0 0 4 0 0 0 0 0 1 7 0 0 3 0 0 0 0 0 **91**	1 350 1 00 7 18 5 62 13 33 3 65 6 50 0 64 13 51 27 1 76 66 5 27 7 24 7 32 11 1 04 6 90 **7 399**	340 25 1 24 5 9 14 9 12 8 23 0 27 4 4 53 35 15 7 65 36 10 1 11 6 27 **1 713**	572 5 7 6 1 4 8 3 8 6 1 5 1 4 4 2 3 6 0 4 0 9 1 2 1 3 4 6 2 3 8 5 1 2 9 1 1 5 3 0 1 2 5 5 7 5 3 **4 013**	20 5 0 0 0 2 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 **32**	932 8 3 2 1 7 2 4 3 1 5 3 0 2 5 7 0 5 9 0 6 7 1 3 1 6 1 8 9 9 7 5 4 6 1 9 4 1 5 1 4 0 1 3 6 7 8 8 0 **5 767**	378 17 1 22 7 2 75 12 6 21 0 13 4 3 33 20 68 96 36 3 5 11 3 19 **1 376**	766 5 3 6 1 2 2 2 9 3 1 0 4 6 0 2 3 7 0 2 6 6 1 0 1 2 8 2 8 1 4 9 1 5 1 7 7 1 6 1 0 4 6 9 4 6 **3 675**	10 0 0 0 0 2 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 **15**	1 154 7 0 7 1 4 4 3 7 5 1 8 2 7 2 8 5 8 0 3 9 1 0 1 3 1 6 2 4 8 2 1 9 2 4 7 1 1 3 1 9 1 5 5 8 4 6 5 **5 072**	0 4 0 2 0 0 0 0 0 0 0 0 0 0 8 0 0 0 0 0 0 **16**	0 1 7 0 5 0 0 0 0 0 0 0 3 0 0 6 7 0 0 0 0 0 0 **93**	Denmark Estonia Finland France Germany[e] Greece Hungary Iceland Ireland Italy Latvia Liechtenstein Lithuania
3		2 2 - 1	0 - 0 0 0	28 - 17 4 39	6 - 42 67	1 8 - 1	0 - 0 0 0	2 4 - 1 5	13 - 36 67	1 6 -	0 - 0 0 0	2 9 -	0 - 0 0	0 - 0 0	Luxembourg[f]

Malta Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden **Total EU/EEA** **Non-EU/EEA** Albania Andorra Armenia Azerbaijan Belarus Bosnia and Herzegovina Georgia Israel Kazakhstan Kyrgyzstan Mold

3

3 0 2 9 0 2 4 2
10
13 3 69 91 6 21 9 19 6 009 0 - 11 17 9 38 4 0 59 1 018 1 8 83 **9 199** 8 9 1 41 7 - 2 28 1 1 12 9 - **16 79 1**
2 487 5 56 8 063 5 2 54 3 14 08 0 **22 18 8**

0
0 1 0 0 0 - 0 0 0 0 - 0 - 0 0 0 - 0 0 - **1**
92 0 0 **92**

0 35 6
13
172 97 1 257 331 297 - 13 17 15 393 0 60 51 9 113 315 1 674 - 3 299 2 008 - **26 007**
8 168 3 095 22 143 **33 406**

15 0
0
42 29 415 107 90 - 1 1 7 123 0 4 4 - 22 72 238 - 1 071 760 - **10 240**
2 175 535 9 243 **11 953**

0 8 1 6 6 2 6 7
13
11 9 56 77 4 13 5 17 1 - 12 15 11 77 5 0 45 38 7 51 16 0 1 05 9 - 2 56 1 83 3 - **18 33 8**
4 077 1 934 16 340 **22 351**

0
0 0 1 0 0 - 0 0 0 0 - 0 - 1 0 0 - 0 0 - **2**
33 0 1 **34**

0 2 3 3 4 1 7
13
161 86 1 190 242 261 - 13 16 18 898 0 49 42 7 74 232 1 297 - 3 632 1 596 - **28 584**
6 294 2 473 25 584 **34 351**

15 8
0
40 22 334 104 83 - 1 1 4 528 0 4 3 1 24 66 209 - 997 379 - **7 066**
1 602 378 6 462 **8 442**

9 9 1 0 4 1 6 3
5
9 1 6 2 4 3 6 1 1 1 1 0 8 - 5 5 4 8 6 4 0 2 0 1 9 1 5 7 1 1 6 1 0 2 5 - 1 1 9 9 6 8 3 - **9** **1 6 9**
4 002 1 480 7 362 **12 844**

0
0 0 0 0 0 - 0 0 0 0 - 0 - 0 0 0 - 0 0 - **0**
15 0 0 **15**

1 3 5 1 7 1 3 2 1
5
13 1 84 77 0 21 5 19 1 - 6 6 9 39 2 0 24 22 2 81 18 2 1 23 4 - 2 19 6 1 06 3 - **16 23 6**
5 62 3 1 86 1 13 82 4 **21 30 8**

0
0
0 1 0 0 0 - 0 0 0 0 - 0 - 0 0 0 - 0 1 - **2**
8 1 0 0 **1 8**

0
0
2 1 0 0 0 - 0 0 0 0 - 0 - 0 0 0 - 0 0 - **3**
2 2 7 2 2 **9 6**

Moldova
Monaco
Montenegro
North Macedonia
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo[g]

Kosovo[g]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom

Uzbekistan

Total non-EU/EEA WHO Europea

nRegion West

Centre

East

TotalWHOEuropeanRegion

Table 10: Origin of those diagnosed with HIV in 2024 by country of report or Region, in EU/EEA and other countries of the WHO European Region

Area	Country, territory or area[a]	Country of report		Western Europe		Central & Eastern Europe		Sub-Saharan Af	
		N	%	N	%	N	%	N	
EU/EEA									
West	Austria[c]	86	42.2	18	8.8	59	28.9		
West	Belgium	223	19.6	79	7.0	115	10.1	291	
Centre	Bulgaria	241	84.9	4	1.4	32	11.3		
Centre	Croatia	48	52.7	4	4.4	25	27.5		
Centre	Cyprus	44	35.2	16	12.8	31	24.8		
West	Czechia	157	39.4	7	1.8	208	52.3		
East	Denmark	48	22.6	10	5.0	71	35.7		
West	Estonia	44	80.5	0	0.0	16	12.0		
West	Finland	157	16.8	3	1.3	38	16.8		
West	France	1 045	29.3	75	1.6	166	3.5	1 472	
West	Germany[d]	2 107	38.0	56	1.7	875	26.8	385	
Centre	Greece	38	57.1	26	4.0	82	12.7		
West	Hungary	381	60.0	2	1.0	19	9.0		
West	Iceland	2	5.1	8	20.5	14	35.9		
West	Ireland	89	8.8	26	2.6	107	10.6	324	
East	Italy	512	63.6	26	1.1	153	6.4	284	
West	Latvia	0	0.0	0	0.0	0	0.0		
East	Liechtenstein	0	-	0	-	0	-		
West	Lithuania	128	65.3	2	1.0	59	30.1		
West	Luxembourg	6	14.0	7	16.3	5	11.6		
West	Malta	11	9.5	14	12.1	13	11.2		
West	Netherlands	229	27.2	61	7.2	178	21.1	110	
Centre	Norway	29	11.0	7	2.7	148	56.1		
West	Poland	975	48.5	8	0.4	381	19.0		
Centre	Portugal	441	44.2	16	1.6	8	0.8	264	
Centre	Romania	743	96.4	1	0.1	15	1.9		
Centre	Slovakia	15	13.3	0	0.0	21	18.6		
West	Slovenia	29	52.7	2	3.6	13	23.6		
West	Spain	404	43.5	108	3.3	96	3.0	184	
West	Sweden	55	18.6	12	4.1	67	22.6		

Hungary

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

	Romania							
	Slovakia							
	Slovenia							
	Spain							
	Sweden							
	9 771	**40.4**	**598**	**2.5**	**3 015**	**12.5**	**3 670**	**15.2**
Non-EU/ EEA								
Centre West	Albania	123	100.0	0	0.0	0	0.0
East		-	-	-	-	-	-
East		536	98.5	0	0.0	8	1.5
East			98.4	0	0.0	18	1.5
Centre		-	99.9	0	0.0	0	0.0
			87.5	0	0.0	1	2.5
	Andorra	1					
		152					
	Armenia	1					
		227					
	Azerbaijan	35					
	Belarus						
	Bosnia and Herzegovina						
East	Georgia	615	100.0	0	0.0	0	0.0
West	Isr	11	36.6	5	1.6	72	22.7
East		16		0	0.0	163	4.1
East			95.2	6	0.6	60	5.7

East				0	0.0	14	1.6
West				-	-	-	-
Centre			92.8	0	0.0	9	24.3
Centre East		3		0	0.0	3	5.7
West			98.4	-	-	-	-
Centre		-	-	-	-	-	-
Centre		8	75.7	-	-	5	2.6
Centre West		0		0	0.0	5	3.2
East		7		-	-	-	-
Centre			94.3	40	12.6	37	11.7
			-	0	0.0	3	0.3
			-	100	1.7	236	3.9
			95.3				
		9					
		7	94.9				
		7					
			97.1				
		8					
		6	19.9				
		6					
			98.9				
		-					
			86.3				
		2					
		8					
		5					
		0					
		-					
		-					
		1					
		8					
		3					
		1					
		5					
		0					
		3					
		3					
		6					
		3					
		9					
		9					
		1					
		5					
		1					
		8					
		4					

Kazakhstan

Kyrgyzstan

Moldova

Monaco

Montenegro

North Macedonia

Russian Federation

San Marino

Serbia excluding Kosovo

Switzerland

Tajikista

		n						
		Türkiye						
East		Turkmenistan	-	-	-	-	-	-	
East Ukraine			10	100.0	0	0.0	0	0.0	
West United Kingdom			038	16.1	101	1.7	251	4.3	2 996
East Uzbekistan				-	-	-	-	-	
Total non-EU/EEA WHO European Region				**80.4**	**252**	**0.8**	**880**	**2.6**	**3 204**
	West		951						
			-						
			26						
			942						
			8 288	31.7	698	2.7	2 555	9.8	6 698
	Centre East		7 981	76.0	1448	1.4	999	9.5	170
	Total WHO European Region			**97.2**	**850**	**0.0**	341	1.6	
				63.7		**1.5**	**3 895**	**6.8**	**6 874**
			204						
			444						
			36						
			7136						

[a] Country/territory/area specific comments are in Annex 5.
[b] Cumulative total is the total number of cases reported by the country since the start of reporting.
[c] Austria uses study cohort data.
[d] The cumulative figure for Germany differs from the country's own reported total because of variations in the counting methodology used.
[e] The numbers displayed here may not fully align with the numbers in the country's national statistics as these are presented by the 'date of notification' instead of the 'date of diagnosis' as here.
[f] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

Latin America & Caribbean		South & South-East Asia		Other		Unknown		Total[b]	Total[b] Country, territory or area[a]
N	%	N	%	N	%	N	%		
									EU/EEA
3.4	16	7.8	4	2.0	2	1.0	204		
12.4	25	2.2	33	2.9	22	20.2	1 136		
0.4	0	0.0	2	0.7	9	0.0	284		
7.7	2	0.0	0	0.0	0	0.0	91		
2.4	7	2.5	8	6.4	0	0.0	125		
2.0	10	5.6	0	0.0	0	0.0	398		
11.1	21	2.5	5	2.5	5	2.5	199		
1.5	0	10.6	6	0.0	0	0.0	133		
2.2	17	0.0	3	7.5	0	0.0	226		
6.2	74	7.5	2	1.6	5	2.5	4 716 3		
5.3	13	1.6	4	4.1	0	0.0	259 646		
1.5	2	4.1	0	4.0	92	40.7	210		
2.4	26	2.9	2	0.2		21.5	39		
2.6	6	5.1	4	9.5	1	8.8	1 008 2		
15.8	2	3.5	0	1.3	01	4.5	379 180		
10.2	35	2.9	1	5.1	4	23.8	-		
0.0	0	0.0	1	3.5	28	0.0	196		
0.5	0	0.0	2	3.1	8	25.2	43		
2.3	2	1.0	0	1.0	29	0.8	116		
40.5	1	2.3	2	15.4		100.0	843		
19.7	8	6.9	6	1.4	50	-	264		
7.2	43	5.1	1	3.1		0.0	2 009		
0.5	20	7.6	1	0.0	0	7.0	997		
24.0	11	0.5	1	-	25	0.9	771		
0.0	6	0.6	1	0.0	4	0.5	113		
0.0	0	0.0	1	4.7	19	1.5	55		
0.0	1	0.0	1	4.3		30.0	3 228		
3.6	1	0.9	1	6.2	18	1.5	296		
37.0	33	1.8	1	4.2	0	0.8			
8.1	32	1.0	1	0.1	0	67.3			
		10.8	1	0.8	0	10.9			
			1	0.4	0	3.1			
			1	0.0	3	4.7			
				3.6	1				
				3.4	4				
				3.7	60				
					2				
					15				
					6				
					76				
					6				
					99				
					14				
2 782	11.5	600	2.5	736	3	2 992	12.4	24 164	
									Estonia
0.0	0	0.0	0	0.0	0	0.0	123		
-	-	-	-	-	-	-	-		
0.0	0	0.0	0	0.0	0	0.0	544		
0.0	1	0.0	0	0.0	0	0.1	1 171		
0.0	0	0.1	1	0.0	0	0.0	1 228		
0.0		0.0	0	0.0			40		
0.0		0.0		2.5					
0	0.0	0	0.0	0	0.0	0	0.0	615	
									Finland
3.2	10	3.2	4	13.6	0	0.0	317		
0.0	8	0.2	3	0.5	0	0.0	3 999		
0.0	8	0.8	2	0.0	2	0.2	1 053		
0.0	0	0.0	1	0.0	0	0.0	880		
-	-	-	0	-	-	-	-		
0.0	0	0.0	0	0.0	0	0.0	37		
-	-	-	-	-	0	0.0	53		
0.0	-	0.0	-	0.0	-	-	-		
0.0	-	0.0	-	0.0	-	-	192		
0.0	-	0.0	-	0.0	0	0.0	158		
0.0	-	0.0	-	0.0	-	-	34		
-	0	-	0	-	11	35.0	317		
1.0	50	0.0	4	-	1	0.0	1 002		
0.6	44	0.0	8	0.0	0	0.0	6 005		
2.9		1.6	1	1.3	16	2.8			
7.6		0.0	3	0.8	8				
0.0		0.0	7	2.3					
0.4									Germany[c] Gr

-	-	-	-	-	-	-	-	-
	0.0 7.1 **-1.4**	0 44 7 **-523**	0.0 7.6 **-1.6**	0 1 1 7 **-331**	0.0 2.0 **-1.0**	0 60 9 **-891**	0.0 10.3 **-2.7**	10 038 5 891 **-33 505**
3 196	12.2 0.6 0.0 **5.7**	1 022 82 19 **1 123**	3.9 0.8 0.1 **1.9**	875 157 35 **1 067**	3.3 1.5 0.2 **1.9**	2 792 908 183 **3 883**	10.7 8.6 0.9 **6.7**	26 124 10 506 21 039 **57 669**

Hungary

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

	Romania	Slovakia	Slovenia	Spain	Sweden	**Total EU/EEA**
Non-EU/EEA						
Albania						
Andorra						
Armenia						
Azerbaijan						
Belarus						
Bosnia and Herzegovina						
Georgia						
Israel						
Kazakhstan						
Kyrgyzstan						
Moldova						
Monaco						
Montenegro						
North Macedonia						
Russian Federation						
San Marino						
Serbia						
Serbia excluding Kosovo[f]						
Switzerland						
Tajikistan						
Türkiye						
Turkmenistan						
Ukraine						
United Kingdom						
Uzbekistan						
Total non-EU/EEA						

	WHO European Region West Centre East	**Total WHO Eu**
Non-EU/EEA		
Albania		
Andorra		
Armenia		
Azerbaijan		
Belarus		
Bosnia and Herzegovina		
Georgia		
Israel		
Kazakhstan		
Kyrgyzstan		
Moldova		
Monaco		
Montenegro		
North Macedonia		
Russian Federation		
San Marino		
Serbia		
Serbia excluding Kosovo[f]		
Switzerland		
Tajikistan		
Türkiye		
Turkmenistan		
Ukraine		
United Kingdom		
Uzbekistan		
Total non-EU/EEA		

Table 11: HIV diagnoses, by geographical area, transmission mode and country or subcontinent of origin, in cases reported in 2024

	Country of report		Western Europe		Central & Eastern Europe		Sub-Saharan Africa	
Total WHO European Region	36 713	63.7	850	1.5	3 895	6.8	6 874	11.9

Latin America & Caribbean		South & South-East Asia		Other		Unknown			
3 264	5.7	1 123	1.9	1 067	1.9	3 883	6.7	57 669	Total WHO European Region

Table 12: Percentage of HIV diagnoses (2024) among persons >14 years reported with information about CD4 cell count, by CD4 cell count level (<200 and <350 cells per mm3 blood) and by transmission mode in cases with CD4 <350, in EU/EEA and other countries of the WHO European Region[a]

Area	Country, territory or area[b]	Number of cases with CD4	Completeness (%) CD4[c]	CD4 <200 (%)		CD4 <350 (%)		CD4 < 350 per mm3 blood (%)		
				N	%	N	%	Heterosexual[d]		Sex between men[d]
EU/EEA										
West	187	93.0	57	29.8	97	50.8	53.6	50.0		43.2
Austria West		49.7	103	22.1	165	35.3	52.9	-		19.1
		85.5	87	42.2	130	63.1	72.4	69.2		43.8
Belgium Centre	326	65.1	18	43.9	28	68.3	100.0	-		56.7
		97.6	21	25.9	33	40.7	41.3	-		39.4
Bulgaria Centre		76.0	76	32.2	113	47.9	60.8	71.4		34.4
		77.9	36	36.4	53	53.5	60.3	100.0		24.0
Croatia Centre	206	88.6	31	33.3	49	52.7	38.1			-
		67.9	20	26.3	31	40.8	40.5	100.0		45.8
Cyprus Centre		50.7	622	22.2	1072	38.3	49.3			28.2
		27.3	299	22.8	448	34.1	36.8			25.8
Czechia West	41	38.0	79	36.1	128	58.4	62.5	33.3		47.2
		100.0	-	-	-	-	-	42.4		-
Denmark East	81	35.9	5	33.3	8	53.3	50.0	36.2		66.7
		98.4	56	27.5	90	44.1	45.7	66.7		41.2
Estonia West	199	32.2	941	40.3	1400	59.9	64.4	-		53.2
		78.3	23	39.7	30	51.7	50.0	-		42.9
Finland West		81.6	-	-	-	-	-	33.3		-
		92.9	45	30.8	62	42.5	45.1	59.1		33.3
France West	81	68.6	4	12.9	12	38.7	26.7	100.0		42.9
		63.3	19	36.5	28	53.8	57.9	-		51.5
Germany West	93	-	112	25.3	164	37.1	48.8	18.2		27.7
		69.6	30	37.5	40	50.0	66.7	100.0		28.0
Greece Centre		95.9	-	-	-	-	-	-		-
		34.3	269	34.8	388	50.1	58.9	66.7		38.1
Hungary West	76	85.0	278	38.3	452	62.3	69.2	50.0		50.2
		86.3	9	26.5	15	44.1	50.0	-		33.3
Iceland West	1890	61.6	10	29.4	19	55.9	41.7	43.8		60.0
		63.9	878	31.6	1421	51.1	60.6	51.1		44.4
Ireland West			37	41.1	60	66.7	68.9	100.0		62.9
			4 165	**30.6**	**6 536**	**48.0**	**56.5**	-		**39**
Italy East	882							70.7		
								-		
Latvia West								**52.4**		
	219									
Liechtenstein East	-									
Lithuania West	15									
Luxembourg West	182									
Malta West										
Netherlands West	2337									
Norway Centre	58									
Poland West	-									
Portugal Centre	141									
Romania Centre										
Slovakia Centre	31									
	5									

Slovenia
West

Spain
West

Sweden

Total EU/EEA

Non-EU/EEA
Centre

Albania
West

Andorra
East

Armenia
East

Azerbaijan
East

Belarus
Centre

Bosnia and Herzegovina
East

Georgia
West

Israel
East
Kazakhstan
East
Kyrgyzstan
East
Moldova
West
Monaco
Centre
Montenegro
Centre
North Macedonia
East
Russian Federation[e]
West

San Marino
Centre

Serbia
Centre
Serbia excluding Kosovo[f]
Centre
Kosovo[f]
West
Switzerland
East
Tajikistan
Centre
Türkiye
East
Turkmenistan
East
Ukraine
West
United Kingdom
East
Uzbekistan

Total non-EU/EEA

WHO European Region
West
Centre
East

2
306
69
-
660
726
34
34
2780
90
11
796
108
-
-
-
900
36
532
137
-
723
741
-
27
51
47
384
-
169
14

91.5
-
-
-
73.5
90.0
87.2
83.5
-
70.2
84.8
-
90.0
96.2
98.2
-
88.5
88.6
87.9
64.7
-
11.8
-
91.7
86.6
-
68.1

43	39.8	72	66.7	69.5	50.0	50.0
-	-	-	-	-	-	-
-	-	-	-	-	-	-
229	25.4	444	49.3	51.0	44.1	33.3
20	55.6	29	80.6	100.0	-	69.6
169	31.8	307	57.7	60.7	58.3	45.3
42	30.7	62	45.3	55.1	-	43.7
-	-	-	-	-	-	-
211	29.2	403	55.7	57.6	77.8	40.4
277	37.4	490	66.1	67.1	54.3	58.3
-	-	-	-	-	-	-
13	48.1	16	59.3	66.7	60.0	53.3
20	39.2	38	74.5	93.8	-	64.7
8 023	16.9	15	32.1	-	-	-
-	-	228	-	-	-	-
72	40.7	-	62.1	68.4	66.7	58.8
63	42.6	110	63.5	76.0	66.7	58.6
9	31.0	94	55.2	53.8	-	60.0
55	30.1	16	54.1	65.7	66.7	42.7
-	-	99	-	-	-	-
172	24.4	-	47.7	44.2	33.3	38.5
-	-	336	-	-	-	-
3812	41.7	-	64.7	66.0	59.5	63.6
694	26.6	5920	47.5	52.7	36.4	37.8
-	-	1240	-	-	-	-
5829	**36.2**	-	**59.5**	**62.6**	**58.1**	**45.3**
		9 566				

t **Total WHO European Region**	0 29 183 - 705 - 9151 26122 - **16075**	13 115 2417 12 3339 **27** **8711**	65.8 30.3 87.0 **66.2**	4 358 839 4797 **9 994**	29.3 34.1 38.9 **33.6**	7 006 1391 7705 **16102**	47.0 56.5 62.4 **54.2**	54.8 63.6 63.9 **60.6**	48.9 58.7 58.5 **57.1**	38.5 48.3 51.3 **40.5**

[a] Children under 15 years and previously positive diagnoses are excluded from both the numerator and the denominator. Cases classified as recent infection are excluded from the numerator of the late-diagnosis indicator if CD4 < 350 cells/mm³, but remain in the denominator.

[b] Country/territory/area specific comments are in Annex 5.

[c] These data should be interpreted with caution, as some countries are unable to distinguish between new and previous positive cases, meaning the numbers and proportions may vary and should not be directly compared between countries.

[d] There is some variation by country for CD4 cell count completeness by transmission group and numbers of cases by transmission group (MSM, heterosexual, IDU) and therefore percentages based on five or less cases are censored.

[e] Data on CD4 cell count reported from the Russian Federation do not include about information on previous and recent infection as well as disaggregation by mode of transmission and are excluded from the sub-regional and regional totals.

[f] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

Table 13: AIDS diagnoses and rates per 100 000 population, by country and year of diagnosis (2015–2024) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area	Country, territory or area[a]	Year of start of reporting	2015		2016		2017		2018		2019	
			N	Rate	N	Rate	N	Rate	N	Rate	N	Rate
EU/EEA												
West	Austria[c]	1982	76	0.9	70	0.8	69	0.8	54	0.6		
West	Belgium	1983	105	0.9	78	0.7	66	0.6	60	0.5		
Centre			45	0.6		0.6		0.7		0.8		
Centre				0.5	42	0.6	49	0.6	57	0.7		
Centre		1987	21	8.1		0.5		7.7		8.3		
Centre				0.4	22	8.7	24	0.5	30	0.4		
West		1986	70	0.7		0.4		0.5		0.4		
East				1.4	75	0.4	67	1.5	73	1.9		
West			38	0.3		3.0		0.3		0.4		
	Bulgaria	1986	40		46	0.5	55		39	0.4		
		1986	18		24		29		26			
		1980	18		40		20		25			
					30		18		21			
	Croatia	1992										
		1983										
	Cyprus											
	Czechia											
	Denmark											
	Estonia											
	Finland											
West	France	1982	617	0.9	528	0.8	513	0.8	557	0.8		
West	Germany[d]	1981	362	0.4	310	0.4	295	0.4	242	0.3		
West				1.3		1.4		1.2		1.0		
Centre				0.4		0.5		0.5		0.6		
West		1981	141	0.0	148	1.2	131	0.0	109	0.6		
West				0.4		0.3		0.4		0.3		
West		1986		1.5	53	1.5	52	1.3	57	1.2		
East				6.6	4	5.8	0	6.1	2	5.1		
West		1985	43	0.0	15	0.0	21	0.0	13	0.0		
East				1.2	874	1.7	803	1.9	725	1.3		
West		1983	0	3.2	114	3.3	118	1.5	990	1.2		
	Greece											
		1982	21		0		0		37			
		1990			48		54		7			
		1989	877		19		9					
	Hungary											
		1988	132									
	Iceland		0									
			3									

	and	1983	5 18							
	Ireland									
	Italy									
	Latvia									
	Liechtenstein									
	Lithuania									
	Luxembourg									
West	Malta	1986	2	0.5	5	1.1	0	0.0	0	0.0
West	Netherlands	1999	267	1.6	220	1.3	219	1.3	204	1.2
West				0.4		0.4		0.3		0.2
Centre				0.3		0.3		0.3		0.3
West		1983	22	3.5	22	3.9	14	3.2	12	2.8
Centre			128	1.9	102	1.8	110	1.7	111	1.7
Centre				0.1		0.2		0.2		0.2
Centre		1986	361	0.5	402	0.5	327	0.3	292	0.5
West				1.3		1.2		1.1		0.8
West			369	**-1.0**	356	**-0.9**	336	**-0.9**	329	**-0.8**
	Norway	1985	8		10		9		11	
			11		10		7		10	
		1985	609		541		513		384	
			-454		**-208**		**-928**		**-586**	
		1985								
		1986								
	Poland	1981								
		1982								
	Portugal									
	Romania									
	Slovakia									
	Slov									

			Slovenia	Spain	Sweden	**Total EU/EEA**					
Non-EU/EEA											
Centre	Albania	1993	65	2.3	4.2	58	2.0	33	1.1	47	1.6
West				5.7	2.0	0	0.0	2	2.7	0	0.0
East				2.0	5.1	163	5.7	144	5.0	211	7.4
East	Andorra	2004	3	5.1	0.2		1.6		1.7		1.8
East				0.2	7.2	161	5.3	168	4.5	182	3.9
Centre			16	7.2	0.6		0.2		0.1		0.4
East	Armenia	1988	3	0.6	1.5	512	7.1	439	6.8	382	7.2
West				1.5	0.6		0.6		0.4		0.6
East				0.6	8.9	7	1.9	4	2.0	13	2.3
East	Azerbaijan	1995	19	8.9	0.0	269	0.5	257	0.8	273	0.8
West			3	0.0	2.1		11.3		8.6		11.6
Centre				2.1	0.3	48	0.0	36	0.0	49	0.0
Centre	Belarus	1991	49	0.3		350	2.1	361	2.4	432	2.2
			0				0.4		0.1		0.2
	Bosnia and Herzegovina	1986	8			33		46		47	
						366		274		365	
		1989	27			0		0		0	
	Georgia		0			13		15		14	
		1981	49			9		2		4	
	Israel										
	Kazakhstan	1993	273								
	Kyrgyzstan	1999	35								
	Moldova	1989	293								
	Monaco	1989	0								
	Montenegro	1985	13								
	North Macedonia	1990	6								
East	Russian Federation	2009	-	-	-	-	-	-	-	-	-
West	San Marino	1986	0	0.0	0	0.0	0	0.0	0	0.0	
Centre	Serbia		50	0.5	61	0.7	64	0.7	71	0.8	
Centre excluding	Serbia Kosovo[1]	1985	47	0.6	56	0.7	59	0.8	63	0.8	
			3	0.2	5	0.3	5	0.3	8	0.4	
Centre	Kosovo[1]		64	0.8	71	0.8	74	0.9	66	0.8	
West	Switzerland		281	3.3	237	2.7	264	3.0	212	2.3	
East	Tajikistan	1985	118	0.1	99	0.1	121	0.1	108	0.1	
Centre	Türkiye		-	-	-	-	-	-	-	-	
East	Turkmenistan		8	19.8	8	20.8	9	21.9	8	20.9	
East	Ukraine	2005	468	0.6	852	0.5	308	0.4	839	0.4	
West	United Kingdom			-		-		-		-	
East	Uzbekistan	1980	401	**4.0**	296	**4.1**	259	**4.1**	256	**4.0**	
Total non-EU/EEA			**11 243**		**11 605**		**11 871**		**11 571**		
WHO European Region											
West Centre Eastern		1998									
		1985									
		2002									
		1988									

st								
Total WHO European Region	1981	4 053	1.0	3 705	0.9	3 398	0.8	3 079	0.7
	1992	10 651	2.2	11 145	2.1	11 453	2.1	11 104	2.0
		15 697		**15 813**		**15 799**		**15 157**	

[a] Country/territory/area specific comments are in Annex 5.
[b] Cumulative total is the total number of cases reported by the country since the start of reporting.
[c] Austria uses study cohort data.
[d] The cumulative figure for Germany differs from the country's own reported total because of variations in the counting methodology used.
[e] The numbers displayed here may not fully align with the numbers in the country's national statistics as these are presented by the 'date of notification' instead of the 'date of diagnosis' as here.
[f] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

	2020		2021		2022		2023		2024		Cumulative total[b]	Country, territory or area[a]
	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate		
EU/EEA												
Austria[c]	46	0.5	55	0.6	56	0.6	44	0.5	43	0.5	3 593	
Belgium	63	0.5	79	0.7	73	0.6	110	0.9	64	0.5	5 706	
Bulgaria	42	0.6		0.6		0.8		1.0		1.0	1 055	
Croatia	12	0.3	38	0.7	54	0.5		0.5		0.4	654	
Cyprus	70	7.8		10.3		4.5	66	3.4	65	-	932	
Czechia	45	0.4	26	0.5	20	0.6		0.7		0.6	988	
Denmark	25	0.4		0.3		0.4		0.4		0.5	2 873	
Estonia	23	1.7	92	0.8	41	1.1	18	0.7	17	0.7	634	
Finland	13	0.2		0.3		0.3		0.2		0.3	820	
France			55		66							
Germany												
Greece			17		22		32		63			
Hungary												
Iceland			11		14							
Ireland							79		27			
Italy			18		17							
Latvia							25		9			
Liechtenstein												
Lithuania							10		18			
Luxembourg[e]												
Malta							10					
Netherlands												
Norway												
Poland												
Portugal												
Romania												
Slovakia												
Slovenia												
Spain												
Sweden												
Total EU-EEA	457	0.7	498	0.7	519	0.8	580	0.8	453	0.7	75 950	
Non-EU/EEA												
Albania		-		-		-		-		-	32	
Andorra		1.0	87	0.8	76	0.7	77	0.7	44	0.4	203	
Armenia		0.4	50	0.5		0.4		0.5		0.5	4 751	
Azerbaijan		0.5	2	0.5	43	0.5	46	0.5	50	1.0	1 285	
Belarus		0.2	16	0.3		0.3		0.4		0.3	89	
Bosnia and Herzegovina		0.7	45	0.8	21	0.8	20	1.0	4	0.8	1 389	
Georgia		2.9	5	2.1	8	3.1	6	2.4	17	2.5	73	
Israel		0.0	39	0.0	2	-	3	-	4	-	717	
Kazakhstan		0.8	0	1.4	18	0.9	20	1.3	5	0.7	2	
Kyrgyzstan		2.1	38	3.0	47	1.4	61	1.2	45	1.3	320	
Moldova			19		0		3		0		12	
Monaco					58		45		46		755	
Montenegro					-		-		-		599	
North Macedonia					25		37		21			
Russian Federation					9		8		9			
San Marino					0		0		3			
Serbia	0	0.0	0	0.0	0	0.0	0	0.0	3	0.5	117	
Serbia excluding Kosovo		1.0	14	0.8	15	0.9	16	0.9	13	0.8	8 645	
Switzerland		0.2	4	0.4	6	0.4	6	0.3	5	0.4	1 300	
Tajikistan		0.1	23	0.2	20	0.4	19	0.5	24	1.8	4 380	
Türkiye		2.3	64	2.5		1.7		1.5		1.5	24	
Turkmenistan		1.1	26	1.2	14	1.5	17	1.5	16	0.1	266	
Ukraine		0.1	2	0.1	0	0.1	7	0.1	3	0.5	12	
United Kingdom		0.3	22	0.2	17	0.4	15	0.5	19	-	069	
Uzbekistan		0.8	3	0.5	8	0.7	5	0.6	4	0.7	143	
Total non-EU/EEA		-	5	**0.7**	29	-	27	**0.8**	27	-	320	
WHO European Region		0.7	25		4	**0.7**	7		9	**0.7**	89	
			3		6		4		7		477	
			-		9		10		10		2 192	
			257		33				-		**353**	
			1		5		29		**221**		**234**	
					-		9		**5**			
					272		-					
					1		**292**					
							9					
West		0.6	48	1.7	46	1.6	53	1.9	47	1.7	859	
		-	-	-	-	-	-	-	-	-	15	
		5.4	19	7.1	23	8.3	22	8.0	11	4.2	2 785	
		1.0	7	1.1	0	0.9	1	1.7	6	1.1	3 122	
		2.3	10	3.0	91	-	17	-	12	-	7 253	
		-	9	-	-	-	3	-	0	0.6	197	
		4.8	28	5.8	-	5.7	-	6.7	-	6.8	5 378	
		0.5	6	0.5	21	0.3	24	0.5	19	0.2	2 016	
		2.5	-	2.4	5	2.2	9	1.9	-	1.6	6 167	
		0.4	21	0.5	31	0.6	50	0.4	25	1.3	884	
		6.5	7	6.5	-	7.9	-	7.3	1	8.9	5 640	
		-	46	-	43	-	37	-	21	-	51	
		0.6	45	1.3	0	2.6	1	1.9	32	1.9	214	
		-	9	-	39	-	27	-	4	1.0	190	
			33						90			
			19		25		25		-			
			9		9		2		29			
			-		-		-		8			
			8		16		12		-			
			-		-		-		12			
									-			
									20			
Central		-	-	-	-	-	-	-	-	-	-	
East		0.0	0	0.0	0	0.0	0	0.0	0	0.0	23	

0.4	53	0.6	60	0.7	55	0.6	54	0.6	2 383	st
0.4	50	0.7		0.7		0.7		0.6	2 269	
0.1	3	0.2	54	0.3	50	0.3	42	0.7	114	
0.5	40	0.5		0.5		0.4		0.4	10	
1.2	13	1.3	6	1.1	5	1.1	12	1.0	336	
0.1	0	0.1	43	0.1	39	0.1		0.2	2 778	**Total**
-	80	-		-		-	38	-	2 219	
9.9	-	10.	11	7.3	10	9.1		8.2	1	
0.3	4	0	3	0.3	7	0.3	10	0.3	136	**WHO**
-	15	0.3	84	-	80	-	3	-	335	
2.0	1	-	-	**1.7**	-	**1.9**	13	**1.7**	31	
	19	**2.1**	3		3		2		113	**European**
	2		01		35		-		651	
	-		0		1		3		**220**	
	6		20		20		12		**610**	**Region**
	24		8		5		7			
	8		-		-		17			
			4		**5**		4			
			87		**24**		-			
			5		**5**		**4**			
							94			
							6			
0.6	2	0.	2	0.	2	0.	1	0.	371	
0.3	20	6	23	6	422	7	718	6	253	
5.1	6	0.	3	0.		0.		0.	27	
1.3	74	4	87	4	909	5	938	5	888	
	4	5.	9	4.		4.		4.	174	
	5	2	4	3	4	9	4	4	703	
	86	**1.**	48	**1.**	843	**1.**	505	**1.**	**573**	
	9	**3**	4	**2**		**3**		**2**	**844**	
	8		**7**		**8**		**7**			
	81		**59**		**174**		**161**			
	9		**6**							

Table 14: AIDS diagnoses in males and rates per 100 000 population, by country and year of diagnosis (2015–2024) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area	Country, territory or area[a]	2015		2016		2017		2018		2019		
		N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	
EU/EEA												
West		57	1.4	52	1.2	56	1.3	43	1.0			
		64	1.2	44	0.8	44	0.8	35	0.6			
	Austria[c]	39	1.1	39	1.2	39	1.2	48	1.5			
West		19	0.9	21	1.1	22	1.1	28	1.5			
		62	14.8	63	15.0	50	11.8	63	14.7			
	Belgium	30	0.6	40	0.8	45	0.9	35	0.7			
Centre		28	1.0	19	0.7	25	0.9	21	0.7			
		11	1.8	23	3.7	15	2.4	19	3.1			
	Bulgaria	13	0.5	25	0.9	10	0.4	17	0.6			
Centre		428	1.3	347	1.1	365	1.1	397	1.2			
			0.7	249	0.6	231	0.6	191	0.5			
	Croatia	297	2.2	114	2.2	100	1.9	95	1.8			
Centre			0.8	45	1.0	36	0.8	54	1.2			
		115	0.0	4	2.4	0	0.0	0	0.0			
	Cyprus		0.7	12	0.5	15	0.6	12	0.5			
Centre			2.4	669	2.3	588	2.0	567	1.9			
		37	9.8	90	10.0	73	8.2	63	7.1			
	Czechia	0	0.0	0	0.0	0	0.0	0	0.0			
West		16	1.9	41	3.1	46	3.5	29	2.2			
		689	3.5	16	5.5	7	2.4	6	2.0			
	Denmark		0.9	5	2.2	0	0.0	0	0.0			
East			2.6	171	2.0	175	2.1	158	1.9			
		89	0.6	15	0.6	11	0.4	9	0.3			
	Estonia	0	0.5	90	0.5	95	0.5	86	0.5			
West		26	5.3	289	5.9	236	4.8	195	4.0			
		10	2.7	258	2.7	247	2.6	242	2.5			
	Finland	2	0.3	10	0.4	9	0.3	11	0.4			
West		216	1.1	8	0.8	7	0.7	10	1.0			
			2.2	438	1.9	409	1.8	318	1.4			
	France		-	-	-	-	-	-	-			
West			**1.6**	**3 197**	**1.5**	**2 956**	**1.3**	**2 752**	**1.3**	**2 370**		
		15										
	Germany[d]	97										
West		261										
	Greece	258										
Centre												
		7										
	Hungary	11										
West		492										
		-										
	Iceland	**3 389**										
West												
	Ireland											
West												
	Italy											
East												
	Latvia											
West												
	Liechtenstein											
East												
	Lithuania											
West												
	Luxembourg[e]											
West												
	Malta											
West												
	Netherlands											
West												
	Norway											
Centre												
	Poland											
West												
	Portugal											
Centre												
	Romania											
Centre												
	Slovakia											
Centre												

Slovenia West									
Spain West									
Sweden									
Total EU/EEA									
Non-EU/EEA									
Centre									
Albania West									
Andorra East									
Armenia East									
Azerbaijan East									
Belarus Centre									
Bosnia and Herzegovina East									
Georgia West									
Israel East									
Kazakhstan East									
Kyrgyzstan East									
Moldova West									
Monaco Centre									
Montenegro Centre									
North Macedonia East									
Russian Federation West	50 2 129 150	3.5 5.5 9.8 3.1 6.2	50 0 116 125 311	3.5 0.0 8.9 2.5 6.9	24 1 111 114 274	1.7 2.7 8.6 2.3 6.1	35 0 147 122 229	2.4 0.0 11.4 2.4 5.1	
San Marino Centre	278	0.4 11.0	6 196	0.4 11.0	4 193	0.2 10.9	13 172	0.8 9.7	
Serbia Centre	7 196	0.7 2.1 0.7 11.5	30 231 23 210	0.7 2.7 0.8 13.7	24 225 29 167	0.6 2.6 1.0 11.0	38 278 30 213	0.9 3.1 1.0 14.3	
Serbia excluding Kosovo[1] Centre	29 181 19 179	0.0 3.9 0.5 -	0 13 6 -	0.0 4.2 0.6 -	0 14 2 -	0.0 4.5 0.2 -	0 14 4 -	0.0 4.5 0.4 -	
Kosovo[1] West	0 12 5 -	0.0 1.0 1.2 0.2 1.3 4.4 0.2 -	0 57 52 5 49 173 86 -	0.0 1.3 1.4 0.6 1.2 3.9 0.2 -	0 58 53 5 56 181 103 -	0.0 1.3 1.5 0.6 1.3 4.0 0.3 -	0 63 56 7 50 149 91 -	0.0 1.4 1.6 0.8 1.2 3.2 0.2 -	
Switzerland East	0 47 45 2	23.2 0.9 -	5 462 224 -	27.7 0.7 -	5 612 184 -	28.6 0.6 -	5 405 190 -	27.6 0.6 -	4 661
Tajikistan Centre	52 187	**5.1**	**7 368**	**5.3**	**7 376**	**5.2**	**7 243**	**5.1**	**6 448**
Türkiye East	92 - 5 328								
Turkmenistan East	299 -								
Ukraine West	**7 242**								
United Kingdom East									
Uzbekistan									
Total non-EU/EEA									
WHO European Region	W								

est Centre East	3 085	1.5	2 772	1.3	2 537	1.2	2 342	1.1	2 049
	773	0.8	792	0.8	755	0.8	797	0.8	
	6 773	12.2	7 001	13.3	7 040	13.3	6 856	12.9	6 060
Total WHO European Region	**10 631**	**3.0**	**10 565**	**2.9**	**10 332**	**2.9**	**9 995**	**2.8**	**8 818**

[a] Country/territory/area specific comments are in Annex 5.
[b] Cumulative total is the total number of cases reported by the country since the start of reporting.
[c] Austria uses study cohort data.
[d] The cumulative figure for Germany differs from the country's own reported total because of variations in the counting methodology used.
[e] The numbers displayed here may not fully align with the numbers in the country's national statistics as these are presented by the 'date of notification' instead of the 'date of diagnosis' as here.
[i] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

2020		2021		2022		2023		2024		Cumulative total[b]	Country, territory or area[a]
N	Rate	N	Rate	N	Rate	N	Rate	N	Rate		
											EU/EEA
0.8	44	1.0	36	0.8	33	0.7	29	0.6	2 727		
0.7	46	0.8	49	0.9	73	1.3	44	0.8	3 753		
1.0	35	1.1	45	1.4	51	1.6	49	1.6	832		
0.6	24	1.3	19	1.0	15	0.8	16	0.9	585		
12.6	70	16.0	21	4.8	19	4.1	-	-	729		
0.7	45	0.9	50	1.0	56	1.1	48	0.9	789		
0.7	14	0.5	11	0.4	13	0.4	14	0.5	2 416		
2.9	9	1.4	12	1.9	7	1.1	6	0.9	461		
0.3	11	0.4	13	0.5	2	0.1	13	0.5	644		
1.0	34	1.1	33	1.0	38	1.1	30	0.9	59		
-	6	-	9	-	0	-	0	-	186		
1.7	-	1.2	-	1.1	-	1.3	-	0.7	27		
0.8	64	0.8	58	0.7	68	0.7	34	0.9	494		
1.1	39	1.1	32	0.5	33	0.5	41	1.5	3 944		
0.3	2	0.6	1	0.6	1	0.4	3	0.5	1 094		
1.1	15	1.2	15	1.2	11	1.7	12	1.2	74		
4.4	35	2.7	35	4.8	48	3.7	34	3.1	1 063		
0.0	2	0.0	0	-	1	-	8	-	56		
1.4	24	2.2	42	1.3	32	1.7	27	1.0	834		
2.2	0	4.7	-	1.8	-	1.5	-	1.2	1 592		
0.0	29	0.0	17	0.0	23	0.0	14	1.0	11		
1.5	15	1.4	6	1.4	5	1.5	4	1.3	595		
0.4	0	0.5	0	0.4	0	0.5	3	0.5	448		
0.2	11	0.3	12	0.6	13	0.7	11	0.7	103		
3.5	8	3.3	1	2.7	0	2.2	2	2.5	6 861		
1.6	13	1.7	11	2.5	13	2.3	14	2.3	996		
0.2	52	0.1	10	0.1	13	0.2	12	0.2	3 446		
0.4	16	0.3	7	0.8	2	0.9	0	0.6	18		
1.3	5	0.9	13	1.2	11	1.0	12	-	948		
-	15	-	4	-	1	-	5	-	7 461		
1.1	8	**1.1**	23	**1.1**	21	**1.2**	21	**1.0**	125		
	3		2		2		4		277		
	3		2		4		6		71		
	19		8		10		6		332		
	9		27		23		-		1 787		
	-		3		7		-		**276 607**		
	1 895		-		-		**1 602**				
			2 004		**2 152**						
											Austria[c]
											Belgium
											Bulgaria
											Croatia
											Cyprus
1.1	37	2.6	33	2.3	42	3.0	29	2.1	653		
-	-	-	-	-	-	-	-	-	11		
8.9	14	11.6	17	13.8	16	13.0	91	7.3	2 073		
1.5	6	1.6	3	1.2	2	2.3	88	1.7	2 505		
3.2	82	4.2	63	-	12	-	-	-	4 590		
-	18	-	-	-	0	-	18	1.1	166		
7.6	4	9.2	-	9.5	-	10.7	19	10.9	3 973		
0.8	-	0.8	16	0.5	-	0.7	1	0.3	1 435		
3.2	16	3.1	8	2.9	18	2.5	14	2.1	4 111		
0.4	3	0.6	21	0.8	7	0.5	20	1.8	625		
8.4	35	8.3	27	9.8	31	9.7	1	11.7	3 426		
-	28	-	4	-	23	-	14	-	40		
1.0	9	2.3	26	4.9	2	3.0	20	3.3	185		
-	18	-	15	-	17	-	1	1.8	146		
-	12	-	2	-	15	-	59	-	0		
0.0	0	0.0	-	0.0	9	-	18	0.0	21		
0.6	-	1.2	15	1.3	-	-	-	1.1	1 882		
0.8	7	1.4	-	1.4	9	-	-	1.1	1 791		
0.1	-	0.3	0	0.6	-	-	0	1.3	91		
0.9	0	0.7	55	0.7	0	0.0	48	0.7	7 710		
1.8	52	2.0	50	1.6	46	1.1	37	1.4	2 018		
0.1	49	0.2	5	0.2	41	1.2	11	0.2	1 846		
-	3	-	31	-	5	0.6	30	-	0		
11.1	30	13.1	80	10.0	28	0.6	75	11.4	66		
0.4	98	0.4	71	0.4	65	1.3	10	0.3	677		
-	73	-	-	-	70	0.2	5	-	24		
2.6	-	**2.8**	1	**2.3**	-	-	-	**2.3**	215		
	2		89		2	12.4	1		494		
	51		5		08	0.4	98		**128 802**		
	3		13		1	-	1				
	14		8		13		11				
	6		-		6		2				
	-		**3 195**		-		-				
	3 993				**3 385**		**3 257**				
											Finland
1.0	1	0.9	1	0.9	1	1.0	1	0.8	292		
	615		607		753		21		053		
0.5	59	0.6		0		0	1	0.7	20		
6.3	8	6.9	690	.7	699	.7	72	6.1	216		
1.7	3	**1.8**					9	**1.6**	93		
	67		2	5	3	6	2		140		
	5		902	.9	085	.5	91		**405 409**		
	5 888						9				
			5 199	**1.6**	**5 537**	**1.7**	**4 859**				
											France
											Germany[d]

Greece

Hungary

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

I

Romania

Slovakia

Slovenia

Spain

Sweden

Total EU-EEA

Non-EU/EEA

Albania

Andorra

Armenia

Azerbaijan

Belarus

Bosnia

and Herzegovina

Georgia

Israel

Kazakhstan

Kyrgyzstan

Moldova

Monaco

Montenegro

North Macedonia

Russian Federation

San

San Marino

Serbia

Serbia excluding Kosovo/Kosovo*

Switzerland

Tajikistan

Türkiye

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Total non-EU/EEA

WHO European Region

West

Centre

East

Total WHO European Region

Table 15: AIDS diagnoses in females and rates per 100 000 population, by country and year of diagnosis (2015–2024) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area	Country, territory or area[a]	2015		2016		2017		2018		201
		N	Rate	N	Rate	N	Rate	N	Rate	N
EU/EEA										
West	Austria[c]	18	0.4	18	0.4	13	0.3	11	0.2	
West	Belgium	41	0.7	34	0.6	22	0.4	25	0.4	
Centre	Bulgaria	6	0.2	3	0.1	10	0.3	9	0.3	
Centre	Croatia	2	0.1	1	0.0	2	0.1	2	0.1	2	0.1
Centre	Cyprus	8	1.8	12	2.7	17	3.8	10	2.2	
Centre	Czechia	8	0.1	6	0.1	10	0.2	4	0.1	
West	Denmark	12	0.4	5	0.2	4	0.1	5	0.2	
East	Estonia	7	1.0	17	2.4	5	0.7	6	0.9	
West	Finland	5	0.2	5	0.2	8	0.3	4	0.1	
West	France	185	0.5	177	0.5	144	0.4	157	0.5	
West	Germany[d]	65	0.2	61	0.1	64	0.2	51	0.1	
West	Greece	26	0.5	33	0.6	28	0.5	13	0.2	
Centre	Hungary	6	0.1	8	0.2	16	0.3	3	0.1	
West	Iceland	0	0.0	0	0.0	0	0.0	2	1.2	
West	Ireland	5	0.2	3	0.1	6	0.2	1	0.0	
West	Italy	188	0.6	205	0.7	215	0.7	158	0.5	
East	Latvia	43	4.0	24	2.3	45	4.3	36	3.4	
West	Liechtenstein	0	0.0	0	0.0	0	0.0	0	0.0	
East	Lithuania	9	0.6	7	0.4	8	0.5	8	0.5	
West	Luxembourg[e]	8	2.8	3	1.0	2	0.7	1	0.3	
West	Malta	0	0.0	0	0.0	0	0.0	0	0.0	
West	Netherlands	49	0.6	46	0.5	41	0.5	39	0.5	
West	Norway	7	0.3	7	0.3	3	0.1	3	0.1	
Centre	Poland	31	0.2	12	0.1	15	0.1	25	0.1	
West	Portugal	100	1.8	113	2.1	91	1.7	97	1.8	
Centre	Romania	111	1.1	98	1.0	89	0.9	87	0.9	
Centre	Slovakia	1	0.0	0	0.0	0	0.0	0	0.0	
Centre	Slovenia	0	0.0	2	0.2	0	0.0	0	0.0	
West	Spain	117	0.5	103	0.4	104	0.4	64	0.3	
West	Sweden	-	-	-	-	-	-	-	-	
		1 058	**0.5**	**1 003**	**0.4**	**962**	**0.4**	**821**	**0.4**	
Non-EU/EEA										
Centre		15	1.0	8	0.6	9	0.6	12	0.8	
West	Andorra	1	2.8	0	0.0	1	2.7	0	0.0	
East	Armenia	34	2.2	47	3.0	33	2.1	64	4.1	
East	Azerbaijan	43	0.9	36	0.7	54	1.1	60	1.2	
East	Belarus	212	4.1	201	3.9	165	3.2	153	2.9	
Centre	Bosnia and Herzegovina	1	0.1	1	0.1	0	0.0	0	0.0	
East	Georgia	74	3.7	73	3.7	64	3.2	101	5.1	
West	Israel	20	0.5	18	0.4	12	0.3	11	0.3	
East	Kazakhstan	92	1.0	119	1.3	136	1.4	154	1.6	
East	Kyrgyzstan	16	0.5	10	0.3	17	0.5	17	0.5	
East	Moldova	114	6.6	156	9.2	107	6.4	152	9.2	
West	Monaco	0	0.0	0	0.0	0	0.0	0	0.0	
Centre	Montenegro	1	0.3	0	0.0	1	0.3	0	0.0	
Centre	North Macedonia	1	0.1	2	0.2	0	0.0	0	0.0	
East	Russian Federation	-	-	-	-	-	-	-	-	

West	San Marino	0	0.0	0	0.0	0	0.0	0	0.0
Centre	Serbia	3	0.1	4	0.1	6	0.1	8	0.2
Centre	Serbia excluding Kosovo[f]	2	0.1	4	0.1	6	0.2	7	0.2
Centre	Kosovo[f]	1	0.1	-	-	-	-	1	0.1
West	Switzerland	12	0.3	21	0.5	17	0.4	15	0.3
East	Tajikistan	94	2.2	64	1.5	83	1.9	63	1.4
Centre	Türkiye	26	0.1	13	0.0	18	0.0	17	0.0
East	Turkmenistan	-	-	-	-	-	-	-	-
East	Ukraine	3 140	15.9	3 390	14.8	3 696	16.2	3 434	15.2
West	United Kingdom	100	0.3	72	0.2	74	0.2	66	0.2
East	Uzbekistan	-	-	-	-	-	-	-	-
		3 999	**2.8**	**4 235**	**2.9**	**4 493**	**3.1**	**4 327**	**3.0**
Total non-EU/EEA WHO European Region									
	West	959	0.5	924	0.4	849	0.4	723	0.3
	Centre	220	0.2	170	0.2	193	0.2	177	0.2
	East	3 878	7.0	4 144	7.1	4 413	7.5	4 248	7.2
	Total WHO European Region	**5 057**	**1.4**	**5 238**	**1.4**	**5 455**	**1.5**	**5 148**	**1.4**

[a] Country/territory/area specific comments are in Annex 5.
[b] Cumulative total is the total number of cases reported by the country since the start of reporting.
[c] Austria uses study cohort data.
[d] The cumulative figure for Germany differs from the country's own reported total because of variations in the counting methodology used.
[e] The numbers displayed here may not fully align with the numbers in the country's national statistics as these are presented by the 'date of notification' instead of the 'date of diagnosis' as here.
[f] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

2020		2021		2022		2023		2024		Cumulative total[b]	Country, territory or area[a]
N	Rate	N	Rate	N	Rate	N	Rate	N	Rate		
											EU/EEA
10	0.2	11	0.2	20	0.4	11	0.2	13			
23	0.4	32	0.5	23	0.4	37	0.6	19			
11	0.3	3	0.1	9	0.3	15	0.4	16			Austria[c]
1	0.0	2	0.1	1	0.0	3	0.2	1			
14	3.0	22	4.8	20	4.3	12	2.5	-			
8	0.1	10	0.2	16	0.3	23	0.4	15			Belgium
4	0.1	3	0.1	11	0.4	12	0.4	13			
5	0.7	2	0.3	2	0.3	3	0.4	3			
5	0.2	7	0.3	4	0.1	8	0.3	5			
127	0.4	146	0.4	173	0.5	190	0.5	145			
-	-	-	-	-	-	-	-	-			
17	0.3	23	0.4	18	0.3	9	0.2	10			Bulgaria
7	0.1	11	0.2	11	0.2	13	0.3	9			
0	0.0	0	0.0	1	0.5	1	0.5	1			
3	0.1	1	0.0	3	0.1	9	0.3	5			
110	0.4	103	0.3	120	0.4	132	0.4	102			
16	1.6	15	1.5	16	1.6	13	1.3	19			Croatia
0	0.0	0	0.0	-	-	-	-	-			
5	0.3	9	0.6	8	0.5	14	0.9	7			
6	1.9	4	1.3	3	0.9	3	0.9	5			
0	0.0	0	0.0	0	0.0	0	0.0	0			
39	0.4	23	0.3	34	0.4	33	0.4	22			Cyprus
1	0.0	10	0.4	9	0.3	6	0.2	10			
14	0.1	12	0.1	33	0.2	45	0.2	43			
67	1.2	97	1.8	44	0.8	44	0.8	69			
57	0.6	64	0.7	62	0.6	65	0.7	65			
0	0.0	0	0.0	4	0.1	0	0.0	1			
2	0.2	2	0.2	0	0.0	0	0.0	4			
66	0.3	54	0.2	61	0.3	61	0.2	-			
-	-	-	-	-	-	-	-	-			
618	**0.3**	**666**	**0.4**	**706**	**0.4**	**762**	**0.4**	**602**			
2	0.1	11	0.8	13	0.9	11	0.8	18			Czechia
-	-	-	-	-	-	-	-	-			
39	2.5	51	3.3	57	3.7	59	3.9	25			
28	0.5	27	0.5	28	0.5	53	1.0	32			
77	1.5	102	2.0	-	-	-	-	-			
-	-	-	-	-	-	-	-	1			
47	2.4	54	2.7	47	2.4	62	3.1	60			Denmark
11	0.3	11	0.2	10	0.2	19	0.4	6			
176	1.8	170	1.7	156	1.6	139	1.4	123			
15	0.5	15	0.5	13	0.4	10	0.3	31			
76	4.7	79	4.9	107	6.2	93	5.2	112			
-	-	-	-	-	-	-	-	-			
1	0.3	1	0.3	1	0.3	2	0.6	2			Estonia
-	-	-	-	-	-	-	-	1			
-	-	-	-	-	-	-	-	-			
0	0.0	0	0.0	0	0.0	0	0.0	0			
6	0.1	1	0.0	5	0.1	9	0.2	6			
5	0.1	1	0.0	4	0.1	9	0.2	5			
1	0.1	-	-	1	0.1	-	-	1			
6	0.1	10	0.2	12	0.3	11	0.2	7			Finland
23	0.5	32	0.7	33	0.7	42	0.8	28			
13	0.0	7	0.0	13	0.0	10	0.0	27			
-	-	-	-	-	-	-	-	-			
1 660	8.6	1 638	7.4	1 115	5.1	1 270	6.4	1 146			
36	0.1	45	0.1	70	0.2	69	0.2	61			
-	-	-	-	-	-	-	-	-			
2 216	**1.5**	**2 254**	**1.5**	**1 680**	**1.2**	**1 859**	**1.3**	**1 686**			
531	0.3	580	0.3	616	0.3	655	0.4	493			France
136	0.1	146	0.2	188	0.2	208	0.2	209			
2 167	3.9	2 194	3.7	1 582	2.9	1 758	3.4	1 586			

2 834	**0.9**	**2 920**	**0.9**	**2 386**	**0.7**	**2 621**	**0.8**	**2 288**	

Germany[a]

Greece

Hungary

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg[e]

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Total

EU-EEA

Non-EU/EEA

Albania

Andorra

Armenia

Azerbaijan

Belarus

Bosnia and Herzegovina

Georgia

Israel

Kazakhstan

Kyrgyzstan

Moldova

Monaco

Mont

Montenegro

North Macedonia

Russian Federation

San Marino

Serbia

Serbia excluding Kosovo (Kosovo)

Switzerland

Tajikistan

Türkiye

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Total non-EU/EEA

WHO European Region

West Centre

East

Total WHO European Region

Table 16: The most common AIDS-indicative diseases diagnosed in 2024[a], ordered by frequency

Diseases	Men		Women		Children		Total	
	N	%	N	%	N	%	N	%
	459	22.1	182	23.4	5	16.7	646	22.4
	280	13.5	87	11.2	6	20.0	373	12.9
	249	12.0	97	12.5	2	6.7	348	12.1
	161	7.8	66	8.5	2	6.7	229	7.9
	126	6.1	52	6.7	1	3.3	179	6.2
	152	7.3	15	1.9	0	0.0	167	5.8
	104	5.0	61	7.8	1	3.3	166	5.8
	81	3.9	30	3.9	2	6.7	113	3.9
	65	3.1	43	5.5	2	6.7	110	3.8
	51	2.5	22	2.8	0	0.0	73	2.5
	172	11.4	87	13.0	3	12.5	262	11.9
	169	11.2	72	10.8	4	16.7	245	11.1
	157	10.4	59	8.8	2	8.3	218	9.9
	109	7.2	33	4.9	1	4.2	143	6.5
	91	6.0	34	5.1	0	0.0	125	5.7
	68	4.5	37	5.5	0	0.0	105	4.8
	51	3.4	23	3.4	1	4.2	75	3.4
	47	3.1	24	3.6	1	4.2	72	3.3
	31	2.1	16	2.4	0	0.0	47	2.1
	25	1.7	14	2.1	1	4.2	40	1.8
	346	22.1	136	21.9	3	30.0	485	22.1
	206	13.2	72	11.6	1	10.0	279	12.7
	160	10.2	38	6.1	0	0.0	198	9.0
	152	9.7	43	6.9	1	10.0	196	8.9
	110	7.0	42	6.8	0	0.0	152	6.9
	77	4.9	49	7.9	1	10.0	127	5.8
	68	4.3	40	6.5	0	0.0	108	4.9
	56	3.6	30	4.8	0	0.0	86	3.9
	49	3.1	19	3.1	0	0.0	68	3.1
	41	2.6	18	2.9	0	0.0	59	2.7
	174	19.2	53	19.1	6	23.1	233	19.3
	151	16.7	45	16.2	2	7.7	198	16.4
	95	10.5	23	8.3	2	7.7	120	9.9
	82	9.1	33	11.9	3	11.5	118	9.8
	41	4.5	13	4.7	2	7.7	56	4.6
	36	4.0	13	4.7	1	3.8	50	4.1
	36	4.0	8	2.9	3	11.5	47	3.9
	35	3.9	12	4.3	0	0.0	47	3.9
	42	4.6	2	0.7	0	0.0	44	3.6
	20	2.2	16	5.8	2	7.7	38	3.1
	126	11.3	78	14.2	2	11.1	206	12.2
	130	11.6	64	11.7	2	11.1	196	11.6
	119	10.7	60	10.9	2	11.1	181	10.8
	98	8.8	30	5.5	1	5.6	129	7.7
	89	8.0	37	6.7	0	0.0	126	7.5
	42	3.8	21	3.8	1	5.6	64	3.8
	23	2.1	20	3.6	1	5.6	44	2.6
	18	1.6	12	2.2	0	0.0	30	1.8
	21	1.9	7	1.3	1	5.6	29	1.7
	16	1.4	11	2.0	0	0.0	27	1.6

[a] Numbers and percentages relate to AIDS-indicative disease events reported; some people diagnosed with AIDS have more than one event reported at the time of

Table 17: AIDS-related deaths[a], by geographical area, country and year of death (2015–2024) and cumulative totals in EU/EEA and other countries of the WHO European Region[a]

Area	Country, territory or area[b]	Year of diagnosis										Cumulative total[c]
		2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	
EU/EEA												
West	Austria	15	15	16	15	14	7	14	19	19	10	1
West	Belgium	24	39	30	20	36	31	27	38	31		272
Centre	Bulgaria	8	9	10	9	17	6	13	11	7	38	
Centre	Croatia	17	4	6	7	9	6	5	3	7		2
East	Cyprus	2	0	0	0	0	1	3	1	4		440
Centre	Czechia	12	17	15	16	5	20	23	16	23	6	
West	Denmark	1	2	1	2	1	2	4	4	0	2	
East	Estonia	2	2	4	4	1	6	5	2	0	3	252
West	Finland	6	5	9	6	1	1	3	2	0	15	
West	France	103	130	134	193	207	210	204	209	229		251
West	Germany						-	-	-	-		
West	Greece	76	77	71	71	34	35	25	23	34	2	
Centre	Hungary	50	43	47	42	39	10	12	19	13	1	100
West	Iceland	11	11	8	16	16	1	0	0	0	1	
West	Ireland	0	0	0	0	0	2	1	3	1	15	
West	Italy	1	1	1	0	2	219	194	203	0	7	382
East	Latvia	535	495	309	262	240		6		16	-	
West	Liechtenstein						12	0	16	-	25	
East	Lithuania	38	37	31	29	29	0	18	-	14		1
West	Luxembourg	0	0	0	0	0	12	3	16	3	8	804
West	Malta	7	23	15	14	5	6	0	8	0	0	
West	Netherlands	5	7	2	2	6	0	28	0	43	1	135
West	Norway	1	3	0	0	0	30	0	35	0	0	
Centre	Poland	42	44	35	30	30	0	6	1	20	10	245
West	Portugal	2	0	2	1	1	14	97	24	68	-	
Centre	Romania	33	24	18	17	12	76	158	74	132	9	
Centre	Slovakia	177	189	168	159	116	149	0	214		2	38
Centre	Slovenia							1		1	0	189
West	Spain[b]	200	199	201	182	177	1	39	0	2	79	
West	Sweden						0	-	1	33		14
	Total EU/EEA	4	2	1	3	2	48	**889**	40	-	0	970
		5	3	1	1	0	-		-	**700**	18	
		185	179	110	81	29	**905**		**982**			2
		-	-	-	-	-					48	084
		1 562	**1 560**	**1 245**	**1 182**	**1 029**						482
											13	
											8	40
											0	427
											3	
											3	45
											-	068
											57 9	937
												6
												265
												261
												65
												1
												416
												635
												1
												435
												11
												179
												5
												765
												53
												112
												49
												164
												1
												323
												180 757
Non-EU/EEA		12	12	4	11	8	4	11	10	10	10	226
Centre	Albania	3	0	0	0	-	-	-	-	-	-	
West	Andorra	62	55	76	62	69	56	71	59	72	61	
East	Armenia	45	41	35	42	39	38	34	29	19		4
East	Azerbaijan	257	299	275	266	279	236	241	396	277	8	976
East	Belarus						-	-	-	-	25	
Centre	Bosnia and Herzegovina	5	2	0	2	2	63	38	53	62	9	906
East	Georgia	52	107	78	76	51	27	23	29	34	1	
West	Israel	27		19	23	25	251	207	186	141	64	
East	Kazakhstan	169	33	213	251	263		46				5
East	Kyrgyzstan		180				36	55	51	57		135
		50		59	60	36	110	-	73	106	7	
		91	56	85	104	69	-	4	-	-	11	70
		0	98	0		-	1	-	2	2	8	1
		6	0	4	0	4	-	-	-	-	49	274
		0	2	2	2	-	-	0	0	0		
		-	0	-	0	-	0	14	20	13	18	979
		0	-	0	1	0	16	14	20	13	-	
		13	0	12	-	23	16	-	-	-	3	3
		12	13	12	0	21	-	0	0	0	0	606
		1	10	-	26	2	0	56	46	61	-	
		0	3	0	25	0	73	1	7	6	0	
		91	0	150	1	104	1	-	-	-	11	819
		4	113		0		-	1	1	1		
		-		4	121	4	2	928	293	474	10	
		3	4	-		-	114	122				1
		032	-	3	8	2		-	128	126	1	735
				298	-	977	81	**2 851**				

an											
East	77	3		3		-		-	-	0	
Moldova	-	253		448		**3**		**2**	**2**	35	
West	**3**		69		49	**107**		**382**	**460**		18
Monaco	**996**		-		-						72
Centre		77	**4**	58	**4**					8	67
Monten		-	**383**	-	**002**					-	0
egro		**4**		**4**						1	8
Centre		**345**		**561**						16	1
North										9	262
Macedo										10	
nia										3	1
East										-	230
Russian										**1**	
Federati										**92**	
on										**4**	49
West											0
San											1
Marino											282
Centre											
Serbia											142
Centre											
											1
											59
Serbia											411
excludin											
g											7
Kosovo[d]											953
Centre											
											323
Kosovo[d]											
West											**86**
Switzerl											**269**
and	1	1	1 023	965	830	776	784	816	621	476	179
East	330	339	286				251				550
Tajikista			4 319	301	279	229	2	328	240	226	10
n	332	302	**5 628**				705				671
Centre				4	3	3	**3**	2	2	1	76
Türkiye	3	4		477	922	007	**740**	220	299	801	805
East	896	264									**267**
Turkme				**5**	**5**	**4**		**3**	**3**	**2**	**026**
nistan	**5**	**5**		**743**	**031**	**012**		**364**	**160**	**503**	
East	**558**	**905**									
Ukraine											
West											
United											
Kingdo											
m											
East											
Uzbekis											
tan											

Total non-EU/EEA WHO European Region

West Centre East **Total WHO European Region**

[a] This table includes deaths reported as due to AIDS and excludes deaths reported as not due to AIDS-related cases. In countries and years for which cause of death (AIDS or non-AIDS related) was unknown or could not be reported, deaths among persons (ever) diagnosed with AIDS were included.

[b] Country/territory/area-specific comments are in Annex 5. Spain has changing national coverage of AIDS reporting during the period (see Annex 5) and trends should be interpreted with caution. Mortality statistics for 2021-2022 were unavailable in Italy.

[c] Cumulative total is the total number of deaths reported by country since the start of reporting.

[d] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

Table 18: Number of HIV tests performed, excluding unlinked anonymous testing and testing of blood donations, by country and year (2015–2024) and number of tests per 1 000 population in 2022, in EU/EEA and other countries of the WHO European Region

Area	Country, territory or area[a]	Number of HIV tests										Tests/1 000 population
		2015	2016	2017	2 018	2 019	2 020	2021	2022	2023	2024	
EU/EEA												
West	Austria	-	-	-	-	-	-	-	-	-	-	-
West	Belgium	692 679 290 000	726	715	734 506 360 000	763 413 360 000	629 063 340 000	694	706	745	7	65.2
	Bulgaria											-
Centre	Croatia	-	-	-	-	-	-	-	-	-	-	-
Centre	Cyprus	-	52 385	-	-	-	37 326	41 900	-	-	-	-
Centre		345 274 153	350 234 163	351 650 158	353 425 155	359 327 158	329 433 144	386 943 146	431 832 149	387 381 175	330 003 175	30.3 29.4 78.7
West		050 87 587	779 90 136	331 102 863	609 112 487	009 125 273	859 105 285	263 106 051	263 115 538	440 115 229	510 108 179	- 123.9 -
West		- 5 455	- 5 562	- 5 699	- 5 930	- 6 343	- 5 472	- 6 018	- 6 549	- 7 500	- 8 481	29.5 - -
West	Czechia	257- 192	390- 196	708- 176	256- 187	105- 305	737- 250	234- 263	162- 236	777- 336	095- 306	63.1 -
West		150 91 793	257 - -	966 - -	627 - -	433 - -	450 - -	046 - -	911 - -	812 - -	751 - -	66.9 - 46.3
East		- 178	192 956	223 609	239 571	247 490	206	224 072	243 870	260 355	337 626	13.4
West		267 -	- 79 715	- 82 608	- 90 368	- 98 651	516 -	- 103	- 119	- 122	- 125	- -
West	Denmark	65 552	- 104	- 113	- 109	- 133	93 036	843 -	274 -	647 -	236 -	- 13
Centre		- 105	132 -	917 77 285	825 -	810 72 276	-	125	129	129	133	39.1
West		486 -	- -	- -	- -	- -	112 489	918 65 947	082 65 947	545 84 050	501 90	
	Estonia	- -	- -	- 430	- 385	- 432	72 276 -	- -	- -	- -	097 - -	
	Finland	318 458	440 365	662	173	929	-	460	699	415	474	
	France	282 800	281 992	291 305	308 328	352 926	432 074 272 310	882 333 382	717 437 645	021 460 323	526 415 647	
	Germany											
	Greece											
	Hungary											
	Ice											

		Iceland	Ireland	Italy	Latvia	Liechtenstein	Lithuania	Luxembourg	Malta	Netherlands	Norway	Poland	Portugal
Centre	Romania	346 032	360 893	338 898	323 468	334 410	234 520	243 718	287 865	285 629	296 995		15.5
Centre	Slovakia	127	104	111	177	-	-	-	-	-	-	-	-
Centre	Slovenia	109	876	340	498	40	23	40	5	53	53		25.4
West	Spain	34	35	37	38	462	798-	147-	1	992-	87	-	-
West	Sweden	366-	788	315	570	-	-	-	1		2	-	-
Non-EU/EEA									4				
Centre	Albania								3				
West	Andorra								-				
East	Armenia	5 442	5 582	7 149	11 219	13 261	11 864	10 776	24 972	29 139	27		9.9
East	Azerbaijan	2 212	2 340	2 591		-	-	-	-	-	913		-
East	Belarus	117	99 270	119	2 712	164	159	156	208	214	-		77.6
Centre	Bosnia and Herzegovina	012		628	132	933	281	175	833	595	215		69.5
East	Georgia	714	500	657	509	735	639	459	677	693	472		164.9
West	Israel	621	469	704	753	434	230	196	280	236	727		-
East		1 249	1 464	1 514	568	1 488	1 242	1 316	1 488	1 478	240		105.9
		712	386-	635	1 627	199-	389-	274	640-	722-	1		-
		-		-		441	-	-	298	554	559		222.9

Kazakhstan	78 261	119	207	169	119	-	422	500	060	470	96.7
East Kyrgyzstan	-	868	175	-	-	2 877	900	-	-	-	87.7
East Moldova	2 388	-	-	188	2 877	706	-	3 581	4 117	393	-
West Monaco	347	2 587	2 742	142	706	367	3 315	123	260	568	14.3
Centre	376	065	741	-	424	948	560	612	675	-	25.1
	284	331	376	2 760	087	152	546	785	151	4	377.6
	146	609	431	324	182	500	133	273	269	419	
	762	124	160	356	196	-	141	666	466	250	
	-	010	947	765	-	5 375	100	-	-	661	25.7
Montenegro	6 607	-	-	154	6 575	34 439	-	6 831	8 092	182	17.0
Centre North Macedonia	28 601	6 324	5 606	575	40 596		6 372	39 596	47 308	291	16.2
East Russian Federation		30 211	36 248	-		36 110	40 879		51 002	926	3.1
West San Marino	30 750		36 445	6 890	41 900	128 1	41 277	47 205	495 1	-	-
Centre Serbia	547 1	32 855	059 3	34 634	729 2	550	712	207 2	570	8	125.1
Centre Serbia excluding Kosovo[b]	548	597 3	685		200	64 332	630	627	114	954	
Centre Kosovo[b]	63 189	600	80 918		90 508		86 166	96 389	015	52	102.5
West		68 426	76 367	40 485		63 090	82 737		107	314	-
	61 877		4 551	246 3			3 429		312	54	52.5
		65 827	-	411	88 490		-	89 317	6 703	360	-
			612	81 530		1 242	909		-	488	-
	1 312		123			-	536		1 056	863	
	-	2 599	7 107	76 653	2 018	836	9 379	7 072	582 7	120	
Switzerland	597	-	551		-	487	998-	-	689	488	
East Tajikistan	426	509	-	4 877	1 062	7 067	1 428	919	302-	114	
Centre Türkiye	7 203	092	1 816	-	509 10	571-	952-	083	1 622	990	
East Turkmenistan	959-	6 263	023	780	257	1 501	-	10 092	466-	5	
East Ukraine	1 695	020-	-	688	015-	984-		464-	-	498	
West United Kingdom	926-	1 697	-	7 457	1 961	-		1 068		-	
East Uzbekistan	-	479-		674	711	-		483		1	
		-		-	-	-		-		292	
				1 868						556	
				565						8	
				-						838	
				-						363-	
										1	
										992	
										630	
										-	
										-	

[a] Country/territory/area specific comments are in Annex 5.

[b] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

Maps

Map 1a: HIV diagnoses per 100 000 population, 2024



Map 1b: HIV diagnoses per 100 000 population, 2024, EU/EEA





< 3

3 to < 5

5 to < 10

10 to < 15

≥ 15

Missing or excluded data

Map 2: HIV diagnoses in men per 100 000 male population, 2024



Map 3: HIV diagnoses in women per 100 000 female population, 2024



Map 4: HIV diagnoses in men who have sex with men per 100 000 male population, 2024



Map 5: HIV diagnoses acquired through heterosexual transmission per 100 000 population, 2024



Map 6: HIV diagnoses acquired through injecting drug use per 100 000 population, 2024



Map 7: AIDS diagnoses reported per 100 000 population, 2024



Annexes

Annex 1: Framework for data collection, validation and presentation

Reporting

The Member States' Coordinating Competent Bodies in the European Union (EU) and European Economic Area (EEA) (jointly referred to as EU/EEA) countries have nominated national operational contact points for HIV/AIDS surveillance to work on reporting surveillance data to the joint European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe database for HIV/AIDS surveillance. For non-EU/EEA countries, nominations for national HIV/AIDS surveil-lance focal points were received directly by the WHO Regional Office for Europe via the respective ministries of health.

Data are submitted directly by reporting countries through a web-based platform to a joint database known as The European Surveillance System (TESSy). Four types of data are collected: HIV (case-based and aggregate), AIDS (case-based and aggregate), HIVAIDS (case-based data that link HIV and AIDS diagnoses) and number of HIV tests performed (aggregate). AIDS-related deaths are reported as part of case-based AIDS or HIVAIDS data. All new HIV diagnoses, irrespective of whether the case is diagnosed simultaneously with AIDS or reported as a new AIDS diagnosis, are classified as HIV cases.

Implementation of WHO and EU case definitions for HIV and AIDS surveillance means that only confirmed cases are reported at European level [1,2]. It is recognised that the HIV and AIDS case definitions currently used may dif-fer between countries across the WHO European Region, but the EU and WHO case definitions are compatible for surveillance purposes. Since 2016, the case definitions have been changed in the Russian Federation. Updated forms (N61) from the Federal Statistical Surveillance are submitted by medical facilities to the Ministry of Health and include the number of individuals newly diagnosed with HIV infection; 2009–2015 data therefore cannot be directly compared to 2016–2024 data. A built-in set of validation rules in TESSy ensures verification of the data within the database during the data-uploading process, improving data quality and allowing each country to test their datasets prior to submission. Further validation checks are carried out by ECDC and the WHO Regional Office for Europe in collaboration with countries before the data are considered of sufficient quality to be used for analysis.

Andorra, Monaco, Turkmenistan and Uzbekistan did not report any HIV data through TESSy for 2024 (or previous years for some of the countries − see Table 1). Andorra, Bosnia and Herzegovina, Cyprus, Germany, Liechtenstein, Monaco, North Macedonia, the Russian Federation, Spain, Sweden, Turkmenistan and

Uzbekistan did not report any AIDS data for 2024 (or previous years for some of the countries − see Table 13).

The completeness of key variables is presented for the EU/EEA and the WHO European Region as a whole in Annex 2 and by country in Annex 3.

Surveillance systems – data sources

To describe the national source of data and specify the national surveillance system from which the reported data originate, information on the country data source is included as a compulsory part of reporting (detailed in Annex 4a and 4b.) Some cross-country data comparisons are hampered by differences in surveillance systems, and by the quality and coverage of national surveillance. These issues are detailed in Annex 5 and should be taken into account when interpreting and comparing trends across countries.

Data collection and validation

Data collection 2025

The 2024 data submission for HIV and AIDS surveillance took place between 3 April and 1 October 2025. Data presented in this report were extracted from TESSy on 9 October 2025.

Individual country datasets

Data were uploaded, validated and approved in the joint database for HIV/AIDS surveillance by the report-ing countries. Once the data were submitted, individual datasets were reviewed by ECDC and WHO's Regional Office for Europe and validated by the countries. The HIVAIDS record type was used for the first time in 2014 to collect case-based joined HIV and AIDS data (Annex 4a and 4b). The joined record type allows understanding of the relationship between the HIV and AIDS events and diagnosis dates. Additional details on record type used per country can be found in Annexes 4a and 4b.

Reporting of aggregated HIV and AIDS data has an impact on the data presentation and analysis and the epidemiological overview of HIV/AIDS in Europe because fewer variables are available from the aggregated data-sets, reducing the amount of data that can be presented in certain tables and figures.

Data re-coding and adjustments

Dates used for data presentation

HIV and AIDS data are presented in this report by date of diagnosis. If countries could not provide this date or

preferred to present their data by the date of statistics to avoid discrepancies with their national surveillance reports, this date was used instead. This was the case for four countries: Armenia, Belarus, Türkiye and Ukraine.

Region of origin

Where available, countries were encouraged to provide data on the specific country of origin or nationality of the case. This information was used first and, if absent, the variable 'region of origin' was used to group cases into region of origin, presented in Table 10 (stratified by reporting country) and Table 11 (all countries stratified by mode of transmission).

Origin of reported cases

Cases originating from countries outside of the report-ing country are highlighted in some of the analyses presented here. This approach has been taken to inform epidemiological understanding and guide public health resource allocation and prevention efforts.



Reporting delay

The data in this report has not been adjusted for reporting delays. This is primarily due to the impact of the COVID-19 pandemic and the incorporation of previously reported positive diagnoses into the analysis.

Data presentation

Geographical presentation

Data are presented for the WHO European Region and the EU/EEA. The EU comprises 27 Member States and the EEA an additional three countries (Iceland, Liechtenstein and Norway) which are included in the overview for the EU/EEA.

The tables are presented for EU/EEA countries, non-EU/EEA countries and as totals. The 53 countries of the WHO European Region are also sub-divided into three geographical areas, based on epidemiological considerations and in accordance with the division used in previous reports on HIV/AIDS surveillance in Europe: West (23 countries), Centre (15 countries) and East (15 countries) (Figure A1.1). The division reflects

Figure A1: Geographical/epidemiological division of the WHO European Region

The countries covered by the report are grouped as follows:

- West, 23 countries: Andorra, Austria*, Belgium*, Denmark*, Finland*, France*, Germany*, Greece*, Iceland, Ireland*, Israel, Italy*, Luxembourg*, Malta*, Monaco, Netherlands*, Norway, Portugal*, San Marino, Spain*, Sweden*, Switzerland, United Kingdom.
- Centre, 15 countries: Albania, Bosnia and Herzegovina, Bulgaria*, Croatia*, Cyprus*, Czechia*, Hungary*, the former Yugoslav Republic of Macedonia, Montenegro, Poland*, Romania*, Serbia, Slovakia*, Slovenia*, Türkiye.
- East, 15 countries: Armenia, Azerbaijan, Belarus, Estonia*, Georgia, Kazakhstan, Kyrgyzstan, Latvia*, Lithuania*, Moldova, Russian Federation, Tajikistan, Turkmenistan, Ukraine, Uzbekistan.

* Countries constituting the European Union as of 2022.

similarities in epidemiological dynamics, such as epidemic levels, trends over time and transmission pat-terns. Among the EU/EEA countries, 18 Member States are classified as being in the West, nine in the Centre and three in the East.

Liechtenstein is not a WHO Member State, so its data are included in the totals for the EU/EEA, but not for the WHO European Region. Totals for West, Centre and East therefore may not always equal the EU/EEA and non-EU/EEA totals. Data from Serbia include HIV cases notified in Kosovo[1] in all figures, although these are stratified in tables to allow separate epidemiological presentation of the reported data.

Population data and rates

Data are presented in absolute numbers and rates as cases per 100 000 population.

The population estimates up to 2024 were derived from Eurostat for all EU/EEA countries and from the United Nations Population Division for non-EU/EEA coun-tries[2][3]. The Eurostat data are from May 2024 [4] and the United Nations Population Division statistics are from the 2004 round of estimates [5].

The population data used for AIDS in Spain were adjusted according to the extent of sub-national coverage for the relevant years historically (see Annex 5 for details).

Rates for data presented by gender and age were cal-culated using relevant men and women population denominators from the sources described above. For maps presenting figures for men who have sex with men, rates were calculated using the male population.

Data are presented by year but also as cumulative totals per country. The cumulative total includes all data reported by that particular country since the beginning of national reporting and is not limited to the selected number of years presented in that given table.

Trend data

Only countries reporting consistently were included for presentation of the overall trends; these are noted in the footnotes to the trend graphs.

When presenting HIV trends for 2015−2024 coun-tries reporting data inconsistently (Andorra, Monaco, Turkmenistan and Uzbekistan) and those reporting on transmission mode inconsistently or incompletely (such as Estonia, Latvia, Poland, Russia and Türkiye) were excluded from relevant figures reporting trends by transmission mode.

1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

2 Due to discrepancies in the methodology used for calculating the population rates by the Russian Federal Statistics Service and the United Nations Population Division, rates on overall HIV diagnoses, as well as data disaggregated by sex presented in Tables 1, 2, 3 and elsewhere in the report, may differ from the data presented in national statistics.

AIDS trends for 2015−2024 excluded countries not reporting consistently over the period (Andorra, Cyprus, Germany, Monaco, Russian Federation, Spain, Sweden, Turkmenistan and Uzbekistan).

When analysing trends for AIDS deaths, only countries reporting consistently were included (Andorra, Germany, Italy, Monaco, the Russian Federation, Sweden, Turkmenistan and Uzbekistan were not included).

5. Data limitations

Surveillance systems are not identical across Europe, and differences in testing policies and data collection methods could affect the results and introduce bias into comparisons between countries. Factors such as under-reporting and reporting delay may influence the country figures and rankings presented in the report.

The data in the report for recent years are to be considered as provisional because they are subject to regular updates (such as detection and deletion of duplicate cases, and inclusion of new information on cases already reported). The limitations described below, the country comments in Annex 5 and the information on HIV and AIDS case reporting systems available in Annex 4 and 5 should be taken into account when interpreting the data presented here.

Official reports of HIV diagnoses do not represent true incidence. Reported HIV diagnoses include recently infected people, as well as those who were previously positive, or infected several years ago but only recently tested for HIV. These reports are also influenced by several factors, such as the uptake of HIV testing, patterns of reporting, the long incubation period and a slow progression of the disease. To better interpret trends in HIV case-reporting data, the total numbers of HIV tests performed annually for diagnostic purposes (excluding unlinked anonymous tests and screening of blood donations) are presented to help provide some background on HIV testing patterns. The absence of standardisa-tion and consistent collection of the HIV status variable, which distinguishes between first-time diagnoses and previous positive diagnoses, has presented challenges in interpreting the data from 2023.

In 2024, although it was not feasible to account for reporting delays, it is essential to emphasise that only a limited number of European countries have assessed their surveillance systems for under-reporting and subsequently shared the findings [6]. Previous estimates of under-reporting range from 0% to 41% for AIDS cases [F. Cazein, personal communication, 2021], while national estimates of under-reporting for HIV can range from 0% to 43% [7]. Estimates on the under-reporting of AIDS-related deaths are not available, but according to a country survey from 2006, only around one third of countries were able to comprehensively link HIV and AIDS surveillance death registries with national statis-tics or death certificate information, which results in under-reporting of AIDS-related deaths [8].

References

1. World Health Organization (WHO). WHO case definitions of HIV for surveillance and revised clinical staging and immunologi-cal classification of HIV-related disease in adults and children. Geneva: WHO; 2007. Available at: https://apps.who.int/iris/handle/10665/43699

2. European Commission (EC). European Commission Decision 2002/253/EC laying down case definitions for reporting com-municable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council. OJ L 27.09.12:6–7. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2002D0253:20120927:EN:PDF

3. United Nations (UN). World population prospects: the 2017 revi-sion, DVD edition. New Yorkk (NY): United Nations, Department of Economic and Social Affairs, Population Division; 2017.

4. Eurostat [online database]. Brüsseles: Eurostat; 2024. Available at: http://ec.europa.eu/eurostat/data/database

5. United Nations (UN). World population prospects: the 2022 [revision, medium variant 2025 [website]. In: United Nations Department of Economic and Social Affairs, Population Division. New York (NY): UN Department of Economic and Social Affairs, Population Division; 2022. Available at: https://population.un.org/ wpp/

6. European Centre for Disease Prevention and Control (ECDC)/Mapping surveillance systems for HIV/AIDS in the EU/EEA. Stockholm: ECDC; 2025. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/hiv-aids-mapping-surveill

ance-systems-eu-eea.pdf

7. French National Institute of Health Surveillance. EuroHIV 2006 survey on HIV and AIDS surveillance in the WHO European Region. Saint-Maurice: Institut de veille sanitaire. French National Institute of Health Surveillance; 2007. Available at: https://www.santepubliquefrance.fr/maladies-et-traumatismes/infections-sex-uellement-transmissibles/vih-sida/documents/rapport-synthese/ eurohiv-2006-survey-on-hiv-and-aids-surveillance-in-the-who-eu-ropean-region

Annex 2

Completeness of variables for data reported in 2023 and 2024

	2023				2024			
	Number of countries	Completeness %	Minimal	Maximal	Number of countries	Completeness %	Minimal	Maximal
EU/EEA Countries	30	99.4	89.5	100	29	99.4	91.4	100
Age		99.8	94.7	100			93.8	100
Gender		73.6	22.9	100			24.4	100
	30	82.2	0.6	100	29	99.7	2.6	100
Transmission		61.0					19.7	98.8
Country of birth or region of origin	30	67.1	19.5	100	29	73.8	7.7	100
CD4 cell count			11.5	100				
HIV status	23			100	22	82.5		
WHO European Region								
Age	27				27	60.7		
Gender								
Transmission	27				26	66.2		
Country of birth or region of origin								
CD4 cell count	51	99.9	89.5	100	50	99.9	91.4	100
HIV status	51	99.9	94.7	100	50	99.9	93.8	100
	51	89.9	22.9	100	50	87.7	24.4	100
	41	43.9	0.6	100	41	48.5	2.6	100
	46	37.2	6.9	100	46	37.2	11.8	100
	35	27.2	11.5	100	36	27.4	0.5	98.8
								100

Annex 3

Completeness by country and variable, 2024

Area	Country, territory or area[a]	Age	Gender	Transmission	CD4 cell count	Country of birth/ region of origin[b]	HIV status
EU/EEA							
West	Austria	100	100	87.3	94.1	99.0	100
West	Belgium	100	99.7	70.7	70.4	79.8	100
Centre	Bulgaria		100	100	83.5	95.8	14.1
Centre	Croatia	99.6	100	87.9	45.1	98.9	68.1
Centre	Cyprus		100	98.4	96.8	100	90.4
Centre	Czechia		100	91.5	92.7		98.2
West	Denmark	100	100	81.4	49.7	100	100
East	Estonia		100	34.6	88.0	97.5	49.1
West	Finland	100	100	71.2	77.9	46.6	76.1
West	France		100	68.3	58.6	59.3	100
West	Germany	100	100	72.5	31.7	78.5	100
West	Greece		100	62.4	38.7	91.2	97.4
Centre	Hungary	100	100	73.3	0.0	95.5	100
West	Iceland		93.8	94.9	87.2	76.2	85.6
West	Ireland	100	100.0	66.5	19.7	84.6	9.5
West	Italy		99.9	91.5	98.4	64.1	98.3
East	Latvia	100	100	47.8	32.2	99.2	-
West	Liechtenstein[c]		100	-	-	0.0	52.2
East	Lithuania	100	100	69.4	80.1	-	100
West	Luxembourg		100	90.7	74.4	100	-
West	Malta	100	100	94.8	75.9		95.9
West	Netherlands		100	85.2	98.8	93.0	
West	Norway	100	100	72.0	64.0	96.6	
Centre	Poland		100	24.4	0.0	99.5	
West	Portugal	100	100	93.8		98.5	
Centre	Romania		98.2	99.6	77.3	69.7	
Centre	Slovakia	100	100	69.9	95.8	98.5	
Centre	Slovenia		100	83.6	31.0	98.8	
West	Spain	100	100	85.7	61.8	30.1	
West	Sweden		99.2	78.0	86.2	89.1	
Non-EU/EEA			100		64.5	96.9	
Centre	Albania	99.4				95.3	
West	Andorra						
East	Armenia	100					
East	Azerbaijan						
East	Belarus	91.4					
Centre	Bosnia and Herzegovina						
East	Georgia	100					
West	Israel						
East	Kazakhstan	100					
East	Kyrgyzstan						
East	Moldova	100					
West	Monaco						
Centre	Montenegro	100					
Centre	North Macedonia						
East	Russia	100					
West	San Marino						
Centre	Serbia	100					
Centre	Serbia excluding Kosovo[d]						
Centre	Kosovo[d]	100					
West	Switzerland						
East	Tajikistan	100					
Centre	Türkiye						
East	Turkmenistan	100					
East	Ukraine						
West	United Kingdom	97.4					
East	Uzbekistan						
		100					
		100					
		95.1					

100	100	91.9	91.1	100	0.0
100	-	-	-	-	-
100	100	99.4	0.0	100	100
100	100	98.6	94.9	100	100
100	100	97.3	73.6	99.9	0.0
100	100	87.5	90.0	100	0.0
100	100	93.7	87.0	100	0.0
-	99.7	83.9	68.1	89.6	99.7
100	100	96.0	91.9	99.5	100
100	100	92.4	70.5	99.8	0.0
100	100	88.1	84.9	100	0.0
100	-	-	-	-	-
100	100	78.4	73.0	100	100
100	100	98.1	96.2	100	0.0
100	-	-	-	-	-
100	-	-	-	-	-
100	-	-	-	-	-
100	100	84.2	93.0	100	0.0
-	100	97.1	88.2	100	2.9
100	99.7	64.7	65.6	65.0	30.3
100	100	95.4	95.9	99.2	100
-	100	28.4	11.8	86.3	0.0
-	-	-	-	-	-
100	100	99.7	91.7	100	0.0
100	100	87.2	88.5	89.7	100.0
100	-	-	-	-	-
100					
100					
-					
100					
100					
-					

a Completeness not computed for countries, territories or areas with fewer than five diagnoses reported in 2024 or countries that reported in the aggregated record type which did not allow reporting of all variables (Russia).
b Completeness provided is based on country of birth, region of origin or, for Italy and Switzerland, country of nationality.
c Liechtenstein reported zero cases in 2024.
d All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

Annex 4a

HIV surveillance system overview: data source information

Country, territory or area	HIV data source	Record type[a] for 2024 reporting	Period	Legal[b]	Coverage[c]	Comments
EU/EEA						
Austria	AT-HIV	HIVAIDS	1980–2024	V	Co	HIV surveillance in Austria is based on the AHIVCOS (Austrian HIV cohort study), which in 2022 represented 64% of people who had ever received ART in Austria.
Belgium	BE-HIV/AIDS	HIVAIDS	1985–2024	C	Co	
Bulgaria	BG-HIV	HIVAIDS	1986–2024	C	Co	HIV surveillance is based on exhaustive registration of HIV diagnoses since 1985
Cyprus	CY-HIV/AIDS	HIVAIDS	1986–2024	C	Co	HIV aggregate record type used through 2006; HIV record type 2007–2013
Croatia	HR-CNIPH	HIVAIDS	1985–2024	C	Co	HIV record type used prior to 2016
Czechia	CZ-HIV/AIDS	HIVAIDS	1990–2024	C	Co	HIV record type used 1990–2013 Data source EE-HIV used 1988–2012; HIV aggregate record type used through 2006; HIV record type prior to 2015
Denmark	DK-HIV	HIVAIDS	1985–2024	C	Co	HIV record type used prior to 2016 Although compulsory, HIV diagnoses are not exhaustively reported; underreporting was estimated between 23% and 27% until 2018, then increased during the COVID-19 years (42% in 2021), then decreased (30% in 2023). This underreporting is lower in hospitals (21% in 2023).
Estonia	EE-NAKIS	HIVAIDS	1988–2024	C	Co	
Finland	FI-NIDR	HIVAIDS	1980–2024	C	Co	Data source DE-HIV-PRIS used 1993–2001; HIV recordtype used to report data up to 2016
France	FR-HIVAIDS	HIVAIDS	2003–2024	C	Co	
Germany	DE-SURVNET@RKI7.3-HIV		1993–2024	C	Co	
Greece	EL-HIV/AIDS	HIVAIDS	1984–2024	C	Co	
Hungary	HU-HIV/AIDS	HIVAIDS	1985–2024	C	Co	
Iceland	IS-SUBJECT_TO_REGISTRATION	HIVAIDS	1983–2024	C	Co	HIV record type used 1985–2013 HIV record type used prior to 2017
Ireland	IE-CIDR	HIVAIDS	1985–2024	C	Co	Data source IE-HIV/AIDS used for years 1981–2011; HIV aggregate used for reporting through 2002; HIV record type 2003–2011
Italy	IT-COA-ISS	HIV	1985–2024	C	Co	See country comments about historical coverage; HIV aggregate record type used through 2009. Mortality statistics for 2023-2024 were unavailable.
Latvia	LV-HIV/AIDS	HIVAIDS	1987–2024	C	Co	HIV record type used 1987–2013; HIVAIDS record type used from 2014 Cases reported through Switzerland's surveillance system using another data source through 2020
Liechtenstein	LI-HIVAIDS	HIVAIDS	2021-2024	C	Co	
Lithuania	LT-NPHC	HIVAIDS	1988–2024	C	Co	New data source LT_NPHC (National Public Health Centre under the Ministry of Health) from 2021
Luxembourg	LU-HIVAIDS	HIVAIDS	1983–2024	V	Co	
Malta	MT-DISEASE_SURVEILLANCE	HIVAIDS	2001–2024	C	Co	
Netherla		HIVAIDS	1980–2024	V	Co	
		HIVAIDS	1984–2024	C	Co	HIV record type used in years 1986–2014

nds	NL-HIV/AIDS	HIVAIDS	1985–2024	C	Co	
Norway	NO-MSIS_B	HIVAIDS	1985–2024	C	Co	HIV record type used in years 1980–2013
Poland	PL-HIV					
Portugal	PT-HIVAIDS					
Romania	RO-RSS	HIVAIDS	1987–2024	C	Co	Data source: Compartment for Monitoring and Evaluation of HIV/AIDS Data in Romania, National Institute for Infectious Diseases "Prof. Dr. Matei Bals". National coverage.
Slovakia	SK-EPIS	HIVAIDS HIVAIDS HIV	1985–2024 1985–2024 2003–2024	C C C	Co Co Co	
Slovenia						
Spain	SI-HIVAIDS ES-HIV					HIV record type used in years 1985–2013 See country comments about historical coverage
Sweden	SE-SmiNet	HIVAIDS	1983–2024	C	Co	Data source SE-SweHIVReg used 1983–2009; HIV record type used prior to 2014
non-EU/EEA						
Albania	AL-NIoPH	HIVAIDS	1993–2024	C	Co	
Andorra	AD-MoHWFH	HIVAIDS	2004–2018	V	Co	
Armenia	AM-NAC	HIVAIDS	1988–2024	V	Co	
Azerbaijan	AZ-AIDS-CENTER-NEW	HIVAIDS	1987–2024	V	Se	
Belarus	BY-NAC	HIVAIDS	1981–2024	C	Co	HIVAIDS record type used only for HIV reporting (no linked HIV and AIDS reporting); HIV record type used in years 1981–2013
Bosnia and Herzegovina	BA-FMoH-	HIVAIDS HIVAIDS	1986–2024	C	Co	
Georgia	MoHSW	HIVAIDS HIVAIDS	1989–2024	C	Co	
Israel	RS GE-IDACIR	HIVAIDS HIV	1981–2024	C	Co	
Kazakhstan	C	HIVAIDS HIVAGGR	1987–2024	NS/unk V	NS/unk Co	
Kyrgyzstan	IL-MOH	HIVAGGR HIVAIDS	1987–2024	V	Other	
Moldova	KZ-RCfAPC	HIV	1987–2024	C	Co	HIV record type used in years 1993–2013
Montenegro		HIVAIDS HIV	1989–2024	C	Co	
Monaco	KG-HIV	-	1987–2018	C	Co	
North Macedonia	KG 2008		1993–2024	C	Co	
Russian Fedration	MD-NAC		2009-2024	C	Co	
San Marino	ME-IOPH		1985–2022	C	Co	
Serbia[d]	MC-MoSH-GEN		1984–2024	C	Co	HIV record type used in years 1987–2000
Switzerland	MK-NHASS		1985–2024	C	Co	
Tajikistan	RU-MOH		1991–2024	C	Co	
Türkiye	SM-AIDS/HIV		1985–2024	V	Co	
Turkmenistan	RS-NAC		1990–2012			HIV record type used in years 1993–2016
	CH-FOPH					
	TJ-RHAC					HIV aggregate record type used in years 1984–2001
	TR-MOH					
	TM-NAC					
Ukraine	UA-NAC	HIVAIDS	1987–2024	V	Other	HIVAIDS record type used only for HIV reporting (no linked HIV and AIDS reporting); HIVAGGR record type used in years 1987–2015.
United Kingdom	UK-HIVAIDS	HIVAIDS-HIVAIDS	1981–2024 1981–2010	V V	Co Co	
Uzbekistan	UZ-RAC		1986-2024	V	Co	Did not report data 2011–2020; used HIV record type in years 1981–2010 HIVAIDS record type used for all years
Kosovo[d]	XK-IPH					

[a] Type: HIVAIDS (HIV and AIDS joined case-based record type); HIV (HIV case-based record type); AIDS (AIDS case-based record type); HIVAGGR (HIV aggregate record type); AIDSAGGR (AIDS aggregate record type).
[b] Legal: voluntary reporting (V); compulsory reporting (C); not-specified/unknown (NS/unk).
[c] Coverage: sentinel system (Se); comprehensive (Co); not-specified/unknown (NS/unk).
[d] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

Annex 4b

AIDS surveillance system overview: data source information

Country, territory or area	AIDS Data source		Record type[a] for 2022 reporting	Period	Legal[b]	Coverage[c]	Comments
EU/EEA							
Austria	AT-AIDS	HIVAIDS	1982-2024	V		Co	HIV surveillance in Austria is based on the AHIVCOS (Austrian HIV cohort study), which in 2022 represented 64 % of people who had ever received ART in Austria.
Belgium	BE-HIV/AIDS	HIVAIDS	1983-2024	V		Co	AIDS surveillance is based on reporting of AIDS diagnoses at the time of HIV diagnosis or during medical follow-up; not exhaustively reported
Bulgaria	BG-AIDS	HIVAIDS	1987-2024	C		Co	AIDS record type was used for cases prior to 2014
		HIVAIDS	1986-2024	C		Co	
		HIVAIDS	1986-2024	C		Co	
		HIVAIDS	1986-2024	C		Co	
		HIVAIDS	1980-2024	C		Co	AIDS record type used prior to 2016
		HIVAIDS	1992-2024	C		Co	
Cyprus	CY-HIV/AIDS	HIVAIDS	1983-2024	C		Co	AIDS record type from data source DK-MIS used 1980-2013
Croatia	HR-CNIPH						AIDS record type used prior to 2015
Czechia	CZ-HIV/AIDS						AIDS record type used prior to 2016
Denmark	DK-HIV						Additional data from record type AIDS used for the years 1978-2023.
Estonia	EE-NAKIS						Although compulsory, AIDS diagnoses are not exhaustively reported. Underreporting was estimated at 41% in 2007-2009, then increased to 46% in 2016-2017. It was estimated at 42% in 2023.
Finland	FI-NIDR						Did not report 2020 data, AIDS record type used through 2016
							AIDS record type used 1986–2013
							AIDS record type used prior to 2017
							Data source IE-HIV/AIDS and AIDS record type used for years 1981-2011
							Mortality statistics for 2023-2024 were unavailable.
France	FR-HIVAIDS; FR-AIDS	HIVAIDS	1982-2024	C		Co	Same data source in AIDS record type used for 1990-2013
Germany	DE-AIDS	HIVAIDS	1981-2019	V		Co	Cases reported through Switzerland's surveillance system using another data source through 2020
	EL-HIV/AIDS	HIVAIDS	1981-2024	C		Co	
	HU-HIV/AIDS	HIVAIDS	1986-2024	C		Co	
	IS-SUBJECT_TO_REGISTRATION	HIVAIDS	1985-2024	V		Co	New data source LT_NPHC (National Public Health Centre under the Ministry of Health) from 2021
	IE-CIDR	AIDS	1983-2024	C		Co	
Greece	IT-COA-ISS	HIVAIDS	1982-2024	C		Co	Same data source and AIDS record type used 1986-2014
	LV-AIDS		1990-2024				
Hun							Data source NO-MSIS-A and record type AIDS used in years 1980-2013

Liechtenstein	LI-HIVAIDS	HIVAIDS	2021-2024	C	Co	
Lithuania	LT-NPHC	HIVAIDS	1988-2024	C	Co	
Luxembourg	LU-HIVAIDS	HIVAIDS	1983-2024	V	Co	
	MT-DISEASE_SURVEILLANCE	HIVAIDS	1986-2024	C	Co	
	NL-HIV/AIDS	HIVAIDS	1999-2024	C	Co	
	NO-MSIS_B	HIVAIDS	1983-2024	C	Co	
Malta		HIVAIDS	1986-2024			
Netherlands	PL-HIV	HIVAIDS	1985-2024			
Norway	PT-HIVAIDS					
Poland						
Portugal						
Romania	RO-RSS	HIVAIDS	1985-2024	C	Co	
Slovakia	SK-EPIS	HIVAIDS	1985-2024	C	Co	
Slovenia		HIVAIDS	1986-2024	C	Co	
Spain		AIDS	1981-2024	C	Co	
Sweden			1982-2007	V	Co	
non-EU/EEA						
Albania	SI-HIVAIDS					
Andorra						
Armenia						
Azerbaijan						
Belarus						
Bosnia and Herzegovina						
Georgia						
Israel						
Kazakhstan						
Kyrgyzstan						
Moldova						
Montenegro						
Monaco						
North Macedonia	ES-AIDS					
Russian Federation						
San Marino						
Serbia[d]						
Switzerland	AL-NIoPH	HIVAIDS	1993-2024	C	Co	
		HIVAIDS	2004-2018	V	Co	
Tajikistan		HIVAIDS	1988-2024	V	Se	
Türkiye		HIVAIDS	1995-2024	V	Co	
Turkmenistan	AD-MoHWFHAM-NAC-AZ-AI	AIDS	1991-2022	C	Co	
		HIVAIDS	1986-2024	C	Co	
		HIVAIDS	1989-2024	C	Co	
		HIVAIDS	1981-2024	C	Co	
		HIVAIDS	1993-2024	NS	NS	
		HIVAIDS	1999-2024	V	Co	
		HIVAIDS	1989-2024	V	Co	
		HIVAIDS	1990-2024	C	Co	
		AIDS	1985-2018	C	Co	
		HIVAIDS-AIDS	1989-2024-1986-2022	C-C	Co-Co	
		HIVAIDS	1985-2024	C	Co	
		AIDS	1980-2024	C	Co	

Data source: Compartment for Monitoring and Evaluation of HIV/AIDS Data in Romania, National Institute for Infectious Diseases "Prof. Dr. Matei Balș". National coverage. AIDS record type used in years 1985-2013	
See country comments about coverage AIDS surveillance discontinued in 2008	
AIDS record type used in years 1986–2013	
AIDS record type used in years 1987-2000	
AIDS record type used in years 1993–2016	
AIDS record type used in years 1985-2001	
HIVAIDS record type used only for HIV reporting (i.e. no linked HIV and AIDS reporting).	
Did not report data 2011-2020; used AIDS	

	DS-CENTER-NEWBY-NAC-BA-FMoH-MoHSWRSGE-IDACIRC-IL-MOH	HIVAIDS AIDS	1998-2024 1985-2024 2002-2013	C C C V	Co Co Co Co	record type in years 1992-2010 HIVAIDS record type used for all years
	KZ-RCfAPC					
	KG-HIVKG2008MD-NAC-ME-IOPH					
	MC-MoSH-GEN					
	MK-NHASS-SM-AIDS/HIV					
	RS-NAC-CH-FOPH					
	TJ-RHAC					
	TR-MOH					
	TM-NAC					
Ukraine	UA-NAC	AIDSAGGR	1988-2024	V	Co	
United Kingdom	UK-HIV	HIVAIDS-HIVAIDS	1981-2024 1992-2010	V V	Co Co	
Uzbekistan	UZ-RAC		1986-2024	V	Co	
Kosovo[d]	XK-IPH					

[a] Type: HIVAIDS (HIV and AIDS joined case-based record type); HIV (HIV case-based record type); AIDS (AIDS case-based record type); HIVAGGR (HIV aggregate record type); AIDSAGGR (AIDS aggregate record type).
[b] Legal: voluntary reporting (V); compulsory reporting (C); not-specified/unknown (NS/unk).
[c] Coverage: sentinel system (Se); comprehensive (Co); not-specified/unknown (NS/unk).
[d] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

Annex 5

Country-specific comments regarding national HIV and AIDS reporting

Country, territory or area	Comments
EU/EEA	
Austria	HIV surveillance in Austria is based on the AHIVCOS (Austrian HIV cohort study), which in 2022 represented 64% of people who had ever received ART in Austria.
Belgium	HIV surveillance is based on the exhaustive registration of HIV diagnoses in Belgium since 1985; a distinction is made between new diagnoses and previously known diagnoses. Since 2006 this surveillance is complemented with a data collection of persons with HIV who are in medical follow-up at an HIV Reference Centre (= specialised outpatient clinic); this is the Belgian HIV-cohort which covers more than 80% of persons with HIV in medical follow-up. Within the cohort, clinical, biological and therapeutic data are collected.
Bulgaria	Case-based reporting of HIV is available from 2007 onwards.
Croatia	
Cyprus	
Czechia	Foreigners with short-term stays in Czechia are not included in cases notified. The increase in the number of cases in
2022-2024 compared to	the previous years is clearly due to the arrival of Ukrainians in connection with the war.
Denmark	
Estonia	The surveillance system was modified substantially in 2008. Previously, the probable mode of HIV transmission was not reported by Estonia (from 2003 to 2007, Estonia supplied partial information on people who inject drugs only).
Finland	All HIV cases have been reported to the national registry since the beginning of the epidemic. Notification is made by both the laboratory and the physician, and it is mandatory. Previous positive cases are classified, according to the year of diagnosis in Finland. In addition to HIV cases, AIDS cases are reported.
France	Since 2016, HIV and AIDS diagnoses should be reported online, and physicians should report HIV diagnoses spontaneously, without waiting for the laboratory report. Case-based data reported through TESSy are not exhaustive because of reporting delays (cases reported several months or years after the diagnosis) and underreporting (cases that are diagnosed but never reported). The COVID-19 pandemic has affected the French HIV surveillance by increasing underreporting in 2020 and 2021, which affects the reliability of adjusted number of HIV and AIDS diagnoses. The most recent estimates of underreporting in France are 42% in 2023 for AIDS and 30% in 2023 for HIV. Considering only reports in hospitals, HIV underreporting would be estimated at 21% in 2023. To assess the real numbers and trends of HIV and AIDS diagnoses in France, it is essential to use adjusted data, which take into account reporting delays, underreporting and missing data (incomplete reports). The actual number of new HIV diagnoses in 2023, after adjustment, is estimated at 5 473 [CI 95% IS 5 343–5 603]. The actual number of AIDS diagnoses in 2023 is estimated at 937 [862–1013]. Transgender people known to be infected by sexual intercourse are not classified as HSH nor heterosexual, but as "Sexual transmission" in French surveillance data. This category does not exist in TESSy, so transgender people infected through sexual intercourse are listed as 'unknown transmission mode'.
Germany	
Greece	Previous positive cases are classified, according to the year of diagnosis abroad. In case the date of HIV diagnosis abroad
is not available, the	date of the first positive HIV test in Greece is used
Hungary	Case report for HIV has been available since 1985 and for AIDS since 1986.
Iceland	
Ireland	HIV was made a notifiable disease in September 2011. The HIV reporting system was modified substantially in 2012. AIDS cases and deaths among AIDS cases are now only reported if at the time of HIV diagnosis. HIV diagnoses include a growing proportion of so-called previous-positive people, who are transferring their HIV care when moving to Ireland and tested positive and were notified within the Irish system when moving to the country. These people are excluded when reviewing late diagnosis. There was a change in the implementation of the case definition in 2015 (requiring confirmatory testing on a single sample rather than two samples) which resulted in more people being notified to the surveillance system.
Italy	Data on new HIV diagnoses have been collected since 1985 in some regions of Italy. New HIV diagnoses were reported by 10 of the 21 Italian regions between 2004 and 2006, 11 regions in 2007, 12 in 2008, 18 in 2009 and all of the 21 regions of Italy since 2012. Between 2004 and 2011, population denominators were based on the annual resident population in the regions reporting cases. From 2012, the coverage of the surveillance system has been national, so the total Italian population is used as a denominator. AIDS deaths are not reported after 2023 due to lack of updated data from the national mortality register.
Latvia	
Liechtenstein	Liechtenstein is a small country with about 40 000 inhabitants. Under a customs treaty with Switzerland, it applied Swiss epidemiology law and reported to ECDC through Switzerland until 2021. Since then, Liechtenstein has been reporting directly to ECDC.
Lithuania	A new HIV reporting system started in 2004.
Luxembourg	In Luxembourg, laboratories electronically notify HIV cases to the national surveillance system. However, there is currently no medical case notification system in place, and HIV/AIDS surveillance is done in collaboration with the national infectious diseases unit's hospital for data management.
Malta	"A new HIV reporting system started in 2004. Due to the different time periods when the ECDC data cut-off is done, compared to the national data, there are some discrepancies between the ECDC data and the national reports. These differences are explained as follows: HIV diagnosis in men who acquired HIV through sex with men should read 41 in 2019 HIV diagnosis in men who acquired HIV through intersexual contact should read 15 in 2019 AIDS diagnosis and rates per 100 000 population should read 1 in 2020 and 2 in 2023 AIDS diagnosis in males and rates per 100 000 population should read 2 in 2023 AIDS diagnosis in females and rates per 100 000 population should read 1 in 2020"
Netherlands	HIV surveillance is based on the ATHENA cohort, which includes 98% of people who entered HIV care in the Netherlands. Data collection started from 1996 onwards and HIV diagnoses before 1996 are incomplete. The national Dutch HIV monitoring report publishes slightly different figures than those displayed in the European report because migrants with a documented HIV diagnosis before arrival in Netherlands are excluded in the national report.
Norway	

Poland	There was an increase in the number of cases in Poland due to the arrival of Ukraine war refugees, who account for 22,3% of reported cases in 2023.
Portugal	The PT-HIV database is fully case-based, containing details of HIV and AIDS cases diagnosed from 1983. Strategies to address underreporting and reporting delay implemented in 2013 and 2017, by the Portuguese HIV/AIDS Programme, resulted in a significant increase in the number of reported cases and deaths for all previous years.

Country, territory or area	Comments
Romania	The Romanian surveillance and reporting system has been implemented since the beginning of the 1990s, in real time. The data is collected in the National HIV/AIDS Registry, where the patients are recorded once-time only, without duplicates. Updates in the patients' data are made constantly with changes from HIV to AIDS. The national reporting addressess to the Ministry of Health, the National Public Health Institute on a quarterly basis. Also, the information is available, in real time, for the respective year. Annually, the data is transmitted to ECDC and any other international entity involved in the field- UNAIDS, WHO- in the case where they are requested. The statistical evaluation is made with SPECTRUM. The national HIV/AIDS Regsitry is stored at The National Institute for Infectious Diseases "Prof. Dr. matei Bals" through the Compartment for Monitoring and Evaluation of HIV/AIDS.
Slovakia	
Slovenia	The Slovenian HIV system is based on mandatory, universal reporting of newly diagnosed HIV cases by physicians following laboratory confirmation.
Spain	HIV reporting has existed since the 1980s in some of the 19 Autonomous Regions of Spain. For 2003-11 data are available only for 9 Regions: Asturias, Balearic Islands, Basque Country, Canary Islands, Catalonia, Ceuta, Extremadura, La Rioja, and Navarre; since 2004, data are available for 10 Regions (+Galicia); since 2007, data are available for 11 Regions (+Madrid); since 2008, data are available for 14 Regions (+Aragon, Castilla-La Mancha and Melilla); since 2009, data are available for 17 Regions (+Cantabria, Castilla-Leon and Murcia); since 2012 data are available for 18 Regions (+Valencia); and since 2013 data are available for all the 19 Regions of Spain (+Andalucia). In 2018, data from Catalonia are not available. AIDS data: For technical reasons, it has not been possible to include AIDS data from one region in 2014, two regions from 2015 to 2022, and three in 2023. Rates are based on the corresponding population for each year.
Sweden	Due to changes in the HIV/AIDS surveillance system, AIDS reporting has not been mandatory since 2005. Since 2008, AIDS data are not reported from Sweden because the national AIDS surveillance system had been discontinued.
Non-EU/EEA	
Armenia	
Montenegro	
North Macedonia	
Russian Federation	All data are presented by "date of statistics" (instead of "date of diagnosis"). Data on HIV tests refer to the number of people tested and do not include people tested in the private laboratories. AIDS cases include only people diagnosed with AIDS at the time of HIV diagnosis.
Serbia	"The Russian Federation reported aggregated dataset with new HIV diagnoses registered in 2024 disaggregated by sex, age group and mode of transmission and data on testing for 2024. Whereas data reported for 2009-2019 was limited to new HIV diagnoses by sex only. This enabled the inclusion of the country's data in Tables 1–12 and 18 and in the figures showing the trend of HIV diagnosis but not in the rest of the trend figures due to inconsistent reporting. The country also reported separately information about CD4 cell count at the time of diagnosis. These data were manually entered into Table 12.
Türkiye	
Ukraine	Since 2016, case definitions have been changed in the Russian Federation. Updated Forms (№1) of the Federal Statistical Surveillance are submitted by medical facilities to the Ministry of Health and include the number of individuals newly diagnosed with HIV infection. Data for 2009–2015 cannot therefore be compared directly with those for 2016–2024. Due to discrepancies in the methodology used for calculating the population rates by the Russian Federal Statistics Service and the United Nations Population Division, rates on overall HIV diagnoses, as well as data disaggregated by sex, presented in the report in Tables 1,2 and 3 and elsewhere in the report may differ from the data presented in national statistics. Data on HIV tests refer to the number of people tested and do not include people tested in the reference laboratory or private laboratories. Reported HIV cases exclude people diagnosed with AIDS at the time of HIV diagnosis. Reported AIDS cases only include people diagnosed with AIDS at the time of HIV diagnosis. Table 14 (see Tables section): CD4 cell count data exclude people diagnosed with AIDS at the time of HIV diagnosis. All data are presented by "date of statistics" (instead of "date of diagnosis"). Ukraine's national HIV and AIDS case notification system was established in 1987. It is a mandatory reporting system where health facilities routinely collect data from all 25 regions of Ukraine and, since 2018, report the data to the information system for monitoring socially significant diseases. The major gap in HIV surveillance in Ukraine is that there is no HIV case electronic registration right after the confirmation of positive test results, so all data for TESSy are presented by "date of statistics" (instead of "date of diagnosis"). The war in Ukraine starting in 2022 caused a significant population migration, which has had a negative impact on the completeness and quality of data.

Annex 6

HIV/AIDS surveillance in Europe: participating countries and national institutions

Country, territory or area	National institutions
EU/EEA	
Austria	Austrian Agency for Health and Food Safety; Federal Ministry of Social Affairs, Health, Care and Consumer Protection Sciensano
Belgium	Ministry of Health
Bulgaria	Croatian National Institute of Public Health
Croatia	Ministry of Health
Cyprus	Finnish Institute of Public Health
Czechia	Statens Serum Institut
Denmark	Health Board
Estonia	National Institute for Health and Welfare (THL).
Finland	Santé Publique France (French National Public Health Agency)
France	Robert Koch Institute
Germany	Hellenic Center for Disease Control and Prevention
Greece	National Center for Public Health and Pharmacy
Hungary	Directorate of Health, Centre for Health Security and Communicable Disease Control
Iceland	Health Protection Surveillance Centre (HPSC)
Ireland	Ministry of Health DG Prevention - Unit V
Italy	Centre for Disease Prevention and Control of Latvia
Latvia	Principality of Liechtenstein
Liechtenstein	National Public Health Center under the Ministry of Health
Lithuania	Luxembourg Health Directorate; national infectious diseases unit's hospital
Luxembourg	Department of Health Promotion and Disease Prevention
Malta	National Institute for Public Health and the Environment (RIVM)
Netherlands	Norwegian Institute of Public Health
Norway	National Institute of Public Health NIH - National Research Institute
Poland	Directorate-General of Health (Direção-Geral da Saúde) and National Institute of Health Dr Ricardo Jorge (Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P.)
Portugal	Institute of Public Health and National Institute for Infectious Diseases "Prof. Dr. Matei Bals"
Romania	Regional Public Health Authority of capital Bratislava
Slovakia	National Institute of Public Health
Slovenia	Instituto de Salud Carlos III - Centro Nacional de Epidemiología
Spain	Public Health Agency of Sweden
Sweden	
Non-EU/EEA	
Albania	National Institute of Public Health
Andorra	Ministry of Health, Social Welfare and Family
Armenia	National Center For Infectious Diseases
Azerbaijan	Azerbaijan AIDS Center
Belarus	National Centre for Hygiene, Epidemiology and Public Health
Bosnia and Herzegovina	Ministry of Civil Affairs of Bosnia and Herzegovina; Federal Ministry of Health; Ministry of Health and Social Welfare the Republica Srpska and Public Health Institutes of the Federation of Bosnia and Herzegovina and Republica Srpska
Georgia	Infectious Diseases, AIDS & Clinical Immunology Research Center
Israel	Ministry of Health
Kazakhstan	National Center for the Prevention and Control of AIDS
Kyrgyzstan	Republican Center for Blood Borne Viral Hepatitis and HIV Control
Moldova	National Agency for Public Health
Monaco	Ministry of Social Health
Montenegro	Institute of Public Health of Montenegro
North Macedonia	Public Health Institute
Russian Federation San Marino	Ministry of Health of the Russian Federation
Serbia[a]	Ospedale di Stato
Switzerland	Institute of Public Health of Serbia
Tajikistan	Bundesamt für Gesundheit
Türkiye	Republican HIV/AIDS Center
Turkmenistan	General Directorate of Public Health, Ministry of Health
Ukraine	National AIDS Prevention Center
United Kingdom	State Institution "Public Health Center of the Ministry of Health of Ukraine"
Uzbekistan	UK Health Security Agency
Kosovo[a]	Republican AIDS Center Institute of Public Health

[a] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999) and the ICJ Opinion on the Kosovo Declaration of Independence.

EU publications

European Region

European Centre for Disease Prevention and Control (ECDC)

Gustav III:s Boulevard 40
SE-169 73 Solna, Sweden

World Health Organization Regional Office for Europe

UN City, Marmorvej 51
DK-2100 Copenhagen
Ø, Denmark

Tel. +46 858 60 10 00
Fax +46 858 60 10 01
www.ecdc.europa.eu

Contact us
publications@ecdc.europa.eu

Tel. +45 45 33 70 00
Fax +45 45 33 70 01
www.who.int/europe

Contact us
eucontact@who.int

ECDC PDF ISBN 978-92-9498-844-7

WHO PDF ISBN 978-92-890-6267-1